<pmc-articleset>
  <article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4">
    <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
      <restricted-by>pmc</restricted-by>
    </processing-meta>
    <front>
      <journal-meta>
        <journal-id journal-id-type="nlm-ta">Nat Med</journal-id>
        <journal-id journal-id-type="iso-abbrev">Nat Med</journal-id>
        <journal-id journal-id-type="pmc-domain-id">981</journal-id>
        <journal-id journal-id-type="pmc-domain">npgopen</journal-id>
        <journal-title-group>
          <journal-title>Nature Medicine</journal-title>
        </journal-title-group>
        <issn pub-type="ppub">1078-8956</issn>
        <issn pub-type="epub">1546-170X</issn>
        <custom-meta-group>
          <custom-meta>
            <meta-name>pmc-is-collection-domain</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-collection-title</meta-name>
            <meta-value>Nature Portfolio</meta-value>
          </custom-meta>
        </custom-meta-group>
      </journal-meta>
      <article-meta>
        <article-id pub-id-type="pmcid">PMC11835752</article-id>
        <article-id pub-id-type="pmcid-ver">PMC11835752.1</article-id>
        <article-id pub-id-type="pmcaid">11835752</article-id>
        <article-id pub-id-type="pmcaiid">11835752</article-id>
        <article-id pub-id-type="pmid">39753968</article-id>
        <article-id pub-id-type="doi">10.1038/s41591-024-03362-3</article-id>
        <article-id pub-id-type="publisher-id">3362</article-id>
        <article-version article-version-type="pmc-version">1</article-version>
        <article-categories>
          <subj-group subj-group-type="heading">
            <subject>Article</subject>
          </subj-group>
        </article-categories>
        <title-group>
          <article-title>Clinicogenomic landscape of pancreatic adenocarcinoma identifies KRAS mutant dosage as prognostic of overall survival</article-title>
        </title-group>
        <contrib-group>
          <contrib contrib-type="author" equal-contrib="yes">
            <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0001-5426-0885</contrib-id>
            <name name-style="western">
              <surname>Varghese</surname>
              <given-names initials="AM">Anna M.</given-names>
            </name>
            <xref ref-type="aff" rid="Aff1">1</xref>
            <xref ref-type="aff" rid="Aff2">2</xref>
          </contrib>
          <contrib contrib-type="author" equal-contrib="yes">
            <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-8789-251X</contrib-id>
            <name name-style="western">
              <surname>Perry</surname>
              <given-names initials="MA">Maria A.</given-names>
            </name>
            <xref ref-type="aff" rid="Aff3">3</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Chou</surname>
              <given-names initials="JF">Joanne F.</given-names>
            </name>
            <xref ref-type="aff" rid="Aff4">4</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Nandakumar</surname>
              <given-names initials="S">Subhiksha</given-names>
            </name>
            <xref ref-type="aff" rid="Aff4">4</xref>
            <xref ref-type="aff" rid="Aff5">5</xref>
          </contrib>
          <contrib contrib-type="author">
            <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0001-7936-4365</contrib-id>
            <name name-style="western">
              <surname>Muldoon</surname>
              <given-names initials="D">Daniel</given-names>
            </name>
            <xref ref-type="aff" rid="Aff3">3</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Erakky</surname>
              <given-names initials="A">Amanda</given-names>
            </name>
            <xref ref-type="aff" rid="Aff2">2</xref>
          </contrib>
          <contrib contrib-type="author">
            <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-9283-7072</contrib-id>
            <name name-style="western">
              <surname>Zucker</surname>
              <given-names initials="A">Amanda</given-names>
            </name>
            <xref ref-type="aff" rid="Aff2">2</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Fong</surname>
              <given-names initials="C">Christopher</given-names>
            </name>
            <xref ref-type="aff" rid="Aff5">5</xref>
          </contrib>
          <contrib contrib-type="author">
            <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0003-0443-0625</contrib-id>
            <name name-style="western">
              <surname>Mehine</surname>
              <given-names initials="M">Miika</given-names>
            </name>
            <xref ref-type="aff" rid="Aff3">3</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Nguyen</surname>
              <given-names initials="B">Bastien</given-names>
            </name>
            <xref ref-type="aff" rid="Aff4">4</xref>
            <xref ref-type="aff" rid="Aff5">5</xref>
          </contrib>
          <contrib contrib-type="author">
            <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0003-2747-1366</contrib-id>
            <name name-style="western">
              <surname>Basturk</surname>
              <given-names initials="O">Olca</given-names>
            </name>
            <xref ref-type="aff" rid="Aff3">3</xref>
          </contrib>
          <contrib contrib-type="author">
            <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0003-4703-1560</contrib-id>
            <name name-style="western">
              <surname>Balogun</surname>
              <given-names initials="F">Fiyinfolu</given-names>
            </name>
            <xref ref-type="aff" rid="Aff1">1</xref>
            <xref ref-type="aff" rid="Aff2">2</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Kelsen</surname>
              <given-names initials="DP">David P.</given-names>
            </name>
            <xref ref-type="aff" rid="Aff1">1</xref>
            <xref ref-type="aff" rid="Aff2">2</xref>
          </contrib>
          <contrib contrib-type="author">
            <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0003-4610-0149</contrib-id>
            <name name-style="western">
              <surname>Brannon</surname>
              <given-names initials="AR">A. Rose</given-names>
            </name>
            <xref ref-type="aff" rid="Aff3">3</xref>
          </contrib>
          <contrib contrib-type="author">
            <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0003-4154-0567</contrib-id>
            <name name-style="western">
              <surname>Mandelker</surname>
              <given-names initials="D">Diana</given-names>
            </name>
            <xref ref-type="aff" rid="Aff3">3</xref>
          </contrib>
          <contrib contrib-type="author">
            <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0003-0227-3523</contrib-id>
            <name name-style="western">
              <surname>Vakiani</surname>
              <given-names initials="E">Efsevia</given-names>
            </name>
            <xref ref-type="aff" rid="Aff3">3</xref>
          </contrib>
          <contrib contrib-type="author">
            <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-8006-3102</contrib-id>
            <name name-style="western">
              <surname>Park</surname>
              <given-names initials="W">Wungki</given-names>
            </name>
            <xref ref-type="aff" rid="Aff1">1</xref>
            <xref ref-type="aff" rid="Aff2">2</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Yu</surname>
              <given-names initials="KH">Kenneth H.</given-names>
            </name>
            <xref ref-type="aff" rid="Aff1">1</xref>
            <xref ref-type="aff" rid="Aff2">2</xref>
          </contrib>
          <contrib contrib-type="author">
            <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-6985-2864</contrib-id>
            <name name-style="western">
              <surname>Stadler</surname>
              <given-names initials="ZK">Zsofia K.</given-names>
            </name>
            <xref ref-type="aff" rid="Aff1">1</xref>
            <xref ref-type="aff" rid="Aff2">2</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Schattner</surname>
              <given-names initials="MA">Mark A.</given-names>
            </name>
            <xref ref-type="aff" rid="Aff1">1</xref>
            <xref ref-type="aff" rid="Aff2">2</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Jarnagin</surname>
              <given-names initials="WR">William R.</given-names>
            </name>
            <xref ref-type="aff" rid="Aff2">2</xref>
            <xref ref-type="aff" rid="Aff6">6</xref>
          </contrib>
          <contrib contrib-type="author">
            <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-2505-959X</contrib-id>
            <name name-style="western">
              <surname>Wei</surname>
              <given-names initials="AC">Alice C.</given-names>
            </name>
            <xref ref-type="aff" rid="Aff2">2</xref>
            <xref ref-type="aff" rid="Aff6">6</xref>
          </contrib>
          <contrib contrib-type="author">
            <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0001-8629-5732</contrib-id>
            <name name-style="western">
              <surname>Chakravarty</surname>
              <given-names initials="D">Debyani</given-names>
            </name>
            <xref ref-type="aff" rid="Aff3">3</xref>
            <xref ref-type="aff" rid="Aff5">5</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Capanu</surname>
              <given-names initials="M">Marinela</given-names>
            </name>
            <xref ref-type="aff" rid="Aff4">4</xref>
          </contrib>
          <contrib contrib-type="author">
            <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-0131-4904</contrib-id>
            <name name-style="western">
              <surname>Schultz</surname>
              <given-names initials="N">Nikolaus</given-names>
            </name>
            <xref ref-type="aff" rid="Aff4">4</xref>
            <xref ref-type="aff" rid="Aff5">5</xref>
            <xref ref-type="aff" rid="Aff7">7</xref>
          </contrib>
          <contrib contrib-type="author">
            <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0003-3882-5000</contrib-id>
            <name name-style="western">
              <surname>Berger</surname>
              <given-names initials="MF">Michael F.</given-names>
            </name>
            <xref ref-type="aff" rid="Aff3">3</xref>
            <xref ref-type="aff" rid="Aff5">5</xref>
            <xref ref-type="aff" rid="Aff7">7</xref>
          </contrib>
          <contrib contrib-type="author">
            <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-4672-3023</contrib-id>
            <name name-style="western">
              <surname>Iacobuzio-Donahue</surname>
              <given-names initials="CA">Christine A.</given-names>
            </name>
            <xref ref-type="aff" rid="Aff2">2</xref>
            <xref ref-type="aff" rid="Aff3">3</xref>
            <xref ref-type="aff" rid="Aff7">7</xref>
          </contrib>
          <contrib contrib-type="author" corresp="yes">
            <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0003-1108-4919</contrib-id>
            <name name-style="western">
              <surname>Bandlamudi</surname>
              <given-names initials="C">Chaitanya</given-names>
            </name>
            <address>
              <email>bandlamc@mskcc.org</email>
            </address>
            <xref ref-type="aff" rid="Aff3">3</xref>
            <xref ref-type="aff" rid="Aff5">5</xref>
          </contrib>
          <contrib contrib-type="author" corresp="yes">
            <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-8076-9199</contrib-id>
            <name name-style="western">
              <surname>O’Reilly</surname>
              <given-names initials="EM">Eileen M.</given-names>
            </name>
            <address>
              <email>oreillye@mskcc.org</email>
            </address>
            <xref ref-type="aff" rid="Aff1">1</xref>
            <xref ref-type="aff" rid="Aff2">2</xref>
          </contrib>
          <aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02yrq0923</institution-id><institution-id institution-id-type="GRID">grid.51462.34</institution-id><institution-id institution-id-type="ISNI">0000 0001 2171 9952</institution-id><institution>Department of Medicine, </institution><institution>Memorial Sloan Kettering Cancer Center, </institution></institution-wrap>New York City, NY USA </aff>
          <aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02yrq0923</institution-id><institution-id institution-id-type="GRID">grid.51462.34</institution-id><institution-id institution-id-type="ISNI">0000 0001 2171 9952</institution-id><institution>David M. Rubenstein Center for Pancreatic Cancer Research, </institution><institution>Memorial Sloan Kettering Cancer Center, </institution></institution-wrap>New York City, NY USA </aff>
          <aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02yrq0923</institution-id><institution-id institution-id-type="GRID">grid.51462.34</institution-id><institution-id institution-id-type="ISNI">0000 0001 2171 9952</institution-id><institution>Department of Pathology and Laboratory Medicine, </institution><institution>Memorial Sloan Kettering Cancer Center, </institution></institution-wrap>New York City, NY USA </aff>
          <aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02yrq0923</institution-id><institution-id institution-id-type="GRID">grid.51462.34</institution-id><institution-id institution-id-type="ISNI">0000 0001 2171 9952</institution-id><institution>Department of Epidemiology and Biostatistics, </institution><institution>Memorial Sloan Kettering Cancer Center, </institution></institution-wrap>New York City, NY USA </aff>
          <aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02yrq0923</institution-id><institution-id institution-id-type="GRID">grid.51462.34</institution-id><institution-id institution-id-type="ISNI">0000 0001 2171 9952</institution-id><institution>Marie-Josée and Henry R. Kravis Center for Molecular Oncology, </institution><institution>Memorial Sloan Kettering Cancer Center, </institution></institution-wrap>New York City, NY USA </aff>
          <aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02yrq0923</institution-id><institution-id institution-id-type="GRID">grid.51462.34</institution-id><institution-id institution-id-type="ISNI">0000 0001 2171 9952</institution-id><institution>Department of Surgery, </institution><institution>Memorial Sloan Kettering Cancer Center, </institution></institution-wrap>New York City, NY USA </aff>
          <aff id="Aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02yrq0923</institution-id><institution-id institution-id-type="GRID">grid.51462.34</institution-id><institution-id institution-id-type="ISNI">0000 0001 2171 9952</institution-id><institution>Human Oncology and Pathogenesis Program, </institution><institution>Memorial Sloan Kettering Cancer Center, </institution></institution-wrap>New York City, NY USA </aff>
        </contrib-group>
        <pub-date pub-type="epub">
          <day>3</day>
          <month>1</month>
          <year>2025</year>
        </pub-date>
        <pub-date pub-type="ppub">
          <year>2025</year>
        </pub-date>
        <volume>31</volume>
        <issue>2</issue>
        <issue-id pub-id-type="pmc-issue-id">482490</issue-id>
        <fpage>466</fpage>
        <lpage>477</lpage>
        <history>
          <date date-type="received">
            <day>26</day>
            <month>2</month>
            <year>2024</year>
          </date>
          <date date-type="accepted">
            <day>17</day>
            <month>10</month>
            <year>2024</year>
          </date>
        </history>
        <pub-history>
          <event event-type="pmc-release">
            <date>
              <day>03</day>
              <month>01</month>
              <year>2025</year>
            </date>
          </event>
          <event event-type="pmc-live">
            <date>
              <day>20</day>
              <month>02</month>
              <year>2025</year>
            </date>
          </event>
          <event event-type="pmc-last-change">
            <date iso-8601-date="2025-02-22 13:25:21.873">
              <day>22</day>
              <month>02</month>
              <year>2025</year>
            </date>
          </event>
        </pub-history>
        <permissions>
          <copyright-statement>© The Author(s) 2025, corrected publication 2025</copyright-statement>
          <copyright-year>2025</copyright-year>
          <license>
            <ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref>
            <license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>.</license-p>
          </license>
        </permissions>
        <self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="41591_2024_Article_3362.pdf"/>
        <abstract id="Abs1">
          <p id="Par2">Nearly all pancreatic adenocarcinomas (PDAC) are genomically characterized by <italic toggle="yes">KRAS</italic> exon 2 mutations. Most patients with PDAC present with advanced disease and are treated with cytotoxic therapy. Genomic biomarkers prognostic of disease outcomes have been challenging to identify. Herein leveraging a cohort of 2,336 patients spanning all disease stages, we characterize the genomic and clinical correlates of outcomes in PDAC. We show that a genomic subtype of <italic toggle="yes">KRAS</italic> wild-type tumors is associated with early disease onset, distinct somatic and germline features, and significantly better overall survival. Allelic imbalances at the <italic toggle="yes">KRAS</italic> locus are widespread. <italic toggle="yes">KRAS</italic> mutant allele dosage gains, observed in one in five (20%) <italic toggle="yes">KRAS</italic>-mutated diploid tumors, are correlated with advanced disease and demonstrate prognostic potential across disease stages. With the rapidly expanding landscape of <italic toggle="yes">KRAS</italic> targeting, our findings have potential implications for clinical practice and for understanding de novo and acquired resistance to RAS therapeutics.</p>
        </abstract>
        <abstract id="Abs2" abstract-type="web-summary">
          <p id="Par3">Analyses of clinical and genomic data from a cohort of 2,336 patients with pancreatic adenocarcinoma find that <italic toggle="yes">KRAS</italic> dosage gains are a hallmark of disease progression and are predictive of poor outcomes across different disease stages.</p>
        </abstract>
        <kwd-group kwd-group-type="npg-subject">
          <title>Subject terms</title>
          <kwd>Cancer genetics</kwd>
          <kwd>Pancreatic cancer</kwd>
        </kwd-group>
        <funding-group>
          <award-group>
            <funding-source>
              <institution-wrap>
                <institution-id institution-id-type="FundRef">https://doi.org/10.13039/100000054</institution-id>
                <institution>U.S. Department of Health &amp; Human Services | NIH | National Cancer Institute (NCI)</institution>
              </institution-wrap>
            </funding-source>
            <award-id>CA008748</award-id>
            <award-id>CA257881-01A1</award-id>
            <award-id>P30 CA008748</award-id>
            <award-id>P50 CA257881-01A1</award-id>
            <award-id>CA008748</award-id>
            <award-id>CA008748</award-id>
            <award-id>CA008748</award-id>
            <award-id>CA257881-01A1</award-id>
            <award-id>CA008748</award-id>
            <award-id>CA257881-01A1</award-id>
            <award-id>CA008748</award-id>
            <principal-award-recipient>
              <name name-style="western">
                <surname>Varghese</surname>
                <given-names>Anna M.</given-names>
              </name>
              <name name-style="western">
                <surname>Perry</surname>
                <given-names>Maria A.</given-names>
              </name>
              <name name-style="western">
                <surname>Chou</surname>
                <given-names>Joanne F.</given-names>
              </name>
              <name name-style="western">
                <surname>Park</surname>
                <given-names>Wungki</given-names>
              </name>
              <name name-style="western">
                <surname>Iacobuzio-Donahue</surname>
                <given-names>Christine A.</given-names>
              </name>
              <name name-style="western">
                <surname>Bandlamudi</surname>
                <given-names>Chaitanya</given-names>
              </name>
              <name name-style="western">
                <surname>O’Reilly</surname>
                <given-names>Eileen M.</given-names>
              </name>
            </principal-award-recipient>
          </award-group>
        </funding-group>
        <custom-meta-group>
          <custom-meta>
            <meta-name>pmc-status-qastatus</meta-name>
            <meta-value>0</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-status-live</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-status-embargo</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-status-released</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-open-access</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-olf</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-manuscript</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-legally-suppressed</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-has-pdf</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-has-supplement</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-pdf-only</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-suppress-copyright</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-is-real-version</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-is-scanned-article</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-preprint</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-in-epmc</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>issue-copyright-statement</meta-name>
            <meta-value>© Springer Nature America, Inc. 2025</meta-value>
          </custom-meta>
        </custom-meta-group>
      </article-meta>
    </front>
    <body>
      <sec id="Sec1">
        <title>Main</title>
        <p id="Par4">Pancreatic cancer is the third-highest cause of cancer-related mortality and has the lowest 5-year overall survival (OS) rate of all cancer types<sup><xref ref-type="bibr" rid="CR1">1</xref></sup>. For most patients with pancreatic adenocarcinoma (PDAC), the most common pancreatic cancer histology, chemotherapy remains the mainstay of therapy<sup><xref ref-type="bibr" rid="CR2">2</xref>–<xref ref-type="bibr" rid="CR5">5</xref></sup>. More than 90% of PDACs exhibit activating mutations in <italic toggle="yes">KRAS</italic> hotspot residues, a majority of which have eluded targeted therapeutic approaches until recently<sup><xref ref-type="bibr" rid="CR6">6</xref></sup>. <italic toggle="yes">KRAS</italic> wild-type (WT) tumors are enriched for actionable alterations in mitogen-activated protein kinase (MAPK) pathway genes such as <italic toggle="yes">BRAF</italic>, <italic toggle="yes">NTRK1,</italic>
<italic toggle="yes">NTRK</italic><italic toggle="yes">3</italic> and <italic toggle="yes">NRG1</italic> (refs. <sup><xref ref-type="bibr" rid="CR7">7</xref>–<xref ref-type="bibr" rid="CR14">14</xref></sup>).</p>
        <p id="Par5">Superior outcomes are observed in molecularly selected cohorts, such as patients with pathogenic variants in <italic toggle="yes">BRCA1</italic>, <italic toggle="yes">BRCA</italic><italic toggle="yes">2</italic> and <italic toggle="yes">PALB2,</italic> and with tumors harboring targetable alterations<sup><xref ref-type="bibr" rid="CR2">2</xref>,<xref ref-type="bibr" rid="CR3">3</xref>,<xref ref-type="bibr" rid="CR15">15</xref>–<xref ref-type="bibr" rid="CR18">18</xref></sup>. Molecular profiling studies have also identified several prognostic features associated with poor outcomes in PDAC<sup><xref ref-type="bibr" rid="CR19">19</xref>,<xref ref-type="bibr" rid="CR20">20</xref></sup>. In addition, gene expression-based stratification has identified two main subtypes of PDAC, classical and basal-like, that differ in molecular pathology, therapeutic vulnerabilities and outcomes<sup><xref ref-type="bibr" rid="CR21">21</xref>–<xref ref-type="bibr" rid="CR27">27</xref></sup>.</p>
        <p id="Par6">More recently, allelic imbalance (unequal number of maternal and paternal copies) at the <italic toggle="yes">KRAS</italic> locus has been associated with poor outcomes in PDAC<sup><xref ref-type="bibr" rid="CR28">28</xref></sup>. Moreover, <italic toggle="yes">KRAS</italic> mutant allele gains promote aggressive phenotypes in mouse models of pancreatic cancer<sup><xref ref-type="bibr" rid="CR29">29</xref></sup>. Whole-genome doubling (WGD), a hallmark of advanced cancer and a negative prognostic factor for OS, is a key driver promoting allelic imbalances leading to <italic toggle="yes">KRAS</italic> mutant dosage gains<sup><xref ref-type="bibr" rid="CR30">30</xref>,<xref ref-type="bibr" rid="CR31">31</xref></sup>. However, the prevalence of <italic toggle="yes">KRAS</italic> mutant allele dosage gains in PDAC and its association with disease progression remains poorly understood.</p>
        <p id="Par7">In this study, we leverage germline and somatic profiling of <italic toggle="yes">n</italic> = 2,336 patients to study the genomic and clinical correlates of outcomes for patients with PDAC. We incorporate clinical histories of <italic toggle="yes">n</italic> = 1,480 patients with long-term follow-up. We demonstrate that <italic toggle="yes">KRAS</italic> mutant dosage gains are a hallmark of disease progression and are prognostic of poor outcomes across all stages of PDAC.</p>
      </sec>
      <sec id="Sec2" sec-type="results">
        <title>Results</title>
        <sec id="Sec3">
          <title>MSK-IMPACT PDAC study cohort</title>
          <p id="Par8">This study included <italic toggle="yes">n</italic> = 2,336 patients with PDAC whose tumors were prospectively sequenced as part of standard care at Memorial Sloan Kettering Cancer Center (MSK; <xref rid="Sec12" ref-type="sec">Methods</xref>; Supplementary Tables <xref rid="MOESM2" ref-type="media">1</xref> and <xref rid="MOESM2" ref-type="media">2</xref>). At diagnosis, 31% (<italic toggle="yes">n</italic> = 731) of patients had resectable tumors, 25% (<italic toggle="yes">n</italic> = 581) had borderline resectable/locally advanced tumors and 44% (<italic toggle="yes">n</italic> = 1,024) had metastatic disease (Table <xref rid="Tab1" ref-type="table">1</xref>). Detailed clinical information including lines of treatments, time on treatment and best overall responses were manually curated for 63% (<italic toggle="yes">n</italic> = 1,480) of patients. The majority (61%) of the sequenced specimens were from primary PDAC, and 39% were from distant metastases. Median age at diagnosis was 67 years. Tumor specimens were sequenced to median depth of 606× using the FDA-authorized MSK-IMPACT clinical sequencing assay that encompasses up to 505 cancer genes<sup><xref ref-type="bibr" rid="CR32">32</xref></sup>. Somatic substitutions, insertions, deletions, focal copy number amplifications, homozygous deletions and fusions in select genes were identified using a clinically validated pipeline and annotated using the FDA-recognized precision oncology knowledge base, OncoKB<sup><xref ref-type="bibr" rid="CR33">33</xref>,<xref ref-type="bibr" rid="CR34">34</xref></sup>.<table-wrap id="Tab1" position="float" orientation="portrait"><label>Table 1</label><caption><p>MSK-IMPACT PDAC study cohort characteristics</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" colspan="1">Characteristics</th><th colspan="1" rowspan="1">Resectable</th><th colspan="1" rowspan="1">BR/LA</th><th colspan="1" rowspan="1">Metastatic</th><th colspan="1" rowspan="1">Overall</th></tr><tr><th colspan="1" rowspan="1"><italic toggle="yes">n</italic> = 731</th><th colspan="1" rowspan="1"><italic toggle="yes">n</italic> = 581</th><th colspan="1" rowspan="1"><italic toggle="yes">n</italic> = 1,024</th><th colspan="1" rowspan="1"><italic toggle="yes">n</italic> = 2,336</th></tr></thead><tbody><tr><td colspan="1" rowspan="1">Age at diagnosis (years)</td><td colspan="1" rowspan="1">68 (24–91)<sup>a</sup></td><td colspan="1" rowspan="1">66 (32–93)<sup>a</sup></td><td colspan="1" rowspan="1">66 (30–89)<sup>a</sup></td><td colspan="1" rowspan="1">67 (24–93)<sup>a</sup></td></tr><tr><td colspan="5" rowspan="1">Sex</td></tr><tr><td colspan="1" rowspan="1"> Male</td><td colspan="1" rowspan="1">382 (52%)<sup>b</sup></td><td colspan="1" rowspan="1">293 (50%)<sup>b</sup></td><td colspan="1" rowspan="1">539 (53%)<sup>b</sup></td><td colspan="1" rowspan="1">1,214 (52%)<sup>b</sup></td></tr><tr><td colspan="1" rowspan="1"> Female</td><td colspan="1" rowspan="1">349 (48%)</td><td colspan="1" rowspan="1">288 (50%)</td><td colspan="1" rowspan="1">485 (47%)</td><td colspan="1" rowspan="1">1,122 (48%)</td></tr><tr><td colspan="5" rowspan="1">Genetic ancestry</td></tr><tr><td colspan="1" rowspan="1"> European (EUR)</td><td colspan="1" rowspan="1">618 (85%)</td><td colspan="1" rowspan="1">443 (76%)</td><td colspan="1" rowspan="1">828 (81%)</td><td colspan="1" rowspan="1">1,889 (81%)</td></tr><tr><td colspan="1" rowspan="1"> Ashkenazi Jewish (ASJ)</td><td colspan="1" rowspan="1">198 (27%)</td><td colspan="1" rowspan="1">111 (19%)</td><td colspan="1" rowspan="1">263 (26%)</td><td colspan="1" rowspan="1">572 (25%)</td></tr><tr><td colspan="1" rowspan="1"> East Asian (EAS)</td><td colspan="1" rowspan="1">42 (5.7%)</td><td colspan="1" rowspan="1">27 (4.6%)</td><td colspan="1" rowspan="1">44 (4.3%)</td><td colspan="1" rowspan="1">113 (4.8%)</td></tr><tr><td colspan="1" rowspan="1"> African (AFR)</td><td colspan="1" rowspan="1">11 (1.5%)</td><td colspan="1" rowspan="1">36 (6.2%)</td><td colspan="1" rowspan="1">35 (3.4%)</td><td colspan="1" rowspan="1">82 (3.5%)</td></tr><tr><td colspan="1" rowspan="1"> South Asian (SAS)</td><td colspan="1" rowspan="1">8 (1.1%)</td><td colspan="1" rowspan="1">9 (1.5%)</td><td colspan="1" rowspan="1">22 (2.1%)</td><td colspan="1" rowspan="1">39 (1.7%)</td></tr><tr><td colspan="1" rowspan="1"> Admixed/other</td><td colspan="1" rowspan="1">52 (7.1%)</td><td colspan="1" rowspan="1">66 (11%)</td><td colspan="1" rowspan="1">95 (9.3%)</td><td colspan="1" rowspan="1">213 (9.1%)</td></tr><tr><td colspan="5" rowspan="1">Sample type</td></tr><tr><td colspan="1" rowspan="1"> Primary</td><td colspan="1" rowspan="1">651 (89%)</td><td colspan="1" rowspan="1">473 (81%)</td><td colspan="1" rowspan="1">300 (29%)</td><td colspan="1" rowspan="1">1,424 (61%)</td></tr><tr><td colspan="1" rowspan="1"> Metastasis</td><td colspan="1" rowspan="1">80 (11%)</td><td colspan="1" rowspan="1">108 (19%)</td><td colspan="1" rowspan="1">724 (71%)</td><td colspan="1" rowspan="1">912 (39%)</td></tr><tr><td colspan="1" rowspan="1">MSI-H</td><td colspan="1" rowspan="1">4 (0.5%)</td><td colspan="1" rowspan="1">3 (0.5%)</td><td colspan="1" rowspan="1">3 (0.3%)</td><td colspan="1" rowspan="1">10 (0.4%)</td></tr><tr><td colspan="1" rowspan="1">TMB-H</td><td colspan="1" rowspan="1">10 (1.4%)</td><td colspan="1" rowspan="1">11 (1.9%)</td><td colspan="1" rowspan="1">14 (1.4%)</td><td colspan="1" rowspan="1">35 (1.5%)</td></tr><tr><td colspan="5" rowspan="1">Genomic subtype</td></tr><tr><td colspan="1" rowspan="1"> <italic toggle="yes">KRAS</italic><sup><italic toggle="yes">MUT</italic></sup></td><td colspan="1" rowspan="1">690 (94%)</td><td colspan="1" rowspan="1">557 (96%)</td><td colspan="1" rowspan="1">962 (94%)</td><td colspan="1" rowspan="1">2,209 (95%)</td></tr><tr><td colspan="1" rowspan="1"> Other-MAPK<sup><italic toggle="yes">MUT</italic></sup></td><td colspan="1" rowspan="1">26 (3.6%)</td><td colspan="1" rowspan="1">9 (1.5%)</td><td colspan="1" rowspan="1">41 (4.0%)</td><td colspan="1" rowspan="1">76 (3.3%)</td></tr><tr><td colspan="1" rowspan="1"> MAPK<sup><italic toggle="yes">WT</italic></sup></td><td colspan="1" rowspan="1">15 (2.1%)</td><td colspan="1" rowspan="1">15 (2.6%)</td><td colspan="1" rowspan="1">21 (2.1%)</td><td colspan="1" rowspan="1">51 (2.2%)</td></tr><tr><td colspan="1" rowspan="1">Resection surgery performed</td><td colspan="1" rowspan="1">719 (98%)</td><td colspan="1" rowspan="1">221 (38%)</td><td colspan="1" rowspan="1">11 (1.1%)</td><td colspan="1" rowspan="1">951 (41%)</td></tr><tr><td colspan="1" rowspan="1">OS (months)</td><td colspan="1" rowspan="1">31 (28, 34)<sup>c</sup></td><td colspan="1" rowspan="1">19 (18, 20)<sup>c</sup></td><td colspan="1" rowspan="1">11 (10, 12)<sup>c</sup></td><td colspan="1" rowspan="1">18 (17, 19)<sup>c</sup></td></tr><tr><td colspan="1" rowspan="1">Clinical curation</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic> = 502</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic> = 362</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic> = 616</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic> = 1,480</td></tr><tr><td colspan="5" rowspan="1">Tumor location</td></tr><tr><td colspan="1" rowspan="1"> Head</td><td colspan="1" rowspan="1">356 (71%)</td><td colspan="1" rowspan="1">232 (64%)</td><td colspan="1" rowspan="1">260 (43%)</td><td colspan="1" rowspan="1">848 (58%)</td></tr><tr><td colspan="1" rowspan="1"> Body/tail</td><td colspan="1" rowspan="1">145 (29%)</td><td colspan="1" rowspan="1">130 (36%)</td><td colspan="1" rowspan="1">339 (57%)</td><td colspan="1" rowspan="1">614 (42%)</td></tr><tr><td colspan="1" rowspan="1">Smoking history (former/current)</td><td colspan="1" rowspan="1">265 (53%)</td><td colspan="1" rowspan="1">176 (49%)</td><td colspan="1" rowspan="1">288 (47%)</td><td colspan="1" rowspan="1">729 (49%)</td></tr><tr><td colspan="1" rowspan="1">First-line systemic therapy for metastatic/recurrent disease</td><td colspan="1" rowspan="1">288 (57%)</td><td colspan="1" rowspan="1">227 (63%)</td><td colspan="1" rowspan="1">508 (82%)</td><td colspan="1" rowspan="1">1,023 (69%)</td></tr><tr><td colspan="1" rowspan="1"> FOLFIRINOX</td><td colspan="1" rowspan="1">102 (35%)</td><td colspan="1" rowspan="1">39 (17%)</td><td colspan="1" rowspan="1">248 (49%)</td><td colspan="1" rowspan="1">389 (38%)</td></tr><tr><td colspan="1" rowspan="1"> Gemcitabine/nab-paclitaxel</td><td colspan="1" rowspan="1">88 (31%)</td><td colspan="1" rowspan="1">107 (47%)</td><td colspan="1" rowspan="1">188 (37%)</td><td colspan="1" rowspan="1">383 (37%)</td></tr><tr><td colspan="1" rowspan="1"> Other</td><td colspan="1" rowspan="1">98 (34%)</td><td colspan="1" rowspan="1">81 (36%)</td><td colspan="1" rowspan="1">72 (14%)</td><td colspan="1" rowspan="1">251 (25%)</td></tr></tbody></table><table-wrap-foot><p><sup>a</sup>Median (range); <sup>b</sup><italic toggle="yes">n</italic> (%); <sup>c</sup>median (95% CI).</p><p>BR/LA, borderline resectable/locally advanced.</p></table-wrap-foot></table-wrap></p>
        </sec>
        <sec id="Sec4">
          <title>Genomic characteristics of PDACs</title>
          <p id="Par9">Overall, 95% (<italic toggle="yes">n</italic> = 2,209) of tumors harbored oncogenic alterations in <italic toggle="yes">KRAS</italic> (Fig. <xref rid="Fig1" ref-type="fig">1a</xref>). Notably, this includes 1% (<italic toggle="yes">n</italic> = 22) of tumors in which <italic toggle="yes">KRAS</italic> mutations were identified with sequencing read evidence below thresholds for clinical reporting (<xref rid="Sec12" ref-type="sec">Methods</xref>). Expectedly, tumors WT for <italic toggle="yes">KRAS</italic> (<italic toggle="yes">KRAS</italic><sup><italic toggle="yes">WT</italic></sup>) were significantly enriched for oncogenic alterations in other MAPK pathway genes such as <italic toggle="yes">BRAF</italic>, <italic toggle="yes">NRAS</italic>, <italic toggle="yes">NF1</italic>, <italic toggle="yes">NTRK1</italic>, <italic toggle="yes">NTRK</italic><italic toggle="yes">3</italic>, <italic toggle="yes">FGFR2</italic>, <italic toggle="yes">ERBB2</italic>, <italic toggle="yes">MAP2K1, ROS1</italic>, <italic toggle="yes">MET</italic> and <italic toggle="yes">RAF1</italic> (collectively, 60% in <italic toggle="yes">KRAS</italic><sup><italic toggle="yes">WT</italic></sup> versus 7% in <italic toggle="yes">KRAS</italic><sup><italic toggle="yes">MUT</italic></sup>, <italic toggle="yes">P</italic> = 1.6 × 10<sup>−47</sup>; Fig. <xref rid="Fig1" ref-type="fig">1a</xref>). Seven of 26 oncogenic <italic toggle="yes">BRAF</italic> alterations were in-frame deletions between amino acids N486 and P490, which were nearly absent in <italic toggle="yes">BRAF</italic><sup><italic toggle="yes">MUT</italic></sup> tumors of melanoma (2 of 749) and thyroid cancer (0 of 473)<sup><xref ref-type="bibr" rid="CR14">14</xref>,<xref ref-type="bibr" rid="CR35">35</xref></sup> (Extended Data Fig. <xref rid="Fig6" ref-type="fig">1a</xref>). Moreover, gain-of-function oncogenic fusions involving MAPK genes were nearly exclusive to <italic toggle="yes">KRAS</italic><sup><italic toggle="yes">WT</italic></sup> tumors (3.2% in <italic toggle="yes">KRAS</italic><sup><italic toggle="yes">WT</italic></sup> versus 0.04% in <italic toggle="yes">KRAS</italic><sup><italic toggle="yes">MUT</italic></sup>, <italic toggle="yes">P</italic> = 2 × 10<sup>−35</sup>). Collectively, these other MAPK pathway-altered <italic toggle="yes">KRAS</italic><sup><italic toggle="yes">WT</italic></sup> (referred to as other-MAPK<sup><italic toggle="yes">MUT</italic></sup>) tumors comprise 3% (<italic toggle="yes">n</italic> = 76) of tumors. Finally, 2% (<italic toggle="yes">n</italic> = 51) of tumors were WT for any MAPK pathway alteration (referred to as MAPK<sup><italic toggle="yes">WT</italic></sup>). Hypothesizing that these MAPK<sup><italic toggle="yes">WT</italic></sup> tumors may harbor occult MAPK alterations that eluded detection by genomic sequencing, we performed transcriptome sequencing on 11 tumors where sufficient quality material was available. We identified activating fusions involving MAPK pathway genes <italic toggle="yes">BRAF</italic> and <italic toggle="yes">NRG1</italic> in two of 11 tumors (18%), suggesting that a substantial fraction of these tumors may be driven by alterations in non-MAPK pathway genes.<fig id="Fig1" position="float" orientation="portrait"><label>Fig. 1</label><caption><title>Somatic alteration landscape in PDAC.</title><p><bold>a</bold>, Oncoprint of somatic oncogenic alterations in selected genes (<xref rid="Sec12" ref-type="sec">Methods</xref>) across the following three genomic groups: <italic toggle="yes">KRAS</italic><sup><italic toggle="yes">MUT</italic></sup>, other-<italic toggle="yes">MAPK</italic><sup><italic toggle="yes">MUT</italic></sup> and <italic toggle="yes">MAPK</italic><sup><italic toggle="yes">WT</italic></sup>. Tile plot on the left indicates gene-level alteration enrichment in other-<italic toggle="yes">MAPK</italic><sup><italic toggle="yes">MUT</italic></sup> and MAPK<sup><italic toggle="yes">WT</italic></sup> subtypes compared to <italic toggle="yes">KRAS</italic><sup><italic toggle="yes">MUT</italic></sup> using two-sided Fisher exact test. An asterisk indicates that <italic toggle="yes">NRG1</italic> was not included in the enrichment analysis as it was profiled only in a subset of samples (<xref rid="Sec12" ref-type="sec">Methods</xref>). Other MAPK pathway genes include <italic toggle="yes">FGFR1</italic>, <italic toggle="yes">ERBB3</italic>, <italic toggle="yes">FGFR4</italic>, <italic toggle="yes">EGFR</italic>, <italic toggle="yes">RASA1</italic>, <italic toggle="yes">CBL</italic>, <italic toggle="yes">MAPK1</italic>, <italic toggle="yes">ALK</italic>, <italic toggle="yes">MAP2K2</italic>, <italic toggle="yes">ERRFI1</italic>, <italic toggle="yes">FLT3</italic>, <italic toggle="yes">JAK2</italic>, <italic toggle="yes">KIT</italic>, <italic toggle="yes">PDGFRA</italic>, <italic toggle="yes">RAC1</italic>, <italic toggle="yes">RET</italic>, <italic toggle="yes">RRAS2</italic>, <italic toggle="yes">SOS1</italic> and <italic toggle="yes">SPRED1</italic>. <bold>b</bold>, TMB-H and MSI-H prevalence by genomic subtype among tumor samples with ≥30% purity (<italic toggle="yes">n</italic> = 1,126). <bold>c</bold>, Age at diagnosis by genomic subtype with statistical comparison by two-sided Wilcoxon rank sum test (<italic toggle="yes">n</italic> = 2,336). Boxes represent the 25th, 50th (median) and 75th percentiles. Whiskers represent the minimum and maximum values, no further than 1.5× the interquartile range from the respective quartiles, with points beyond this range plotted individually. <bold>d</bold>, Kaplan–Meier curves showing OS for three genomic subtypes (<xref rid="Sec12" ref-type="sec">Methods</xref>). <bold>e</bold>, Forest plot of multivariable Cox proportional hazards model of OS in overall cohort (top, corresponding to <bold>d</bold>; <italic toggle="yes">n</italic> = 2,270) and among patients who did not receive targeted therapies (bottom; <italic toggle="yes">n</italic> = 2,187). Models were stratified by stage at diagnosis and adjusted for sex, age, ancestry, disease status, resection and interval between diagnosis and sample collection (full model shown in Extended Data Table <xref rid="Tab2" ref-type="table">1</xref>). <bold>f</bold>, Distribution of stage at diagnosis by genomic subtypes (<italic toggle="yes">n</italic> = 2,336). <bold>g</bold>, Prevalence of oncogenic alterations in <italic toggle="yes">GNAS</italic> and <italic toggle="yes">CDKN2A</italic>/<italic toggle="yes">CDKN2</italic><italic toggle="yes">B</italic> by stage at diagnosis among tumor samples with purity &gt;30% (<italic toggle="yes">n</italic> = 1076). <bold>h</bold>, Genetic ancestry by stage at diagnosis (<italic toggle="yes">n</italic> = 2,336). <bold>i</bold>, Tumor location (body/tail versus head) by stage (<italic toggle="yes">n</italic> = 1,462). Statistical significance is displayed as nominal <italic toggle="yes">P</italic> value for significant results after multiple test correction by FDR by Wilcoxon rank sum test for <bold>c</bold>, two-sided chi-squared test for <bold>h</bold> and two-sided Fisher’s exact test for <bold>b</bold>, <bold>g</bold> and <bold>i</bold>. Error bars represent 95th percentile binomial CI around the mean for <bold>b</bold>, <bold>g</bold> and <bold>i</bold>, and 95th percentile confidence intervals of the HR estimate (colored squares) for <bold>e</bold>. mo, month.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e1396" position="float" orientation="portrait" xlink:href="41591_2024_3362_Fig1_HTML.jpg"/></fig></p>
          <p id="Par10">Several significant differences in oncogenic alterations were identified among these three genomic subtypes of PDAC (<italic toggle="yes">KRAS</italic><sup><italic toggle="yes">MUT</italic></sup>, other-<italic toggle="yes">MAPK</italic><sup><italic toggle="yes">MUT</italic></sup> and <italic toggle="yes">MAPK</italic><sup><italic toggle="yes">WT</italic></sup>; Fig. <xref rid="Fig1" ref-type="fig">1a</xref> and Extended Data Fig. <xref rid="Fig6" ref-type="fig">1b</xref>). <italic toggle="yes">TP53</italic> mutations were significantly more frequent in <italic toggle="yes">KRAS</italic><sup><italic toggle="yes">MUT</italic></sup> (78%) compared to other<italic toggle="yes">-MAPK</italic><sup><italic toggle="yes">MUT</italic></sup> (38%, <italic toggle="yes">P</italic> = 1.4 × 10<sup>−9</sup>) and <italic toggle="yes">MAPK</italic><sup><italic toggle="yes">WT</italic></sup> (45%, <italic toggle="yes">P</italic> = 1.7 × 10<sup>−5</sup>) tumors. Interestingly, the <italic toggle="yes">TP53</italic> alteration rate among <italic toggle="yes">BRAF-</italic>mutated tumors was indistinguishable from that of <italic toggle="yes">KRAS</italic><sup><italic toggle="yes">MUT</italic></sup> tumors, supporting prior observations that <italic toggle="yes">BRAF</italic> mutations phenocopy <italic toggle="yes">KRAS</italic> mutations in pancreas cancers (78% in <italic toggle="yes">KRAS</italic><sup><italic toggle="yes">MUT</italic></sup> versus 73% in other-<italic toggle="yes">MAPK</italic><sup><italic toggle="yes">MUT</italic></sup>/<italic toggle="yes">BRAF</italic><sup><italic toggle="yes">MUT</italic></sup>, <italic toggle="yes">P</italic> = 0.6)<sup><xref ref-type="bibr" rid="CR36">36</xref></sup>. In contrast, <italic toggle="yes">GNAS</italic>, <italic toggle="yes">SMARCB1</italic> and <italic toggle="yes">PIK3CA</italic> alterations were significantly enriched in <italic toggle="yes">MAPK</italic><sup><italic toggle="yes">WT</italic></sup> tumors compared to <italic toggle="yes">KRAS</italic><sup><italic toggle="yes">MUT</italic></sup> (16% versus 2%, <italic toggle="yes">P</italic> = 1.5 × 10<sup>−5</sup>; 8% versus &lt;1%, <italic toggle="yes">P</italic> = 2.4 × 10<sup>−6</sup>; 10% versus 2%, <italic toggle="yes">P</italic> = 0.002, respectively). <italic toggle="yes">SMARCB1</italic> loss in <italic toggle="yes">KRAS</italic><sup><italic toggle="yes">WT</italic></sup> tumors has previously been associated with the monomorphic anaplastic subtype of undifferentiated carcinomas with rhabdoid features<sup><xref ref-type="bibr" rid="CR37">37</xref></sup>. Here, three of four <italic toggle="yes">SMARCB1</italic>-altered tumors in <italic toggle="yes">MAPK</italic><sup><italic toggle="yes">WT</italic></sup> subtype presented with aggressive histologic features of either poor differentiation or high grade, although none exhibited undifferentiated rhabdoid features. <italic toggle="yes">FOXP1</italic> and <italic toggle="yes">CREBBP</italic> alterations were nearly exclusive to other-<italic toggle="yes">MAPK</italic><sup><italic toggle="yes">MUT</italic></sup> (<italic toggle="yes">P</italic> = 5.3 × 10<sup>−5</sup> and <italic toggle="yes">P</italic> = 1.3 × 10<sup>−5</sup>, respectively, compared to <italic toggle="yes">KRAS</italic><sup><italic toggle="yes">MUT</italic></sup>; 0% prevalence in <italic toggle="yes">MAPK</italic><sup><italic toggle="yes">WT</italic></sup>). <italic toggle="yes">ARID1A</italic> alterations were enriched in other-<italic toggle="yes">MAPK</italic><sup><italic toggle="yes">MUT</italic></sup> compared to <italic toggle="yes">KRAS</italic><sup><italic toggle="yes">MUT</italic></sup> tumors (21% versus 8% prevalence, <italic toggle="yes">P</italic> = 2.4 × 10<sup>−4</sup>). High tumor mutational burden (10 or more nonsynonymous mutations per megabase, TMB-H) and microsatellite instability-high (MSI-H) tumors were infrequent (1.5% and 0.4%, respectively) and were enriched in <italic toggle="yes">KRAS</italic><sup><italic toggle="yes">WT</italic></sup> tumors (TMB-H—6.1% versus 1.8% in <italic toggle="yes">KRAS</italic><sup><italic toggle="yes">MUT</italic></sup> tumors, <italic toggle="yes">P</italic> = 0.03; MSI-H—3.7% versus 0.3%, <italic toggle="yes">P</italic> = 0.006; Fig. <xref rid="Fig1" ref-type="fig">1b</xref>)<sup><xref ref-type="bibr" rid="CR11">11</xref></sup>.</p>
          <p id="Par11">We next explored the association between various clinical characteristics and genomic subtypes of PDAC. Age at diagnosis significantly varied by <italic toggle="yes">KRAS</italic> alteration status. Compared to <italic toggle="yes">KRAS</italic><sup><italic toggle="yes">MUT</italic></sup> tumors (median age = 67 years), patients in other-<italic toggle="yes">MAPK</italic><sup><italic toggle="yes">MUT</italic></sup> (64 years, <italic toggle="yes">P</italic> = 0.03) and <italic toggle="yes">MAPK</italic><sup><italic toggle="yes">WT</italic></sup> (58 years, <italic toggle="yes">P</italic> = 2 × 10<sup>−4</sup>) subtypes presented with a significantly earlier age at diagnosis (Fig. <xref rid="Fig1" ref-type="fig">1c</xref> and Extended Data Fig. <xref rid="Fig6" ref-type="fig">1c</xref>). Patients with <italic toggle="yes">MAPK</italic><sup><italic toggle="yes">WT</italic></sup> tumors also had a significantly different ancestry composition compared to patients with <italic toggle="yes">KRAS</italic><sup><italic toggle="yes">MUT</italic></sup> (two-sided chi-squared test, <italic toggle="yes">P</italic> = 0.004) or other-<italic toggle="yes">MAPK</italic><sup><italic toggle="yes">MUT</italic></sup> tumors (<italic toggle="yes">P</italic> = 0.04), marked by elevated rates of East Asian patients in other-<italic toggle="yes">MAPK</italic><sup><italic toggle="yes">MUT</italic></sup> and patients with African ancestry in <italic toggle="yes">MAP</italic>K<sup><italic toggle="yes">WT</italic></sup> subtypes, indicating the possibility of unrecognized driver alterations in underrepresented patient populations (Fig. <xref rid="Fig1" ref-type="fig">1c</xref>). No significant differences were observed in gene-level alteration frequencies across sex or ancestry group (Extended Data Fig. <xref rid="Fig6" ref-type="fig">1d,e</xref>).</p>
          <p id="Par12">To evaluate differences in OS across the three genomic subtypes, we used a multivariable Cox proportional hazards model stratified by clinical stage accounting for age, resection status, disease status, sex and genetic ancestry (<xref rid="Sec12" ref-type="sec">Methods</xref>). We observed that patients with other-<italic toggle="yes">MAPK</italic><sup><italic toggle="yes">MUT</italic></sup> and <italic toggle="yes">MAPK</italic><sup><italic toggle="yes">WT</italic></sup> tumors had significantly longer OS compared to patients with <italic toggle="yes">KRAS</italic><sup><italic toggle="yes">MUT</italic></sup> tumors (<italic toggle="yes">KRAS</italic><sup><italic toggle="yes">MUT</italic></sup> versus <italic toggle="yes">MAPK</italic><sup><italic toggle="yes">WT</italic></sup>—adjusted hazard ratio (HR<sub>adj</sub>) = 0.69, CI = 0.48–0.98, <italic toggle="yes">P</italic> = 0.041; <italic toggle="yes">KRAS</italic><sup><italic toggle="yes">MUT</italic></sup> versus other-<italic toggle="yes">MAPK</italic><sup><italic toggle="yes">MUT</italic></sup>—HR<sub>adj</sub> = 0.69, CI = 0.51–0.93, <italic toggle="yes">P</italic> = 0.014; Fig. <xref rid="Fig1" ref-type="fig">1d,e</xref>, top, and Extended Data Table <xref rid="Tab2" ref-type="table">1</xref>). Improved outcomes among <italic toggle="yes">KRAS</italic><sup><italic toggle="yes">WT</italic></sup> patients have been attributed to higher prevalence of targetable alterations in this group<sup><xref ref-type="bibr" rid="CR14">14</xref></sup>. After excluding patients who received targeted therapies (<italic toggle="yes">n</italic> = 83), we noted that OS was indistinguishable between patients with <italic toggle="yes">KRAS</italic><sup><italic toggle="yes">MUT</italic></sup> and other-MAPK<sup><italic toggle="yes">MUT</italic></sup> tumors (HR<sub>adj</sub> = 0.95, <italic toggle="yes">P</italic> = 0.7), whereas patients with MAPK<sup><italic toggle="yes">WT</italic></sup> tumors had significantly better OS (HR<sub>adj</sub> = 0.68, CI = 0.47–0.97, <italic toggle="yes">P</italic> = 0.035; Fig. <xref rid="Fig1" ref-type="fig">1e</xref>, bottom, and Extended Data Table <xref rid="Tab2" ref-type="table">1</xref>). This suggests that the well-recognized OS advantage among patients with <italic toggle="yes">KRAS</italic><sup><italic toggle="yes">WT</italic></sup> tumors extends beyond those with targetable alterations.</p>
        </sec>
        <sec id="Sec5">
          <title>Somatic and clinical characteristics across clinical stages</title>
          <p id="Par13">The stage at diagnosis was similar across genomic subtypes (Fig. <xref rid="Fig1" ref-type="fig">1f</xref>). Among other genes, <italic toggle="yes">GNAS</italic>, which is associated with IPMN precursor lesions with improved outcomes over PanIN-derived PDACs, was significantly enriched in resectable tumors (7.9%) while <italic toggle="yes">CDKN2A</italic>/<italic toggle="yes">CDKN2</italic><italic toggle="yes">B</italic> alteration rate increased with disease progression ranging from 44% in resectable disease to 60% in metastatic tumors (<italic toggle="yes">P</italic> = 6.9 × 10<sup>−5</sup>; Fig. <xref rid="Fig1" ref-type="fig">1g</xref> and Extended Data Fig. <xref rid="Fig7" ref-type="fig">2a</xref>)<sup><xref ref-type="bibr" rid="CR38">38</xref>,<xref ref-type="bibr" rid="CR39">39</xref></sup>. No pathway-level differences in alteration rates were observed across disease stages (Extended Data Fig. <xref rid="Fig7" ref-type="fig">2b</xref>). Patients with African ancestry presented with more advanced disease (87%) compared to other ancestries (67% in European and 63% in East Asian; Fig. <xref rid="Fig1" ref-type="fig">1h</xref>). The location of the tumor in the pancreas was also strongly associated with stage—resectable tumors most commonly arose in the head (71%), while metastatic tumors frequently arose in the body/tail (57%; Fig. <xref rid="Fig1" ref-type="fig">1i</xref> and Extended Data Fig. <xref rid="Fig7" ref-type="fig">2d</xref>).</p>
        </sec>
        <sec id="Sec6">
          <title>Germline mutations and concomitant somatic alterations</title>
          <p id="Par14">Ten percent of all patients harbored germline pathogenic mutations in high- and moderate-penetrance genes, including <italic toggle="yes">BRCA2</italic> (<italic toggle="yes">n</italic> = 86, 3.7%), <italic toggle="yes">BRCA1</italic> (<italic toggle="yes">n</italic> = 41, 1.8%), <italic toggle="yes">ATM</italic> (<italic toggle="yes">n</italic> = 41, 1.8%) and <italic toggle="yes">PALB2</italic> (<italic toggle="yes">n</italic> = 11, 0.5%; Fig. <xref rid="Fig2" ref-type="fig">2a</xref>). Lynch syndrome with germline mutations in mismatch repair genes <italic toggle="yes">MLH1</italic>, <italic toggle="yes">MSH2</italic>, <italic toggle="yes">MSH6</italic> and <italic toggle="yes">PMS2</italic> was identified in 17 patients (0.7%), of which six (35%) presented with MSI inferred from sequencing<sup><xref ref-type="bibr" rid="CR40">40</xref>,<xref ref-type="bibr" rid="CR41">41</xref></sup>. Although pathogenic germline variants in <italic toggle="yes">BRCA1</italic>, <italic toggle="yes">BRCA</italic><italic toggle="yes">2</italic> and <italic toggle="yes">CHEK2</italic> were more frequent among those with Ashkenazi Jewish (ASJ) ancestry, <italic toggle="yes">ATM</italic> and <italic toggle="yes">PALB2</italic> germline variants were more common among those without ASJ ancestry (Extended Data Fig. <xref rid="Fig8" ref-type="fig">3a</xref>). Patients with metastatic disease presented with slightly elevated rates of germline pathogenic variants compared to those with earlier stage disease (12.3% versus 9.6%, <italic toggle="yes">P</italic> = 0.01), driven primarily by an enrichment in <italic toggle="yes">BRCA1</italic>/<italic toggle="yes">BRCA</italic><italic toggle="yes">2</italic> alterations in tumors from patients with metastatic disease (Extended Data Fig. <xref rid="Fig8" ref-type="fig">3b</xref>). Germline pathogenic variants were more frequent among <italic toggle="yes">MAPK</italic><sup><italic toggle="yes">WT</italic></sup> (25%) compared to other-<italic toggle="yes">MAPK</italic><sup><italic toggle="yes">MUT</italic></sup> (17%, <italic toggle="yes">P</italic> = 0.05) and <italic toggle="yes">KRAS</italic><sup><italic toggle="yes">MUT</italic></sup> (10%, <italic toggle="yes">P</italic> = 0.001). This elevated rate was underpinned by higher prevalence of pathogenic germline mutations in <italic toggle="yes">ATM</italic> (<italic toggle="yes">gATM</italic>) in <italic toggle="yes">MAPK</italic><sup><italic toggle="yes">WT</italic></sup> patients compared to <italic toggle="yes">KRAS</italic><sup><italic toggle="yes">MUT</italic></sup> (18% versus 1.4%, <italic toggle="yes">P</italic> = 2 × 10<sup>−6</sup>; Fig. <xref rid="Fig2" ref-type="fig">2a</xref>). Germline <italic toggle="yes">ATM</italic> mutations also co-occurred with somatic <italic toggle="yes">GNAS</italic> mutations, possibly attributed to IPMN-derived PDAC<sup><xref ref-type="bibr" rid="CR42">42</xref>,<xref ref-type="bibr" rid="CR43">43</xref></sup>. Notably, this increased <italic toggle="yes">gATM</italic> burden in <italic toggle="yes">MAPK</italic><sup><italic toggle="yes">WT</italic></sup> tumors was specific to mutations of germline origin as the rate of somatic <italic toggle="yes">ATM</italic> mutations (<italic toggle="yes">sATM</italic>) in <italic toggle="yes">MAPK</italic><sup><italic toggle="yes">WT</italic></sup> tumors was not different from the other genomic subtypes (<italic toggle="yes">P</italic> &gt; 0.05; Fig. <xref rid="Fig2" ref-type="fig">2a</xref>)<sup><xref ref-type="bibr" rid="CR43">43</xref></sup>.<fig id="Fig2" position="float" orientation="portrait"><label>Fig. 2</label><caption><title>Germline alteration landscape in PDAC.</title><p><bold>a</bold>, Oncoprint of pathogenic germline variants and somatic oncogenic alterations by genomic subtype. Displayed <italic toggle="yes">sBRCA2</italic>, <italic toggle="yes">sBRCA1</italic> and <italic toggle="yes">sATM</italic> alterations are exclusively in sporadic tumors without a pathogenic germline variant in these genes. An asterisk indicates that MMR includes <italic toggle="yes">MSH2</italic>, <italic toggle="yes">MSH6</italic>, <italic toggle="yes">MLH1</italic> and <italic toggle="yes">PMS2</italic>. ‘Other’ includes all other pathogenic variants in high- and moderate-penetrance genes—<italic toggle="yes">BRIP1</italic>, <italic toggle="yes">CDKN2A</italic>, <italic toggle="yes">CHEK2</italic>, <italic toggle="yes">FLCN</italic>, <italic toggle="yes">HOXB13</italic>, <italic toggle="yes">MITF</italic>, <italic toggle="yes">NBN</italic>, <italic toggle="yes">NF1</italic>, <italic toggle="yes">RAD51D</italic>, <italic toggle="yes">SDHA</italic>, <italic toggle="yes">SMARCA4</italic>, <italic toggle="yes">STK11</italic>, <italic toggle="yes">TP53</italic> and <italic toggle="yes">TSC1</italic>. Tiles at left show gene-level enrichment in other-<italic toggle="yes">MAPK</italic><sup><italic toggle="yes">MUT</italic></sup> and <italic toggle="yes">MAPK</italic><sup><italic toggle="yes">WT</italic></sup> subtypes compared to <italic toggle="yes">KRAS</italic><sup><italic toggle="yes">MUT</italic></sup> by two-sided Fisher’s exact test. <bold>b</bold>, Rates of loss of heterozygosity (<xref rid="Sec12" ref-type="sec">Methods</xref>) at <italic toggle="yes">BRCA2</italic>, <italic toggle="yes">BRCA1</italic>, <italic toggle="yes">ATM, PALB2</italic>, MMR and other loci (as in <bold>a</bold>) in <italic toggle="yes">n</italic> = 1,946 patients with germline pathogenic variants, somatic mutations in sporadic cancers and patients WT for any alteration in corresponding genes (comparisons by two-sided Fisher's exact test). Error bars represent 95th percentile binomial confidence intervals around the mean. <bold>c</bold>, Pattern of germline and somatic <italic toggle="yes">ATM</italic> and <italic toggle="yes">TP53</italic> alterations, with monoallelic or biallelic zygosity status indicated. <bold>d</bold>, Pattern of germline and somatic <italic toggle="yes">BRCA1</italic> and <italic toggle="yes">TP53</italic> alterations, as in <bold>c</bold>.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e2220" position="float" orientation="portrait" xlink:href="41591_2024_3362_Fig2_HTML.jpg"/></fig></p>
          <p id="Par15">Strong selection for biallelic inactivation through copy number loss of heterozygosity (LOH) was observed in <italic toggle="yes">gBRCA1</italic>, <italic toggle="yes">gBRCA2</italic>, <italic toggle="yes">gPALB2</italic> and <italic toggle="yes">gATM</italic> carriers (Fig. <xref rid="Fig2" ref-type="fig">2b</xref>; <xref rid="Sec12" ref-type="sec">Methods</xref>). The rate of LOH was higher in sporadic tumors with somatic mutations in <italic toggle="yes">BRCA2</italic> and <italic toggle="yes">ATM</italic> compared to tumors without mutations in these genes, but lower compared to LOH rates observed in germline carriers<sup><xref ref-type="bibr" rid="CR18">18</xref>,<xref ref-type="bibr" rid="CR44">44</xref>–<xref ref-type="bibr" rid="CR46">46</xref></sup>. As previously reported, <italic toggle="yes">gATM</italic> and <italic toggle="yes">sTP53</italic> mutations were mutually exclusive (<italic toggle="yes">P</italic> = 4 × 10<sup>−11</sup>), and <italic toggle="yes">sTP53</italic> alterations and <italic toggle="yes">gBRCA1</italic> mutations co-occurred (<italic toggle="yes">P</italic> = 4 × 10<sup>−7</sup>)<sup><xref ref-type="bibr" rid="CR44">44</xref>,<xref ref-type="bibr" rid="CR47">47</xref></sup>. Interestingly, taking zygosity into account, irrespective of origin of mutation (somatic or germline), tumors with biallelic loss of <italic toggle="yes">ATM</italic> were notably depleted for <italic toggle="yes">sTP53</italic> mutations (Fig. <xref rid="Fig2" ref-type="fig">2c</xref>)<sup><xref ref-type="bibr" rid="CR44">44</xref></sup>. In contrast, both monoallelic and biallelic <italic toggle="yes">BRCA1</italic> mutations showed equal co-occurrence with <italic toggle="yes">sTP53</italic> mutations (Fig. <xref rid="Fig2" ref-type="fig">2d</xref>).</p>
        </sec>
        <sec id="Sec7">
          <title>Mutant allelic imbalance at KRAS locus</title>
          <p id="Par16">We next evaluated the extent to which <italic toggle="yes">KRAS</italic><sup><italic toggle="yes">MUT</italic></sup> tumors harbor copy number allelic imbalance (unequal number of maternal and paternal alleles) at <italic toggle="yes">KRAS</italic> locus and mechanism by which allelic imbalance occurs<sup><xref ref-type="bibr" rid="CR28">28</xref></sup> (Fig. <xref rid="Fig3" ref-type="fig">3a</xref>). To increase sensitivity and specificity to infer allelic state, we restricted our analysis to <italic toggle="yes">n</italic> = 1,157 <italic toggle="yes">KRAS</italic><sup><italic toggle="yes">MUT</italic></sup> tumors with sufficiently high-quality copy number fits (<xref rid="Sec12" ref-type="sec">Methods</xref>). Of these 1,157 tumors, 42% presented with allelic imbalance at <italic toggle="yes">KRAS</italic> locus including focal or arm-level amplifications (4%, <italic toggle="yes">n</italic> = 48), shallow gains (16%, <italic toggle="yes">n</italic> = 186), copy-neutral LOH (CNLOH; 5%, <italic toggle="yes">n</italic> = 62), LOH (11%, <italic toggle="yes">n</italic> = 129) and losses after WGD (5%, <italic toggle="yes">n</italic> = 56; Fig. <xref rid="Fig3" ref-type="fig">3b</xref>). Selection for <italic toggle="yes">KRAS</italic> mutant allele was widespread with 93% of all imbalance events preferentially gaining or retaining the mutant allele. One in five (19%) <italic toggle="yes">KRAS</italic><sup><italic toggle="yes">MUT</italic></sup> tumors harbored WGD, and the rate of allelic imbalance was substantially higher in WGD tumors (75%) versus non-WGD tumors (30%; Fig. <xref rid="Fig3" ref-type="fig">3c</xref>). Consequently, <italic toggle="yes">KRAS</italic><sup><italic toggle="yes">MUT</italic></sup> allele gain was more than twice as common in WGD tumors (43% with three or more mutant copies) compared to non-WGD tumors (20% with two or more mutant copies; Fig. <xref rid="Fig3" ref-type="fig">3d</xref>). Moreover, the magnitude of mutant-allele gains also varied by WGD status. Tumors with two or more mutant-allele gains (that is, ≥4 mutant-alleles in WGD and ≥3 mutant-alleles in non-WGD tumors) were substantially more frequent in tumors with WGD (20% versus 6% in non-WGD tumors).<fig id="Fig3" position="float" orientation="portrait"><label>Fig. 3</label><caption><title><italic toggle="yes">KRAS</italic> mutant allele dosage gains and their prognostic implications.</title><p><bold>a</bold>, Schematic of copy number states as related to mutant copy gain and retention of the WT allele in cases of allelic imbalance. The ‘Loss after WGD’ state indicates any copy number losses of the minor allele following WGD but excludes complete losses of the minor allele which are considered as CNLOH (<xref rid="Sec12" ref-type="sec">Methods</xref>). <bold>b</bold>, Overall prevalence of copy number states in <italic toggle="yes">KRAS</italic><sup><italic toggle="yes">MUT</italic></sup> tumors. <bold>c</bold>, Prevalence of copy number state with allele selection by WGD status. <bold>d</bold>, Estimated number of gained mutant <italic toggle="yes">KRAS</italic> copies by WGD status. Tumors in which the WT allele was gained, or the mutant allele was lost are not shown here (<italic toggle="yes">n</italic> = 32, ‘WT selection’ in <bold>c</bold>). <bold>e</bold>, Kaplan–Meier curves of OS stratified by the number of mutant <italic toggle="yes">KRAS</italic> copies in diploid (non-WGD) <italic toggle="yes">KRAS</italic><sup><italic toggle="yes">MUT</italic></sup> tumors excluding tumors with gain of WT allele (<italic toggle="yes">n</italic> = 865; Extended Data Table <xref rid="Tab3" ref-type="table">2</xref>). <bold>f</bold>, Prevalence of <italic toggle="yes">KRAS</italic> copy number states (left) and mutant copy gain (two or more mutant copies; right) by clinical stage at diagnosis (<italic toggle="yes">n</italic> = 874). Statistical comparisons show pairwise two-sided Fisher's exact tests. <bold>g</bold>, Kaplan–Meier curves of OS stratified by the number of mutant <italic toggle="yes">KRAS</italic> copies as in <bold>e</bold>, within each clinical stage at diagnosis (Extended Data Table <xref rid="Tab3" ref-type="table">2</xref>). <bold>h</bold>, Kaplan–Meier curves of OS stratified by copy number state in diploid (non-WGD) <italic toggle="yes">KRAS</italic><sup><italic toggle="yes">MUT</italic></sup> tumors excluding tumors with gain of WT allele (<italic toggle="yes">n</italic> = 865; Extended Data Table <xref rid="Tab4" ref-type="table">3</xref>). <bold>i</bold>, Forest plots of multivariable Cox proportional hazards model of OS by <italic toggle="yes">KRAS</italic> copy number state as in <bold>h</bold>, within each clinical stage at diagnosis (<italic toggle="yes">n</italic> = 865; Extended Data Table <xref rid="Tab4" ref-type="table">3</xref>). Error bars represent 95th percentile binomial CI in <bold>f</bold>, and 95th percentile CI of the HR in <bold>i</bold>. Displayed <italic toggle="yes">P</italic> values in <bold>e</bold>, <bold>g</bold>–<bold>i</bold> are two-sided nominal <italic toggle="yes">P</italic> values from multivariable Cox proportional hazards models that include age, sex, ancestry and time from diagnosis to sample collection as covariates. Models for <bold>e</bold> and <bold>h</bold> are stratified by clinical stage at diagnosis (Extended Data Tables <xref rid="Tab4" ref-type="table">3</xref> and <xref rid="Tab5" ref-type="table">4</xref>). R, resectable; M, metastatic.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e2538" position="float" orientation="portrait" xlink:href="41591_2024_3362_Fig3_HTML.jpg"/></fig></p>
        </sec>
        <sec id="Sec8">
          <title>KRAS mutant dosage and prognostic effect</title>
          <p id="Par17"><italic toggle="yes">KRAS</italic><sup><italic toggle="yes">MUT</italic></sup> PDAC tumors with a gain of mutant-allele present with aggressive phenotypes in mice and have worse OS in patients<sup><xref ref-type="bibr" rid="CR28">28</xref>,<xref ref-type="bibr" rid="CR29">29</xref></sup>. Herein we sought to evaluate the prognostic effect of dosage gains of <italic toggle="yes">KRAS</italic><sup><italic toggle="yes">MUT</italic></sup> on OS across disease stages. To mitigate the confounding effects of WGD, a notable negative predictor of OS, we limited our analysis to non-WGD tumors (<italic toggle="yes">n</italic> = 934; <xref rid="Sec12" ref-type="sec">Methods</xref>)<sup><xref ref-type="bibr" rid="CR30">30</xref></sup>. In a multivariable Cox model of OS stratified by stage at diagnosis and adjusted for sex, age at diagnosis, genetic ancestry, and time from diagnosis to sample collection, we observed that patients with tumors with any gain of <italic toggle="yes">KRAS</italic><sup><italic toggle="yes">MUT</italic></sup> allele had significantly lower OS compared to those with tumors with one mutant allele (<italic toggle="yes">P</italic> = 3.5 × 10<sup>−7</sup>, HR<sub>adj</sub> = 1.7, CI = 1.4–2.0; Fig. <xref rid="Fig3" ref-type="fig">3e</xref> and Extended Data Table <xref rid="Tab3" ref-type="table">2</xref>). Although no significant difference in OS was observed between patients with tumors harboring two mutant copies (<italic toggle="yes">n</italic> = 130) and those with 3 or more mutant copies (<italic toggle="yes">n</italic> = 49) when stratifying by stage, a larger sample size may be required to identify incremental effects of additional dosage gains on prognosis.</p>
          <p id="Par18"><italic toggle="yes">KRAS</italic><sup><italic toggle="yes">MUT</italic></sup> allele dosage gains were more frequent in metastatic tumors (29%) compared to tumors from patients with locally advanced (14%) or resectable (8%) disease and were strongly correlated with advanced disease (<italic toggle="yes">P</italic> = 5.7 × 10<sup>−11</sup>, chi-squared trend test; Fig. <xref rid="Fig3" ref-type="fig">3f</xref>). This supports prior observations in mouse models with <italic toggle="yes">KRAS</italic> G12D dosage gains, which demonstrated amplified RAS transcriptional programs and exhibited rapid disease progression<sup><xref ref-type="bibr" rid="CR29">29</xref></sup>. Notably, we observe the poor prognostic effect of mutant allele dosage across disease stages (Fig. <xref rid="Fig3" ref-type="fig">3g</xref>). Among patients with resectable disease, the median OS was significantly lower in patients with tumors harboring dosage gains of the mutant-allele compared to those whose tumors had one mutant copy (23 months versus 32 months; HR<sub>adj</sub> = 2.16, CI = 1.1–4.3, <italic toggle="yes">P</italic> = 0.03). Similarly, among patients with metastatic disease, <italic toggle="yes">KRAS</italic><sup><italic toggle="yes">MUT</italic></sup> dosage gains were associated with 5 months shorter OS compared to patients whose tumors had a single <italic toggle="yes">KRAS</italic><sup><italic toggle="yes">MUT</italic></sup> copy (8.5 months versus 13 months; HR<sub>adj</sub> = 1.63, CI = 1.3–2.1, <italic toggle="yes">P</italic> = 4.9 × 10<sup>−5</sup>; Extended Data Table <xref rid="Tab3" ref-type="table">2</xref>).</p>
          <p id="Par19">The WT <italic toggle="yes">KRAS</italic> allele in <italic toggle="yes">KRAS</italic><sup><italic toggle="yes">MUT</italic></sup> tumors has previously been shown to act as a tumor suppressor<sup><xref ref-type="bibr" rid="CR14">14</xref>,<xref ref-type="bibr" rid="CR48">48</xref>,<xref ref-type="bibr" rid="CR49">49</xref></sup>. Tumors adapt during disease progression by losing the WT allele or acquiring additional copies of the mutant allele<sup><xref ref-type="bibr" rid="CR50">50</xref>,<xref ref-type="bibr" rid="CR51">51</xref></sup>. We therefore hypothesized that patients with <italic toggle="yes">KRAS</italic><sup><italic toggle="yes">MUT</italic></sup> tumors with either gain of mutant or with loss of WT should have substantially worse prognosis compared to patients with balanced <italic toggle="yes">KRAS</italic><sup><italic toggle="yes">MUT</italic></sup> tumors. However, we observed that only the <italic toggle="yes">KRAS</italic><sup><italic toggle="yes">MUT</italic></sup> allele dosage is a notable predictor of poor prognosis, independent of loss or retention of the WT allele. Among patients with <italic toggle="yes">KRAS</italic><sup><italic toggle="yes">MUT</italic></sup> tumors that have a single copy of the mutant allele, OS was indistinguishable between patients with tumors that retained the WT allele and those that lost the WT allele (Fig. <xref rid="Fig3" ref-type="fig">3h</xref> and Extended Data Table <xref rid="Tab4" ref-type="table">3</xref>). Both groups of patients also demonstrated significantly improved OS compared to patients with <italic toggle="yes">KRAS</italic><sup><italic toggle="yes">MUT</italic></sup> tumors with mutant-allele gains, irrespective of WT allele status. However, interestingly, among patients with tumors with <italic toggle="yes">KRAS</italic><sup><italic toggle="yes">MUT</italic></sup> dosage gains, patients with tumors with loss of WT had significantly worse OS compared to patients with tumors with WT retained (HR<sub>adj</sub> = 1.64, 95% confidence interval (CI) = 1.1–2.5, <italic toggle="yes">P</italic> = 0.016 for CNLOH with gain-of-mutant as reference). This effect was most prominent among metastatic tumors (Fig. <xref rid="Fig3" ref-type="fig">3i</xref> and Extended Data Table <xref rid="Tab4" ref-type="table">3</xref>). Taken together, our findings indicate a synergistic effect of losing the WT allele in tumors with <italic toggle="yes">KRAS</italic><sup><italic toggle="yes">MUT</italic></sup> dosage gains in promoting worse disease outcomes.</p>
        </sec>
        <sec id="Sec9">
          <title>KRAS mutant allele-specific differences</title>
          <p id="Par20">Over 98% of all codon substitutions in <italic toggle="yes">KRAS</italic> were at G12 (91%) and Q61 (7%) residues (Fig. <xref rid="Fig4" ref-type="fig">4a</xref>). Among <italic toggle="yes">KRAS</italic><sup><italic toggle="yes">MUT</italic></sup> tumors, G12D (41%) was the most abundant hotspot mutation followed by G12V (32%), and G12R (16%). Fourteen tumors (0.6%) harbored multiple <italic toggle="yes">KRAS</italic> hotspot mutations (Extended Data Fig. <xref rid="Fig9" ref-type="fig">4a,b</xref>). No significant differences were observed in <italic toggle="yes">KRAS</italic> variant prevalence by stage at diagnosis, sex, genetic ancestry or age at diagnosis (Fig. <xref rid="Fig4" ref-type="fig">4a</xref> and Extended Data Fig. <xref rid="Fig9" ref-type="fig">4c</xref>). Patients with G12R-mutant tumors compared to those with G12D-mutant tumors were less likely to have a smoking history (40% versus 55%, <italic toggle="yes">P</italic> = 2 × 10<sup>−4</sup>; Extended Data Fig. <xref rid="Fig9" ref-type="fig">4c</xref>).<fig id="Fig4" position="float" orientation="portrait"><label>Fig. 4</label><caption><title>Differential genomic and prognostic features of <italic toggle="yes">KRAS</italic> variants.</title><p><bold>a</bold>, Top, prevalence of the most common <italic toggle="yes">KRAS</italic> variants among all <italic toggle="yes">KRAS</italic><sup><italic toggle="yes">MUT</italic></sup> tumors. Bottom, disease stage composition, distributions of allelic imbalances and <italic toggle="yes">KRAS</italic><sup><italic toggle="yes">MUT</italic></sup> allele dosage gains across patients with different <italic toggle="yes">KRAS</italic> variants. Allelic imbalances and dosage gains are shown only for non-WGD tumors as indicated. Displayed nominal <italic toggle="yes">P</italic> value denotes statistical comparison of distribution of gene-level copy number state by two-sided chi-squared test. Tumors with multiple driver <italic toggle="yes">KRAS</italic> mutations are not shown here (<italic toggle="yes">n</italic> = 14; Extended Data Fig. <xref rid="Fig9" ref-type="fig">4a,b</xref>). Error bars for <italic toggle="yes">KRAS</italic><sup><italic toggle="yes">MUT</italic></sup> CN represent 95th percentile binomial CIs around the mean. <bold>b</bold>, Kaplan–Meier curve of OS among <italic toggle="yes">KRAS</italic> G12D, G12V and G12R variants. Displayed <italic toggle="yes">P</italic> values are nominal two-sided <italic toggle="yes">P</italic> values from a multivariable Cox proportional hazards model stratified by stage at diagnosis and accounting for <italic toggle="yes">KRAS</italic> mutant allele copy number, sex, age, ancestry, disease status and interval from diagnosis to sample collection (Extended Data Table <xref rid="Tab5" ref-type="table">4</xref>). <bold>c</bold>, Oncoprint showing the prevalence of co-occurring <italic toggle="yes">TP53, CDKN2A</italic>/<italic toggle="yes">CDKN2</italic><italic toggle="yes">B, SMAD4, ARID1A, AKT2</italic>, and <italic toggle="yes">RB1</italic> mutations and TGFβ, SWI/SNF, PI3K and RTK–Ras signaling pathway alterations among <italic toggle="yes">KRAS</italic> G12D, G12R and G12V tumors. Tiles on the left indicate pairwise enrichment testing of co-occurring alterations between <italic toggle="yes">KRAS</italic> G12D versus G12R and G12V mutant tumors by two-sided Fisher's exact test.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e2875" position="float" orientation="portrait" xlink:href="41591_2024_3362_Fig4_HTML.jpg"/></fig></p>
          <p id="Par21">In a multivariable Cox model stratified by stage at diagnosis and accounting for mutant <italic toggle="yes">KRAS</italic> gain, we evaluated the differences in OS among patients with tumors harboring the most common <italic toggle="yes">KRAS</italic> variants (Extended Data Table <xref rid="Tab5" ref-type="table">4</xref>). Patients with <italic toggle="yes">KRAS</italic> G12R-mutant tumors had significantly better OS compared with G12D-driven cancers (HR<sub>adj</sub> = 0.78, CI = 0.67–0.92, <italic toggle="yes">P</italic> = 0.003; Fig. <xref rid="Fig4" ref-type="fig">4b</xref>). Among patients with de novo metastatic disease, those with <italic toggle="yes">KRAS</italic> G12D, G12V or G12R mutations did not show significant differences in progression-free survival between those who received first-line FOLFIRINOX compared to gemcitabine-based therapy (Extended Data Fig. <xref rid="Fig9" ref-type="fig">4e,f</xref>). Despite the noted differences in functional effects of different <italic toggle="yes">KRAS</italic> alleles, the rates of genome doubling and mutant-allele dosage gains were similar across alleles (Fig. <xref rid="Fig4" ref-type="fig">4a</xref> and Extended Data Fig. <xref rid="Fig9" ref-type="fig">4d</xref>)<sup><xref ref-type="bibr" rid="CR52">52</xref></sup>. However, in comparing G12D and G12R tumors, <italic toggle="yes">SMAD4</italic> alterations were significantly more common in G12R tumors (30% in G12R versus 21% in G12D, <italic toggle="yes">P</italic> = 0.001), while <italic toggle="yes">ARID1A</italic> alterations were more frequent in G12D tumors (10% in G12D versus 5% in G12R, <italic toggle="yes">P</italic> = 0.002; Fig. <xref rid="Fig4" ref-type="fig">4c</xref>)<sup><xref ref-type="bibr" rid="CR53">53</xref></sup>.</p>
        </sec>
        <sec id="Sec10">
          <title>Clinical actionability in PDAC</title>
          <p id="Par22">Approximately 10% of patients with PDAC harbored standard-of-care biomarkers of response to targeted therapies as defined by OncoKB level 1 (for example, MSI-H, TMB-H and oncogenic MAPK pathway alterations in <italic toggle="yes">NTRK1</italic>, <italic toggle="yes">NTRK</italic><italic toggle="yes">3</italic> and <italic toggle="yes">RET</italic>) and level 2 (<italic toggle="yes">KRAS G12C</italic>, <italic toggle="yes">BRCA1</italic>/<italic toggle="yes">BRCA</italic><italic toggle="yes">2</italic>, <italic toggle="yes">PALB2</italic>; OncoKB version 4.12, December 2023)<sup><xref ref-type="bibr" rid="CR34">34</xref></sup>. Most strikingly, an additional 78% of patients harbored biomarkers with compelling clinical evidence of response to specific drugs (OncoKB level 3A), nearly all of which (98%) were attributed to <italic toggle="yes">KRAS</italic> G12D/V/R/A/S mutations for which favorable responses to RAS inhibitors have been observed in recent phase I trials (Fig. <xref rid="Fig5" ref-type="fig">5a</xref>)<sup><xref ref-type="bibr" rid="CR6">6</xref>,<xref ref-type="bibr" rid="CR34">34</xref></sup>. The clinical actionability varied across the genomic subtypes with other-MAPK<sup><italic toggle="yes">MUT</italic></sup> patients, expectedly, harboring the highest fraction (18%) of OncoKB level 1 alterations (Extended Data Fig. <xref rid="Fig10" ref-type="fig">5</xref>). For patients with metastatic PDAC who were fit for systemic therapy, chemotherapy with either a 5-fluorouracil (5-FU) or gemcitabine-based backbone was administered (Table <xref rid="Tab1" ref-type="table">1</xref> and Fig. <xref rid="Fig5" ref-type="fig">5b</xref>)<sup><xref ref-type="bibr" rid="CR5">5</xref></sup>. Treatment selection reflected changes in standard-of-care guidelines over the course of the study<sup><xref ref-type="bibr" rid="CR54">54</xref></sup>.<fig id="Fig5" position="float" orientation="portrait"><label>Fig. 5</label><caption><title>Clinically actionable alterations and treatment landscape.</title><p><bold>a</bold>, Highest OncoKB level of evidence by patient, with actionable (levels 1, 2 and 3A) alterations labeled. <bold>b</bold>, Alluvial diagram of treatment sequence for all 1,480 patients with treatment annotation by clinical stage at diagnosis showing prevalence of neoadjuvant therapy, resection surgery, adjuvant therapy and up to 5 rounds of systemic therapy. Different lines of treatment are shown on the <italic toggle="yes">x</italic> axis. <bold>c</bold>, Clinicogenomic characterization of <italic toggle="yes">n</italic> = 29 patients who were metastatic at presentation and received PARP-inhibitor therapy as part of systemic treatment. Cumulative times on PARP-inhibitor therapy and platinum therapy are shown as bar charts, along with demographic information (age at diagnosis, sex and genetic ancestry), germline and somatic alterations in HRD genes with associated zygosity, and somatic alterations in other commonly altered genes or genes of interest. The patient marked with a plus (+) received PARP-inhibitor therapy to target a germline <italic toggle="yes">RAD50</italic> mutation (not shown). <bold>d</bold>, OS for <italic toggle="yes">n</italic> = 304 patients who were metastatic at presentation and received either 5-FU or gemcitabine-based first-line treatments (top left). Top-right, bottom-left and bottom-right, Kaplan–Meier curves of OS by alteration status of indicated genes. <italic toggle="yes">P</italic> values are nominal two-sided <italic toggle="yes">P</italic> values from a multivariable Cox model that accounts for sex, age, ancestry and interval from diagnosis to sample collection for each gene (<xref rid="Sec12" ref-type="sec">Methods</xref>; Extended Data Table <xref rid="Tab6" ref-type="table">5</xref>).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e3053" position="float" orientation="portrait" xlink:href="41591_2024_3362_Fig5_HTML.jpg"/></fig></p>
          <p id="Par23">We next evaluated molecular correlates of response to poly-ADP ribose polymerase inhibitors (PARPi). In our clinically curated cohort, <italic toggle="yes">n</italic> = 29 patients with stage IV disease at diagnosis received PARPi therapy at any time during their treatment. Of these, 25 patients had germline (<italic toggle="yes">n</italic> = 23) or somatic (<italic toggle="yes">n</italic> = 2) mutations in <italic toggle="yes">BRCA2</italic> (<italic toggle="yes">n</italic> = 18), <italic toggle="yes">BRCA1</italic> (<italic toggle="yes">n</italic> = 6) and <italic toggle="yes">PALB2</italic> (<italic toggle="yes">n</italic> = 1; Fig. <xref rid="Fig5" ref-type="fig">5c</xref>). Twenty-eight of 29 patients had <italic toggle="yes">KRAS</italic><sup><italic toggle="yes">MUT</italic></sup> tumors, 4 of which also had mutant allele dosage gains. Overall, 38% (11 of 29) of patients received PARPi therapy for more than six months (median 17 months; range = 8–56). Ten of 11 (91%) patients had <italic toggle="yes">BRCA2</italic><sup><italic toggle="yes">MUT</italic></sup>; the remaining patient had a <italic toggle="yes">BRCA1</italic><sup><italic toggle="yes">WT</italic></sup>/<italic toggle="yes">BRCA</italic><italic toggle="yes">2</italic><sup><italic toggle="yes">WT</italic></sup> and MAPK<sup><italic toggle="yes">WT</italic></sup> tumor with a <italic toggle="yes">BAP1</italic> loss-of-function fusion. While all ten <italic toggle="yes">BRCA2</italic>-mutant tumors deriving benefit from PARPi (defined as &gt;6 months on treatment) had biallelic inactivation, no benefit was observed among six other <italic toggle="yes">BRCA2</italic>-mutant tumors with biallelic losses, suggesting that biallelic loss of <italic toggle="yes">BRCA1</italic>/<italic toggle="yes">BRCA</italic><italic toggle="yes">2</italic> is an important but insufficient biomarker alone of response to PARPi<sup><xref ref-type="bibr" rid="CR55">55</xref></sup>.</p>
          <p id="Par24">We next sought to identify the genomic correlates of OS in <italic toggle="yes">KRAS</italic><sup><italic toggle="yes">MUT</italic></sup> patients with de novo metastatic disease who received first-line standard-of-care chemotherapy (<italic toggle="yes">n</italic> = 304, median OS = 10.5 months; <xref rid="Sec12" ref-type="sec">Methods</xref>; Fig. <xref rid="Fig5" ref-type="fig">5d</xref>). We evaluated associations between genes altered in at least 3% of patients (<italic toggle="yes">n</italic> = 13 genes) and OS using a multivariable Cox regression model accounting for sex, age, ancestry and interval from diagnosis to biospecimen collection (<xref rid="Sec12" ref-type="sec">Methods</xref>; Extended Data Table <xref rid="Tab6" ref-type="table">5</xref>). Only patients with <italic toggle="yes">BRCA2</italic> alterations (including germline carriers) showed modestly improved outcomes (HR<sub>adj</sub> = 0.66, 95% CI = 0.44–0.98, <italic toggle="yes">P</italic> = 0.038), in line with the established response to platinum therapy<sup><xref ref-type="bibr" rid="CR16">16</xref>,<xref ref-type="bibr" rid="CR18">18</xref>,<xref ref-type="bibr" rid="CR56">56</xref></sup> (Fig. <xref rid="Fig5" ref-type="fig">5d</xref>). After correcting for multiple hypothesis testing, alterations in two genes remained significant. Both were associated with a significantly shorter OS—<italic toggle="yes">RNF43</italic> (HR<sub>adj</sub> = 2.79, 95% CI = 1.40–5.56, <italic toggle="yes">P</italic><sub>adj</sub> = 0.047; median OS = 6.6 months <italic toggle="yes">RNF43</italic><sup><italic toggle="yes">MUT</italic></sup> versus 10.8 months <italic toggle="yes">RNF43</italic><sup>WT</sup>) and <italic toggle="yes">AKT2</italic> amplifications (HR<sub>adj</sub> = 2.03, 95% CI = 1.26, 3.29, <italic toggle="yes">P</italic><sub>adj</sub> = 0.048; median OS = 8.6 months in <italic toggle="yes">AKT2</italic><sup><italic toggle="yes">MUT</italic></sup> versus 10.8 months in <italic toggle="yes">AKT2</italic><sup><italic toggle="yes">WT</italic></sup>). Although not commonly altered in PDAC (&lt;5% in this cohort), <italic toggle="yes">RNF43</italic> loss-of-function activity has been shown to be <italic toggle="yes">KRAS</italic> dependent<sup><xref ref-type="bibr" rid="CR57">57</xref></sup>. While <italic toggle="yes">KRAS</italic> mutant gains were more frequent in <italic toggle="yes">RNF43</italic><sup><italic toggle="yes">MUT</italic></sup> tumors, this did not reach statistical significance in our cohort (67% of <italic toggle="yes">RNF43</italic><sup><italic toggle="yes">MUT</italic></sup> tumors had <italic toggle="yes">KRAS</italic> mutant gains versus 30% in <italic toggle="yes">RNF43</italic><sup><italic toggle="yes">WT</italic></sup>, <italic toggle="yes">P</italic> = 0.2). Together, these results suggest that prognosis in patients with PDAC is most linked to <italic toggle="yes">KRAS</italic> mutation and dosage in the majority of patients, and that somatic alterations in other genes do not explain the wide variation in response to standard therapies.</p>
        </sec>
      </sec>
      <sec id="Sec11" sec-type="discussion">
        <title>Discussion</title>
        <p id="Par25">Herein we study the detailed clinicogenomic profiles of <italic toggle="yes">n</italic> = 2,336 patients to characterize prognostic biomarkers guiding clinical outcomes in PDAC. Compared to prior studies, our cohort has several unique strengths including many molecularly profiled metastatic tumors, detailed clinical histories for two-thirds of patients, and matched tumor and normal sequencing that allowed for incorporation of germline results and robust inference of allele-specific copy number states at the mutated loci. Collectively, these strengths enabled improved classification of PDAC into genomic subtypes and the demonstration of prognostic potential of mutant allele dosage gains in <italic toggle="yes">KRAS</italic><sup><italic toggle="yes">MUT</italic></sup> tumors across all disease stages.</p>
        <p id="Par26">Our findings have several clinical implications. The predictive role of <italic toggle="yes">KRAS</italic> mutant dosage gains in impacting antitumor response and therapeutic outcomes remains unknown, although we expect it to be important. As many RAS-targeted therapies are advancing in clinical trials, it is imperative to conduct analyses to evaluate whether <italic toggle="yes">KRAS</italic> mutant dosage has a role in mediating efficacy as well as depth and duration of response to treatment. Findings from such studies may provide impetus for future trials to stratify patients by <italic toggle="yes">KRAS</italic> mutant dosage in evaluating therapeutic outcomes. For example, randomized clinical trials that evaluate patients with <italic toggle="yes">KRAS</italic> mutant dosage gains in both the intervention as well as control arms are key to evaluate response to RAS inhibitors as well as current standard-of-care therapies. Second, shallow gains of <italic toggle="yes">KRAS</italic> mutant alleles, including single-copy gains, which are associated with poor outcomes and can potentially guide care, are currently not reported by any clinical sequencing assays. There is an imminent need for evaluation, standardization and incorporation of these low-level gains into reports for clinical interpretation. Third, acknowledging the challenge of small biopsy specimens in the diagnosis and management of patients with PDAC, it is essential to understand whether circulating tumor DNA can provide a noninvasive means of assessing <italic toggle="yes">KRAS</italic> mutant dosage and whether sequential analyses could provide a dynamic and real-time assessment to inform response and resistance.</p>
        <p id="Par27">Although PDACs are genomically grouped by <italic toggle="yes">KRAS</italic> status, our data argue that the <italic toggle="yes">KRAS</italic><sup><italic toggle="yes">WT</italic></sup> tumors comprise two distinct molecular groups stratified by whether or not they harbor oncogenic alterations in other MAPK pathway genes. The other-<italic toggle="yes">MAPK</italic><sup><italic toggle="yes">MUT</italic></sup> and <italic toggle="yes">MAPK</italic><sup><italic toggle="yes">WT</italic></sup> subtypes comprise 3% and 2% of all PDACs, respectively, and reveal distinct etiologic and molecular factors underpinning tumorigenesis. However, further molecular and biochemical studies that measure the activity of Ras–ERK signaling as well as the upregulation of downstream components including <italic toggle="yes">MYC</italic> or <italic toggle="yes">YAP</italic> are needed to establish MAPK independence among these <italic toggle="yes">MAPK</italic><sup><italic toggle="yes">WT</italic></sup> tumors<sup><xref ref-type="bibr" rid="CR58">58</xref></sup>.</p>
        <p id="Par28">In this large clinicogenomically characterized cohort of patients with PDAC, several important limitations need highlighting. Patients were evaluated and treated at a major referral center for PDAC with inherent biases of fitness, age and other characteristics. With current trends of increasing incidence of early-onset PDAC, especially in younger women, these characteristics are important to note<sup><xref ref-type="bibr" rid="CR59">59</xref>,<xref ref-type="bibr" rid="CR60">60</xref></sup>. We report a high proportion of patients undergoing resection of primary pancreatic cancer, 41%, which is higher than the broader population of all patients with PDAC (Table <xref rid="Tab1" ref-type="table">1</xref>). Relatedly, only 15% of our cohort was non-European, highlighting the need for these results to be evaluated in subgroups with greater ethnic and racially diverse populations. This study primarily focuses on genomic features derived from MSK-IMPACT. Additional transcriptomic assessments are needed to fully characterize pathway-level activity and to identify the relationship between genomic biomarkers described herein and previously described transcriptomic subtypes (classical and basal) that have been associated with prognosis and for which predictive implications are under evaluation in clinical trials (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT04469556">NCT04469556</ext-link>)<sup><xref ref-type="bibr" rid="CR25">25</xref></sup>. Given the prognostic potential of both <italic toggle="yes">KRAS</italic> dosage and the basal-like transcriptomic subtype, a comprehensive analysis of subtyping is needed to determine whether these are indicative of the same or independent pathways of tumor progression.</p>
        <p id="Par29">Comprehensive analysis of germline and somatic alterations is critically important in PDAC and both have therapeutic implications. Additionally, integration with demographic and clinical information is required to link understanding of underlying tumor biology with treatment implications and outcomes. We identify distinct molecular and clinical features of <italic toggle="yes">KRAS</italic><sup><italic toggle="yes">MUT</italic></sup>, other-<italic toggle="yes">MAPK</italic><sup><italic toggle="yes">MUT</italic></sup> and <italic toggle="yes">MAPK</italic><sup><italic toggle="yes">WT</italic></sup> genomic subtypes and further stratify <italic toggle="yes">KRAS</italic><sup><italic toggle="yes">MUT</italic></sup> tumors by allele-specific copy number. Collectively, these findings demonstrate that increased <italic toggle="yes">KRAS</italic> mutant allele dosage is an important negative prognostic feature that will need to be integrated into clinical practice as we move into the era of RAS-directed therapeutics for PDAC.</p>
      </sec>
      <sec id="Sec12">
        <title>Methods</title>
        <p id="Par30">The research was reviewed and overseen by the Institutional Review Board at Memorial Sloan Kettering Cancer Center.</p>
        <sec id="Sec13">
          <title>Study cohort</title>
          <p id="Par31">Between January 2014 and September 2021, 2,671 tumor and matched normal DNA samples from 2,566 patients with PDAC were subjected to molecular testing using MSK-IMPACT, an FDA-authorized clinical next-generation sequencing panel. Patients provided consent for tumor profiling under an institutional Memorial Sloan Kettering Cancer Center (MSK) IRB-approved research prospective protocol, ‘Tumor Genomic Profiling in Patients Evaluated for Targeted Cancer Therapy’ (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT01775072">NCT01775072</ext-link>). Patients were not compensated financially for participation in the study. Tumor samples with low sequence coverage (&lt;100×) or no detectable somatic alterations likely due to low tumor content quality were excluded (112 samples from 99 patients). Upon further review, 62 patients were excluded for having a diagnosis other than PDAC, and an additional 69 patients were excluded for having incomplete medical records. From the remaining 2,336 patients, one representative sample from each patient was selected for further analysis based on several criteria including higher tumor purity, higher sequence coverage, sample passing of allele-specific copy number (FACETS) quality control criteria (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://github.com/taylor-lab/facets-preview/">https://github.com/taylor-lab/facets-preview/</ext-link>) and the specific IMPACT panel size on which the specimen was sequenced. Of these 2,336 patients, 1,480 patients who had at least one year of clinical follow-up at our center between January 2014 and March 2021 underwent comprehensive clinical annotation after manual curation of medical health records. Genetic ancestry was inferred from IMPACT as described previously<sup><xref ref-type="bibr" rid="CR60">60</xref></sup>. Comprehensive demographic and clinical information are included in Table <xref rid="Tab1" ref-type="table">1</xref>. Self-reported sex information was collected from patient medical records. No sex-based criteria were used to select patients in this study. Gender information was not considered in the study.</p>
        </sec>
        <sec id="Sec14">
          <title>Tumor sequencing and mutation assessment</title>
          <p id="Par32">Tumor samples were sequenced using the MSK-IMPACT targeted sequencing panel as described previously<sup><xref ref-type="bibr" rid="CR33">33</xref></sup>. Briefly, tumor type and purity were assessed by pathology from H&amp;E-stained slides of tumor samples. Genomic DNA from formalin-fixed, paraffin-embedded (FFPE) tumor and matched normal (peripheral blood) samples was extracted, and targeted sequencing was performed using custom DNA probes against all exons and selected introns of a given panel of cancer genes. Tumors were sequenced using four different generations of MSK-IMPACT panels containing 341 genes (<italic toggle="yes">n</italic> = 17 samples), 410 genes (<italic toggle="yes">n</italic> = 438), 468 genes (<italic toggle="yes">n</italic> = 1,536) and 505 genes (<italic toggle="yes">n</italic> = 345). The median sequencing depth of tumors was 606× (25th percentile: 469×, 75th percentile: 749×). The median purity of the tumors, estimated by FACETS, was 31%. For tumors without FACETS estimated purity, the pathologist estimated tumor purity was used to determine if the sample meets sufficient quality criteria to be included in the cohort (see above). Somatic mutations, copy number alterations and structural rearrangements in select genes were identified using a previously described pipeline validated for use in a Clinical Laboratory Improvement Amendments (CLIA)-compliant laboratory<sup><xref ref-type="bibr" rid="CR33">33</xref></sup>. All somatic alterations were annotated for clinical actionability using OncoKB version. 4.12, December 2023<sup><xref ref-type="bibr" rid="CR34">34</xref></sup>. All somatic alterations that were identified as ‘oncogenic’ or ‘likely oncogenic’ by OncoKB were considered as drivers and used exclusively in all analyses (annotated as [<italic toggle="yes">Gene</italic>]<sup><italic toggle="yes">MUT</italic></sup>, regardless of alteration type) unless otherwise noted. Genes were included in the oncoprint in Fig. <xref rid="Fig1" ref-type="fig">1a</xref> if they met any of the following criteria: mutated in &gt;5% of patients, MAPK pathway, MYC pathway, clinically actionable genes mutated in ≥1% of patients, or significantly enriched in either other-MAPK<sup><italic toggle="yes">MUT</italic></sup> or MAPK<sup><italic toggle="yes">WT</italic></sup> tumors. Pathway gene lists were defined by the oncogenic signaling pathways described in ref. <sup><xref ref-type="bibr" rid="CR61">61</xref></sup>. Germline variant discovery and pathogenicity assessment was performed as previously described<sup><xref ref-type="bibr" rid="CR62">62</xref>,<xref ref-type="bibr" rid="CR63">63</xref></sup>. MSI was determined by MSIsensor, with tumors identified with an MSIsensor score of 10 or higher classified as microsatellite instable (MSI-H, microsatellite instability high)<sup><xref ref-type="bibr" rid="CR64">64</xref>,<xref ref-type="bibr" rid="CR65">65</xref></sup>. A select subset of the cohort (<italic toggle="yes">n</italic> = 90 patients) received additional clinical testing for fusions using the custom RNA-seq panel (MSK-Fusion) that utilizes Archer Multiplex PCR technology<sup><xref ref-type="bibr" rid="CR66">66</xref></sup>. All tumors wild-type for <italic toggle="yes">KRAS</italic> mutations were evaluated for read evidence at subdetection thresholds. In these tumors, we genotyped known <italic toggle="yes">KRAS</italic> hotspot mutations using a custom tool (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://github.com/mskcc/GetBaseCountsMultiSample">https://github.com/mskcc/GetBaseCountsMultiSample</ext-link>) and identified reads with mapping quality scores of at least 20. All mapping reads were manually reviewed using IGV (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://software.broadinstitute.org/software/igv/">http://software.broadinstitute.org/software/igv/</ext-link>) to identify high-quality reads. A read is considered high quality if there are no mismatches and if the evidence supporting the mutated base is not in the leading or trailing ten bases of the sequencing read.</p>
        </sec>
        <sec id="Sec15">
          <title>RNA sequencing for fusion detection</title>
          <p id="Par33">We performed RNA sequencing on 11 tumor specimens derived from FFPE tissue blocks. Fusions were called using FusionCatcher v1.20 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://github.com/ndaniel/fusioncatcher">https://github.com/ndaniel/fusioncatcher</ext-link>) and Arriba v2.1.0 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://github.com/suhrig/arriba">https://github.com/suhrig/arriba</ext-link>). Results from each caller were merged into a single output file according to matching gene IDs and breakpoints. Noncoding fusions from FusionCatcher were excluded from the final output of the pipeline. All fusion calls were annotated by OncoKB. Two tumors harbored activating fusions involving MAPK pathway genes. In one sample, the <italic toggle="yes">ATP1B1</italic>–<italic toggle="yes">NRG1</italic> rearrangement fused the third exon of <italic toggle="yes">ATP1B1</italic> to the second exon of <italic toggle="yes">NRG1</italic>. In another sample, the fourteenth exon of <italic toggle="yes">GIT2</italic> was fused to the fourth exon of <italic toggle="yes">BRAF</italic>. In both events, the entire kinase domain of the 3′ gene was retained.</p>
        </sec>
        <sec id="Sec16">
          <title>Allele-specific copy number analysis</title>
          <p id="Par34">Allele-specific copy number was inferred using the FACETS algorithm (v0.5.14)<sup><xref ref-type="bibr" rid="CR67">67</xref></sup>. Briefly, FACETS was run on each tumor sample in a two-step mode as previously described<sup><xref ref-type="bibr" rid="CR28">28</xref></sup>. The first step aims to identify the normalized tumor to normal sequencing coverage ratio corresponding to the diploid state. Using this, the second step aims to identify the focal gains and losses. FACETS-derived purity and ploidy estimate for the tumor sample and the allele-specific integer copy number for each locus was inferred. To identify and exclude tumors with poor quality copy number fits, we applied a series of quality control criteria (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://github.com/taylor-lab/facets-preview/">https://github.com/taylor-lab/facets-preview/</ext-link>) that include degree of evidence supporting the diploid state, the fraction of the genome with homozygous deletions, fraction of the genome that is estimated to be subclonal, hypersegmentation, concordance between integer copy number estimate and the allelic configuration and whether FACETS was able to estimate purity (C.B., D.M., Ino de Bruijn, Mingxuan Zhang, Michael V. Gormally et al., in revision). Overall, 1,555 of 2,322 tumor samples for which we were able to generate FACETS profiles had sufficiently high-quality copy number fits evaluable for further analysis. WGD status is inferred as previously described (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://github.com/mskcc/facets-suite">https://github.com/mskcc/facets-suite</ext-link>)<sup><xref ref-type="bibr" rid="CR30">30</xref></sup>. Briefly, a tumor is deemed to have undergone genome doubling if more than 50% of the autosomal genome has a major copy number of 2 or higher. In our cohort, 339 of 1,555 tumors were WGD-positive. Clonality of somatic mutations was determined as described previously<sup><xref ref-type="bibr" rid="CR68">68</xref></sup>. Briefly, we first infer the cancer cell fraction (CCF) of mutation using the variant allele frequency of the somatic mutation, the integer copy number at the locus, the read coverage and the FACETS estimated tumor purity. A mutation is deemed to be clonal if either the CCF estimate is 80% or higher, or if the CCF estimate is 70% or higher and the upper bound of the 95th percentile CI of the CCF estimate is greater than 90% (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://github.com/mskcc/facets-suite">https://github.com/mskcc/facets-suite</ext-link>). LOH at specific loci harboring germline/somatic mutations or WT alleles was assessed using allele-specific copy number inference from FACETS. A locus is considered to have LOH if the <italic toggle="yes">lcn</italic> is 0.</p>
        </sec>
        <sec id="Sec17">
          <title>KRAS allelic imbalance and mutant allele dosage gains</title>
          <p id="Par35">Of the 1,555 tumors with sufficiently high-quality copy number profiles, 1,157 were <italic toggle="yes">KRAS</italic><sup><italic toggle="yes">MUT</italic></sup> with determinable integer copy number. We then assigned each of these tumors to six different allelic copy number states based on the total copy number (<italic toggle="yes">tcn</italic>) and lower copy number (<italic toggle="yes">lcn</italic>) at the <italic toggle="yes">KRAS</italic> locus as well as the WGD status (Fig. <xref rid="Fig3" ref-type="fig">3a</xref>). In non-WGD tumors, diploid tumors with <italic toggle="yes">tcn</italic>:<italic toggle="yes">lcn</italic> of 2:1 were considered as ‘Balanced’ (heterozygous). Tumors with complete loss of one inherited allele (lcn of 0) were considered as ‘LOH’ if the <italic toggle="yes">tcn</italic> is 1, and ‘CNLOH’ if <italic toggle="yes">tcn</italic> is &gt;1. Tumors were considered to harbor <italic toggle="yes">KRAS</italic> ‘amplifications’ if our clinical pipeline identified focal <italic toggle="yes">KRAS</italic> amplifications or the <italic toggle="yes">tcn</italic> in FACETS was ≥5 in the absence of WGD, or ≥6 with WGD. The tumors that retained both inherited maternal and paternal alleles but have gained additional copies of one or both inherited alleles were considered as ‘Gains’. Among WGD-positive tumors, we accounted for the higher balanced state (<italic toggle="yes">tcn</italic>:<italic toggle="yes">lcn</italic> of 4:2) in ascribing allelic copy number states associated with losses and gains. WGD-positive tumors that acquired single-copy losses (irrespective of whether the loss targeted the WT or the mutant allele) were considered as ‘Loss after WGD’. To be considered as a ‘Gain’ in WGD-positive tumors, the <italic toggle="yes">tcn</italic> is required to be 5 or higher.</p>
          <p id="Par36">The expected number of <italic toggle="yes">KRAS</italic> mutant alleles is estimated using the observed variant allele frequency, tumor purity and total copy number at the <italic toggle="yes">KRAS</italic> locus as previously described<sup><xref ref-type="bibr" rid="CR28">28</xref>,<xref ref-type="bibr" rid="CR69">69</xref></sup>. We considered tumors with a higher number of mutant copies than WT copies to have undergone mutant allele selection. These include tumors identified as having ‘LOH’ (<italic toggle="yes">tcn</italic>:<italic toggle="yes">lcn</italic> of 1:0 for non-WGD tumors and 2:0 for WGD-positive tumors), ‘CNLOH’ (complete loss of wild-type with either ≥2 mutant copies in non-WGD tumors, or, ≥3 mutant copies in WGD-positive tumors), ‘Gain of mutant’ (with higher number of mutant copies than wild-type copies), and finally, among WGD-positive tumors, ‘WGD+Loss of WT’ tumors in which a copy number losses after WGD event targeted the wild-type allele (Fig. <xref rid="Fig3" ref-type="fig">3c</xref>). Tumors in which selection following copy number gains/losses resulted in preferential retention of the <italic toggle="yes">KRAS</italic> WT allele were rare (<italic toggle="yes">n</italic> = 32, ‘WT selection’, Fig. <xref rid="Fig3" ref-type="fig">3c</xref>) and were not considered further.</p>
        </sec>
        <sec id="Sec18">
          <title>Statistics and reproducibility</title>
          <p id="Par37">Enrichment testing was performed using two-sided Fisher’s exact tests with multiple test correction by the FDR method where appropriate. For gene-level enrichment analyses, we evaluated all cancer genes that are captured on all versions of the MSK-IMPACT panels (<italic toggle="yes">n</italic> = 341 genes) and were altered in at least 3 samples in the dataset. Unless otherwise noted, enrichment tests were limited to alterations detected by MSK-IMPACT and annotated as drivers (oncogenic or likely oncogenic) by OncoKB. Error bars on all figures showing counts/prevalence data represent 95% CIs of the binomial probability. Two-sided chi-squared tests were used for testing differences in prevalence of nonbinary variables such as ancestry and clinical stage. Two-sided Wilcoxon rank sum tests were used for comparison of numeric variables such as age. In boxplots, the center line represents the median, lower and upper hinges show the 25th and 75th percentiles, and lower and upper whiskers show the minimum and maximum values no further than 1.5× the interquartile range, respectively, with outlier points beyond this range plotted individually. Analyses were conducted using R version 4.3.0 with the rstatix (v0.7.2), stats (v4.3.0) and binom (v1.1.1.1) packages and visualized using ggplot2 (v3.4.4). Oncoprints were generated using cBioPortal for Cancer Genomics<sup><xref ref-type="bibr" rid="CR70">70</xref>–<xref ref-type="bibr" rid="CR72">72</xref></sup>.</p>
        </sec>
        <sec id="Sec19">
          <title>Survival</title>
          <p id="Par38">OS was calculated as the interval from date of IMPACT sample collection to date of death or last follow-up. Patients with no follow-up after IMPACT sample collection were censored on day 1 (<italic toggle="yes">n</italic> = 9). Patients with missing date of IMPACT specimen collection (<italic toggle="yes">n</italic> = 2) or those with IMPACT specimen collection before January 2014 (<italic toggle="yes">n</italic> = 64) were excluded from survival analyses. All <italic toggle="yes">P</italic> values and adjusted HRs associated with survival analyses are from multivariable Cox proportional hazards models accounting for covariates including age, sex, ancestry and interval from diagnosis to sample collection. Full models are shown in Extended Data Tables. Covariates were selected based on statistically significant univariate associations with OS. MSI type and TMB were not found to have a statistically significant association with OS in a univariate model and therefore were not included as covariates in multivariable models. Models were either stratified by clinical stage at diagnosis or evaluated within each stage to account for known differences in OS by stage. Median OS values were calculated using the univariate Kaplan–Meier estimator. Analyses were conducted using R version 4.3.0 with the tidyverse (v2.0.0), survival (v3.5-5) and gtsummary (v1.7.2) packages.</p>
          <p id="Par39">For stage and survival analyses associated with <italic toggle="yes">KRAS</italic> copy number (Fig. <xref rid="Fig3" ref-type="fig">3</xref>), resectable patients who had experienced a recurrence by the time of sample collection were excluded (<italic toggle="yes">n</italic> = 95) to limit variation in disease progression within the stage. For OS comparison by binary gene alteration status (Fig. <xref rid="Fig5" ref-type="fig">5d</xref>), genes were considered if they had a somatic alteration prevalence of at least 3% of metastatic patients who had received standard-of-care chemotherapy with either 5-FU to gemcitabine backbones who could be evaluated for OS (<italic toggle="yes">n</italic> = 473 patients, 13 genes). Samples were then limited to those with high purity (30% or higher) to reduce the bias of false negatives in the WT group (<italic toggle="yes">n</italic> = 304 patients). Chemotherapy backbone (5-FU versus gemcitabine/nab-paclitaxel) was not significantly associated with OS and was therefore not included as a covariate (<italic toggle="yes">P</italic> &gt; 0.05). Multivariable Cox proportional hazards models were constructed for each gene (Extended Data Table <xref rid="Tab6" ref-type="table">5</xref>), and <italic toggle="yes">P</italic> values of the genomic alterations in each model were adjusted by FDR with <italic toggle="yes">n</italic> = 13.</p>
        </sec>
        <sec id="Sec20">
          <title>Reporting summary</title>
          <p id="Par40">Further information on research design is available in the <xref rid="MOESM1" ref-type="media">Nature Portfolio Reporting Summary</xref> linked to this article.</p>
        </sec>
      </sec>
      <sec id="Sec21" sec-type="materials|methods">
        <title>Online content</title>
        <p id="Par41">Any methods, additional references, Nature Portfolio reporting summaries, source data, extended data, supplementary information, acknowledgements, peer review information; details of author contributions and competing interests and statements of data and code availability are available at 10.1038/s41591-024-03362-3.</p>
      </sec>
      <sec id="Sec23" sec-type="supplementary-material">
        <title>Supplementary information</title>
        <p>
<supplementary-material content-type="local-data" id="MOESM1" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="41591_2024_3362_MOESM1_ESM.pdf" position="float" orientation="portrait"><caption><p>Reporting Summary</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM2" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="41591_2024_3362_MOESM2_ESM.xlsx" position="float" orientation="portrait"><caption><p><bold>Supplementary Table 1</bold> Clinical and advanced genomic features for <italic toggle="yes">n</italic> = 2,336 patients and associated tumor samples. <bold>Supplementary Table 2</bold> Somatic driver mutations, copy number alterations and structural variants.</p></caption></media></supplementary-material>
</p>
      </sec>
    </body>
    <back>
      <app-group>
        <app id="App1">
          <sec id="Sec22">
            <title>Extended data</title>
            <p id="Par46">
<fig id="Fig6" position="float" orientation="portrait"><label>Extended Data Fig. 1</label><caption><title>Somatic alteration landscape in PDAC: additional insights.</title><p><bold>a</bold>, Prevalence of <italic toggle="yes">BRAF</italic> alteration types in PDAC, melanoma and thyroid cancer. <bold>b</bold>, Oncoprint of somatic oncogenic alterations with tumor samples grouped by genomic subtype (as in Fig. <xref rid="Fig1" ref-type="fig">1a</xref>) and by primary or metastasis sample type. <bold>c</bold>, Age at diagnosis across genomic groups including all patients (left, <italic toggle="yes">n</italic> = 2,336) and excluding patients with pathogenic germline variants (right, <italic toggle="yes">n</italic> = 2,006). Nominal <italic toggle="yes">P</italic> values indicate statistical comparison by two-sided Wilcoxon rank sum test. Boxes represent the 25th, 50th (median) and 75th percentiles. Whiskers represent the minimum and maximum values, no further than 1.5× the interquartile range (IQR) from the respective upper and lower quartiles, with points beyond this range plotted individually. <bold>d</bold>, Gene-level alteration enrichment by genetic ancestry (<italic toggle="yes">n</italic> = 75 genes with sufficient sample size). <bold>e</bold>, Gene-level alteration enrichment by sex (<italic toggle="yes">n</italic> = 75 genes with sufficient sample size). Enrichment was calculated using a two-sided Fisher exact test with <italic toggle="yes">P</italic> values adjusted for multiple testing by FDR for assessment of significance for <bold>d</bold> and <bold>e</bold>.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="d33e3877" orientation="portrait" xlink:href="41591_2024_3362_Fig6_ESM.jpg"/></fig>
</p>
            <p id="Par47">
<fig id="Fig7" position="float" orientation="portrait"><label>Extended Data Fig. 2</label><caption><title>Stage differences in pathway and gene alteration patterns, age and additional clinical features.</title><p><bold>a</bold>,<bold>b</bold>, Pathway- (<bold>a</bold>) and gene-level alteration (<bold>b</bold>) prevalence by clinical stage at diagnosis. Analysis limited to high-purity tumor samples (<italic toggle="yes">n</italic> = 1,076) and genes or pathways altered in at least 3 tumors in at least one stage. <bold>c</bold>, Age at diagnosis across the clinical stages at diagnosis including all patients (left, <italic toggle="yes">n</italic> = 2,336) and excluding patients with pathogenic germline variants (right, <italic toggle="yes">n</italic> = 2,006). Boxes represent the 25th, 50th (median) and 75th percentiles. Whiskers represent the minimum and maximum values, no further than 1.5× the interquartile range (IQR) from the respective upper and lower quartiles, with points beyond this range plotted individually. Groups were compared using two-sided Wilcoxon rank sum tests; nominal <italic toggle="yes">P</italic> value displayed. <bold>d</bold>, Tumor location, tobacco exposure and personal history of pancreatitis, hypertension, cancer, autoimmune disease, coronary artery disease and diabetes by clinical stage at diagnosis (<italic toggle="yes">n</italic> = 1,480). Error bars represent 95th percentile binomial CIs around the mean for <bold>a</bold>, <bold>b</bold> and <bold>d</bold>. Enrichment was calculated using a two-sided Fisher exact test for <bold>a</bold>, <bold>b</bold> and <bold>d</bold> with nominal <italic toggle="yes">P</italic> values displayed. <italic toggle="yes">P</italic> values were adjusted for multiple testing by FDR for assessment of significance for <bold>a</bold> and <bold>b</bold> (colored by <italic toggle="yes">P</italic><sub>adj</sub> &lt; 0.05).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="d33e3958" orientation="portrait" xlink:href="41591_2024_3362_Fig7_ESM.jpg"/></fig>
</p>
            <p id="Par48">
<fig id="Fig8" position="float" orientation="portrait"><label>Extended Data Fig. 3</label><caption><title>Pathogenic germline variant prevalence by ancestry and stage.</title><p><bold>a</bold>, Distribution of genetically inferred ancestry across the overall cohort (left) and by germline mutated genes. Asterisks denote enrichment of ASJ-EUR ancestry by Fisher’s exact test (<italic toggle="yes">q</italic> &lt; 0.05). <bold>b</bold>, Distribution of clinical stage at diagnosis across the overall cohort (left) and by germline mutated genes. Asterisks denote chi-squared test (<italic toggle="yes">q</italic> &lt; 0.05).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="d33e3981" orientation="portrait" xlink:href="41591_2024_3362_Fig8_ESM.jpg"/></fig>
</p>
            <p id="Par49">
<fig id="Fig9" position="float" orientation="portrait"><label>Extended Data Fig. 4</label><caption><title>Differential genomic and prognostic features of KRAS variants: additional insights.</title><p><bold>a</bold>, Bubble chart of co-occurring <italic toggle="yes">KRAS</italic> mutations. Number and bubble size indicate the prevalence of a given combination, and number in parentheses is the prevalence of the mutation in the overall cohort. <bold>b</bold>, Purity-adjusted variant allele frequency (VAF) of <italic toggle="yes">KRAS</italic> mutations by tumor, ordered by difference in VAF. Please note the 14 tumors shown here are excluded from Fig. <xref rid="Fig4" ref-type="fig">4</xref>. <bold>c</bold>, Prevalence of sex, genetic ancestry, age at diagnosis and smoking status by <italic toggle="yes">KRAS</italic> variant. Dotted line for age shows overall median. <italic toggle="yes">P</italic> value denotes two-sided Fisher’s exact test. Boxes for age represent the 25th, 50th (median) and 75th percentiles. Whiskers represent the minimum and maximum values, no further than 1.5× the interquartile range (IQR) from the respective upper and lower quartiles, with points beyond this range plotted individually. <bold>d</bold>, Prevalence of WGD by <italic toggle="yes">KRAS</italic> variant (<italic toggle="yes">n</italic> = 1,150); prevalence of <italic toggle="yes">KRAS</italic> allelic imbalance and <italic toggle="yes">KRAS</italic> allele selection state by <italic toggle="yes">KRAS</italic> variant among diploid tumors (<italic toggle="yes">n</italic> = 927). <bold>e</bold>,<bold>f</bold>, Progression-free survival (PFS) differences between first-line standard-of-care treatments across the different <italic toggle="yes">KRAS</italic> variant groups. <bold>e</bold>, Kaplan–Meier curves for PFS differences between FOLFIRINOX (5-FU) and gemcitabine for <italic toggle="yes">KRAS</italic> G12D, G12V and G12R. <italic toggle="yes">P</italic> values represent statistical comparison of univariate Kaplan–Meier curves by log-rank test. <bold>f</bold>, Multivariable Cox proportional hazards model for <bold>e</bold>. <italic toggle="yes">P</italic> values are nominal two-sided <italic toggle="yes">P</italic> values from the Cox regression model. Error bars represent 95th percentile binomial CIs around the mean for <bold>c</bold> and <bold>d</bold>.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="d33e4077" orientation="portrait" xlink:href="41591_2024_3362_Fig9_ESM.jpg"/></fig>
</p>
            <p id="Par50">
<fig id="Fig10" position="float" orientation="portrait"><label>Extended Data Fig. 5</label><caption><title>OncoKB clinical actionability across the three genomic subtypes of PDAC.</title><p>Prevalence of actionable alterations by OncoKB levels of actionability across <italic toggle="yes">KRAS</italic><sup><italic toggle="yes">MUT</italic></sup>, other-<italic toggle="yes">MAPK</italic><sup><italic toggle="yes">MUT</italic></sup> and <italic toggle="yes">MAPK</italic><sup><italic toggle="yes">WT</italic></sup> tumors.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="d33e4107" orientation="portrait" xlink:href="41591_2024_3362_Fig10_ESM.jpg"/></fig>
</p>
            <p id="Par51">
<table-wrap id="Tab2" position="float" orientation="portrait"><label>Extended Data Table 1</label><caption><p>Overall survival by genomic group</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="d33e4117" orientation="portrait" xlink:href="41591_2024_3362_Tab1_ESM.jpg"><caption><p>OS by genomic group</p></caption></graphic><table-wrap-foot><p>OS by genomic group among all patients in the cohort considered for survival analysis (<xref rid="Sec12" ref-type="sec">Methods</xref>, <italic toggle="yes">n</italic> = 2,270; left), and among patients who did not receive targeted treatment for actionable alterations (<italic toggle="yes">n</italic> = 2,187, right). Multivariable Cox proportional hazards model of OS, stratified by stage at diagnosis. Displayed <italic toggle="yes">P</italic> values are nominal two-sided <italic toggle="yes">P</italic> values associated with the observed hazard ratios from the multivariable regression models. HR, hazard ratio; CI, confidence interval. Bold numbers indicate <italic toggle="yes">P</italic> values &lt;0.05.</p></table-wrap-foot></table-wrap>
</p>
            <p id="Par52">
<table-wrap id="Tab3" position="float" orientation="portrait"><label>Extended Data Table 2</label><caption><p>Overall survival by <italic toggle="yes">KRAS</italic> mutant allele dosage</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="d33e4156" orientation="portrait" xlink:href="41591_2024_3362_Tab2_ESM.jpg"><caption><p>OS by KRAS mutant allele dosage</p></caption></graphic><table-wrap-foot><p>OS by <italic toggle="yes">KRAS</italic> mutant allele dosage among patients with <italic toggle="yes">KRAS</italic><sup><italic toggle="yes">MUT</italic></sup> tumors evaluable for <italic toggle="yes">KRAS</italic> allele-specific copy number considered for survival analysis (<xref rid="Sec12" ref-type="sec">Methods</xref>, <italic toggle="yes">n</italic> = 865). Multivariable Cox proportional hazards model of OS, stratified by stage at diagnosis and within each stage. Displayed <italic toggle="yes">P</italic> values are nominal two-sided <italic toggle="yes">P</italic> values associated with the observed hazard ratios from the multivariable regression models. Bold numbers indicate <italic toggle="yes">P</italic> values &lt;0.05.</p></table-wrap-foot></table-wrap>
</p>
            <p id="Par53">
<table-wrap id="Tab4" position="float" orientation="portrait"><label>Extended Data Table 3</label><caption><p>OS by <italic toggle="yes">KRAS</italic> copy number state</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="d33e4204" orientation="portrait" xlink:href="41591_2024_3362_Tab3_ESM.jpg"/><table-wrap-foot><p>OS by <italic toggle="yes">KRAS</italic> copy number state among patients with <italic toggle="yes">KRAS</italic><sup><italic toggle="yes">MUT</italic></sup> tumors and determinate <italic toggle="yes">KRAS</italic> allele-specific copy number considered for survival analysis (<italic toggle="yes">n</italic> = 865). Multivariable Cox proportional hazards model of OS, stratified by stage at diagnosis and within each stage. Displayed <italic toggle="yes">P</italic> values are nominal two-sided <italic toggle="yes">P</italic> values associated with the observed hazard ratios from the multivariable regression models. Bold numbers indicate <italic toggle="yes">P</italic> values &lt;0.05.</p></table-wrap-foot></table-wrap>
</p>
            <p id="Par54">
<table-wrap id="Tab5" position="float" orientation="portrait"><label>Extended Data Table 4</label><caption><p>OS by <italic toggle="yes">KRAS</italic> variant</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="d33e4249" orientation="portrait" xlink:href="41591_2024_3362_Tab4_ESM.jpg"/><table-wrap-foot><p>OS by <italic toggle="yes">KRAS</italic> variant among patients with <italic toggle="yes">KRAS</italic><sup><italic toggle="yes">MUT</italic></sup> tumors with a single <italic toggle="yes">KRAS</italic> variant considered for survival analysis (<xref rid="Sec12" ref-type="sec">Methods</xref>, <italic toggle="yes">n</italic> = 2,130). Multivariable Cox proportional hazards model of OS, stratified by stage at diagnosis. Displayed <italic toggle="yes">P</italic> values are nominal two-sided <italic toggle="yes">P</italic> values associated with the observed hazard ratios from the multivariable regression models. Bold numbers indicate <italic toggle="yes">P</italic> values &lt;0.05.</p></table-wrap-foot></table-wrap>
</p>
            <p id="Par55">
<table-wrap id="Tab6" position="float" orientation="portrait"><label>Extended Data Table 5</label><caption><p>OS by gene-level alterations</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="d33e4293" orientation="portrait" xlink:href="41591_2024_3362_Tab5_ESM.jpg"/><table-wrap-foot><p>OS by genomic alterations in <italic toggle="yes">n</italic> = 13 genes among patients with metastatic disease at diagnosis with <italic toggle="yes">KRAS</italic><sup><italic toggle="yes">MUT</italic></sup> tumors who received first-line chemotherapy considered for survival analysis, limited to high-purity samples (<xref rid="Sec12" ref-type="sec">Methods</xref>, <italic toggle="yes">n</italic> = 304). Multivariable Cox proportional hazards model of OS, stratified by stage at diagnosis. Displayed <italic toggle="yes">P</italic> values are nominal two-sided <italic toggle="yes">P</italic> values associated with the observed hazard ratios from the multivariable regression models. Bold numbers indicate <italic toggle="yes">P</italic> values &lt;0.05.</p></table-wrap-foot></table-wrap>
</p>
          </sec>
        </app>
      </app-group>
      <fn-group>
        <fn>
          <p><bold>Publisher’s note</bold> Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p>
        </fn>
        <fn>
          <p>These authors contributed equally: Anna M. Varghese, Maria A. Perry.</p>
        </fn>
        <fn>
          <p>
            <bold>Change history</bold>
          </p>
          <p>1/21/2025</p>
          <p id="Par1">In the version of the article initially published, the peer review statement was incorrect and has now been amended to “<italic toggle="yes">Nature Medicine</italic> thanks Mariano Ponz-Sarvise, Channing Der and the other, anonymous, reviewer(s) for their contribution to the peer review of this work.” Additionally, the y-axis label of Extended Data Fig. 4e read “OS Probability” and has now been amended to read “PFS Probability.” The changes are made in the HTML and PDF versions of the article.</p>
        </fn>
      </fn-group>
      <sec>
        <sec id="FPar1">
          <title>Extended data</title>
          <p id="Par42">is available for this paper at 10.1038/s41591-024-03362-3.</p>
        </sec>
        <sec id="FPar2" sec-type="supplementary-material">
          <title>Supplementary information</title>
          <p id="Par43">The online version contains supplementary material available at 10.1038/s41591-024-03362-3.</p>
        </sec>
      </sec>
      <ack>
        <title>Acknowledgements</title>
        <p>This work was supported by NIH/NCI P30CA008748 to MSK (to A.M.V., M.A.P., J.F.C., S.N., D. Muldoon, A.E., A.Z., C.F., M.M., B.N., O.B., F.B., D.P.K., A.R.B., D. Mandelker, E.V., W.P., K.H.Y., Z.K.S., M.A.S., W.R.J., A.C.W., D.C., M.C., N.S., M.F.B., C.A.I.-D., C.B., E.M.O.), R01 CA227534 (to M.F.B.), P50CA257881 (to E.M.O., O.B., W.P., A.C.W., M.C. and C.A.I.-D.), Break Through Cancer (to E.M.O., W.P. and C.A.I.-D.) and Parker Institute for Cancer Immunotherapy (to E.M.O. and W.P.). We acknowledge the David M. Rubenstein Center for Pancreatic Cancer Research, the Marie-Josée and Henry R. Kravis Center for Molecular Oncology and the Molecular Diagnostics Service at MSK. We also thank the patients who were included in this study along with their families. The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.</p>
      </ack>
      <notes notes-type="author-contribution">
        <title>Author contributions</title>
        <p>A.M.V., M.A.P., N.S., M.F.B., C.A.I.-D., C.B. and E.M.O. conceived the study. A.M.V, M.A.P., J.F.C., S.N., D. Muldoon, D.C., M.C., N.S., M.F.B., C.B. and E.M.O. designed and performed data analysis. J.F.C. and M.C. provided statistical expertise and analyzed clinical outcomes data. M.M., D. Mandelker and Z.K.S. provided germline variant pathogenicity assessment. A.E. provided project management. A.Z., C.F., B.N., A.R.B, D. Mandelker, E.V., Z.K.S. and M.F.B. assisted with prospective genomic and clinical data collection and sample annotation. Z.K.S., N.S. and M.F.B. supported consent infrastructure. O.B. and E.V. assisted with sample acquisition for additional analysis. A.M.V., F.B., D.P.K., W.P., K.H.Y., M.A.S., W.R.J, A.C.W. and E.M.O. provided samples. A.M.V., M.A.P., C.B. and E.M.O. wrote the manuscript with input from all authors. All authors reviewed and approved the manuscript. C.B. and E.M.O. contributed equally as senior authors.</p>
      </notes>
      <notes notes-type="peer-review">
        <title>Peer review</title>
        <sec id="FPar3">
          <title>Peer review information</title>
          <p id="Par44"><italic toggle="yes">Nature Medicine</italic> thanks Mariano Ponz-Sarvise, Channing Der and the other, anonymous, reviewer(s) for their contribution to the peer review of this work. Primary Handling Editor: Anna Maria Ranzoni, in collaboration with the <italic toggle="yes">Nature Medicine</italic> team.</p>
        </sec>
      </notes>
      <notes notes-type="data-availability">
        <title>Data availability</title>
        <p>Genomic and associated clinical data for all patients and tumor samples included in this study have been deposited in cBioPortal for Cancer Genomics and are publicly accessible and downloadable at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.cbioportal.org/study/summary?id=pdac_msk_2024">https://www.cbioportal.org/study/summary?id=pdac_msk_2024</ext-link>. Raw tumor and normal sequencing data from MSK-IMPACT, as well as all data associated with germline variants, are considered protected information and access is available under restricted access subject to additional institutional approvals. These data may be requested for appropriate use from the corresponding authors by email (bandlamc@mskcc.org, oreillye@mskcc.org); requests will be reviewed within 4 weeks. Data will be shared for a span of 2 years within 2 weeks of execution of a data transfer agreement with MSK, which will retain all title and rights to the data and results from their use.</p>
      </notes>
      <notes notes-type="data-availability">
        <title>Code availability</title>
        <p>Algorithms and R packages used are open-source and described in the <xref rid="Sec12" ref-type="sec">Methods</xref>. The FACETS algorithm for allele-specific copy number is available on GitHub at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://github.com/taylor-lab/facets-preview/">https://github.com/taylor-lab/facets-preview/</ext-link>. The OncoKB knowledge base used for annotation is available at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.oncokb.org/">https://www.oncokb.org/</ext-link> and through the API on GitHub at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://github.com/oncokb/oncokb-annotator">https://github.com/oncokb/oncokb-annotator</ext-link>.</p>
      </notes>
      <notes id="FPar4" notes-type="COI-statement">
        <title>Competing interests</title>
        <p id="Par45">M.A.P. declares stock ownership in Amgen. A.M.V. declares consulting activity from AstraZeneca (spouse), Eli Lilly (spouse) and Paige AI (spouse), and intellectual property rights (SOPHiA Genetics) (spouse). B.N. is a current employee of Eli Lilly and Company. D. Mandelker declares consulting fees from AstraZeneca. F.B. receives research support from BMS. D.P.K. receives funding from the Thompson Family Foundation and Applebaum Foundation and is a consultant at Merck, BMS, BeiGene, Lilly, Abbvie, Incyte, Janssen, Listen and TG Therapeutics. A.R.B. declares stock ownership in Johnson &amp; Johnson and intellectual property rights in SOPHiA Genetics. W.P. receives research funding from Merck, Astellas, Miracogen, Amgen and Revolution Medicines, is a consultancy/advisory board member for Astellas, EXACT Therapeutics, Innovent Biologics and Regeneron and has received honoraria for CME: American Physician Institute, Integrity. M.F.B. declares consulting activity from AstraZeneca, Eli Lilly and Paige AI and intellectual property rights (SOPHiA Genetics). E.M.O. receives research funding from Agenus, Amgen, Genentech/Roche, BioNTech, AstraZeneca, Arcus, Elicio, Parker Institute, NIH/NCI and Digestive Care, consulting/DSMB role at Arcus, Ability Pharma, Alligator, Agenus, BioNTech, Ipsen, Merck, Moma Therapeutics, Novartis, Syros, Leap Therapeutics, Astellas, BMS, Fibrogen, Revolution Medicine, Merus, Moma Therapeutics and Tango; Agios (spouse), Genentech-Roche (spouse), Eisai (spouse) Servier (spouse). The remaining authors declare no competing interests.</p>
      </notes>
      <ref-list id="Bib1">
        <title>References</title>
        <ref id="CR1">
          <label>1.</label>
          <citation-alternatives>
            <element-citation id="ec-CR1" publication-type="journal">
              <person-group person-group-type="author">
                <name name-style="western">
                  <surname>Siegel</surname>
                  <given-names>RL</given-names>
                </name>
                <name name-style="western">
                  <surname>Giaquinto</surname>
                  <given-names>AN</given-names>
                </name>
                <name name-style="western">
                  <surname>Jemal</surname>
                  <given-names>A</given-names>
                </name>
              </person-group>
              <article-title>Cancer statistics, 2024</article-title>
              <source>CA Cancer J. Clin.</source>
              <year>2024</year>
              <volume>74</volume>
              <fpage>12</fpage>
              <lpage>49</lpage>
              <pub-id pub-id-type="pmid">38230766</pub-id>
              <pub-id pub-id-type="doi" assigning-authority="pmc">10.3322/caac.21820</pub-id>
            </element-citation>
            <mixed-citation id="mc-CR1" publication-type="journal">Siegel, R. L., Giaquinto, A. N. &amp; Jemal, A. Cancer statistics, 2024. <italic toggle="yes">CA Cancer J. Clin.</italic><bold>74</bold>, 12–49 (2024).<pub-id pub-id-type="pmid">38230766</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3322/caac.21820</pub-id></mixed-citation>
          </citation-alternatives>
        </ref>
        <ref id="CR2">
          <label>2.</label>
          <citation-alternatives>
            <element-citation id="ec-CR2" publication-type="journal">
              <person-group person-group-type="author">
                <name name-style="western">
                  <surname>Conroy</surname>
                  <given-names>T</given-names>
                </name>
                <etal/>
              </person-group>
              <article-title>FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer</article-title>
              <source>N. Engl. J. Med.</source>
              <year>2011</year>
              <volume>364</volume>
              <fpage>1817</fpage>
              <lpage>1825</lpage>
              <pub-id pub-id-type="pmid">21561347</pub-id>
              <pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa1011923</pub-id>
            </element-citation>
            <mixed-citation id="mc-CR2" publication-type="journal">Conroy, T. et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. <italic toggle="yes">N. Engl. J. Med.</italic><bold>364</bold>, 1817–1825 (2011).<pub-id pub-id-type="pmid">21561347</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa1011923</pub-id></mixed-citation>
          </citation-alternatives>
        </ref>
        <ref id="CR3">
          <label>3.</label>
          <citation-alternatives>
            <element-citation id="ec-CR3" publication-type="journal">
              <person-group person-group-type="author">
                <name name-style="western">
                  <surname>Von Hoff</surname>
                  <given-names>DD</given-names>
                </name>
                <etal/>
              </person-group>
              <article-title>Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine</article-title>
              <source>N. Engl. J. Med.</source>
              <year>2013</year>
              <volume>369</volume>
              <fpage>1691</fpage>
              <lpage>1703</lpage>
              <pub-id pub-id-type="pmid">24131140</pub-id>
              <pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa1304369</pub-id>
              <pub-id pub-id-type="pmcid">PMC4631139</pub-id>
            </element-citation>
            <mixed-citation id="mc-CR3" publication-type="journal">Von Hoff, D. D. et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. <italic toggle="yes">N. Engl. J. Med.</italic><bold>369</bold>, 1691–1703 (2013).<pub-id pub-id-type="pmid">24131140</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa1304369</pub-id><pub-id pub-id-type="pmcid">PMC4631139</pub-id></mixed-citation>
          </citation-alternatives>
        </ref>
        <ref id="CR4">
          <label>4.</label>
          <citation-alternatives>
            <element-citation id="ec-CR4" publication-type="journal">
              <person-group person-group-type="author">
                <name name-style="western">
                  <surname>Wainberg</surname>
                  <given-names>ZA</given-names>
                </name>
                <etal/>
              </person-group>
              <article-title>NAPOLI-3: a randomized, open-label phase 3 study of liposomal irinotecan + 5-fluorouracil/leucovorin + oxaliplatin (NALIRIFOX) versus nab-paclitaxel + gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (mPDAC)</article-title>
              <source>J. Clin. Oncol.</source>
              <year>2023</year>
              <volume>41</volume>
              <fpage>LBA661</fpage>
              <lpage>LBA661</lpage>
              <pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(23)01366-1</pub-id>
              <pub-id pub-id-type="pmcid">PMC11664154</pub-id>
              <pub-id pub-id-type="pmid">37708904</pub-id>
            </element-citation>
            <mixed-citation id="mc-CR4" publication-type="journal">Wainberg, Z. A. et al. NAPOLI-3: a randomized, open-label phase 3 study of liposomal irinotecan + 5-fluorouracil/leucovorin + oxaliplatin (NALIRIFOX) versus nab-paclitaxel + gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (mPDAC). <italic toggle="yes">J. Clin. Oncol.</italic><bold>41</bold>, LBA661–LBA661 (2023).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(23)01366-1</pub-id><pub-id pub-id-type="pmcid">PMC11664154</pub-id><pub-id pub-id-type="pmid">37708904</pub-id></mixed-citation>
          </citation-alternatives>
        </ref>
        <ref id="CR5">
          <label>5.</label>
          <citation-alternatives>
            <element-citation id="ec-CR5" publication-type="journal">
              <person-group person-group-type="author">
                <name name-style="western">
                  <surname>Park</surname>
                  <given-names>W</given-names>
                </name>
                <name name-style="western">
                  <surname>Chawla</surname>
                  <given-names>A</given-names>
                </name>
                <name name-style="western">
                  <surname>O’Reilly</surname>
                  <given-names>EM</given-names>
                </name>
              </person-group>
              <article-title>Pancreatic cancer: a review</article-title>
              <source>JAMA</source>
              <year>2021</year>
              <volume>326</volume>
              <fpage>851</fpage>
              <pub-id pub-id-type="pmid">34547082</pub-id>
              <pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.2021.13027</pub-id>
              <pub-id pub-id-type="pmcid">PMC9363152</pub-id>
            </element-citation>
            <mixed-citation id="mc-CR5" publication-type="journal">Park, W., Chawla, A. &amp; O’Reilly, E. M. Pancreatic cancer: a review. <italic toggle="yes">JAMA</italic><bold>326</bold>, 851 (2021).<pub-id pub-id-type="pmid">34547082</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.2021.13027</pub-id><pub-id pub-id-type="pmcid">PMC9363152</pub-id></mixed-citation>
          </citation-alternatives>
        </ref>
        <ref id="CR6">
          <label>6.</label>
          <citation-alternatives>
            <element-citation id="ec-CR6" publication-type="journal">
              <person-group person-group-type="author">
                <name name-style="western">
                  <surname>Arbour</surname>
                  <given-names>KC</given-names>
                </name>
                <etal/>
              </person-group>
              <article-title>652O Preliminary clinical activity of RMC-6236, a first-in-class, RAS-selective, tri-complex RAS-MULTI(ON) inhibitor in patients with KRAS mutant pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC)</article-title>
              <source>Ann. Oncol.</source>
              <year>2023</year>
              <volume>34</volume>
              <fpage>S458</fpage>
            </element-citation>
            <mixed-citation id="mc-CR6" publication-type="journal">Arbour, K. C. et al. 652O Preliminary clinical activity of RMC-6236, a first-in-class, RAS-selective, tri-complex RAS-MULTI(ON) inhibitor in patients with KRAS mutant pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC). <italic toggle="yes">Ann. Oncol.</italic><bold>34</bold>, S458 (2023).</mixed-citation>
          </citation-alternatives>
        </ref>
        <ref id="CR7">
          <label>7.</label>
          <citation-alternatives>
            <element-citation id="ec-CR7" publication-type="journal">
              <person-group person-group-type="author">
                <name name-style="western">
                  <surname>Drilon</surname>
                  <given-names>A</given-names>
                </name>
                <etal/>
              </person-group>
              <article-title>Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children</article-title>
              <source>N. Engl. J. Med.</source>
              <year>2018</year>
              <volume>378</volume>
              <fpage>731</fpage>
              <lpage>739</lpage>
              <pub-id pub-id-type="pmid">29466156</pub-id>
              <pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa1714448</pub-id>
              <pub-id pub-id-type="pmcid">PMC5857389</pub-id>
            </element-citation>
            <mixed-citation id="mc-CR7" publication-type="journal">Drilon, A. et al. Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. <italic toggle="yes">N. Engl. J. Med.</italic><bold>378</bold>, 731–739 (2018).<pub-id pub-id-type="pmid">29466156</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa1714448</pub-id><pub-id pub-id-type="pmcid">PMC5857389</pub-id></mixed-citation>
          </citation-alternatives>
        </ref>
        <ref id="CR8">
          <label>8.</label>
          <citation-alternatives>
            <element-citation id="ec-CR8" publication-type="journal">
              <person-group person-group-type="author">
                <name name-style="western">
                  <surname>Guan</surname>
                  <given-names>M</given-names>
                </name>
                <etal/>
              </person-group>
              <article-title>Molecular and clinical characterization of BRAF mutations in pancreatic ductal adenocarcinomas (PDACs)</article-title>
              <source>J. Clin. Oncol.</source>
              <year>2018</year>
              <volume>36</volume>
              <fpage>214</fpage>
              <lpage>214</lpage>
            </element-citation>
            <mixed-citation id="mc-CR8" publication-type="journal">Guan, M. et al. Molecular and clinical characterization of BRAF mutations in pancreatic ductal adenocarcinomas (PDACs). <italic toggle="yes">J. Clin. Oncol.</italic><bold>36</bold>, 214–214 (2018).</mixed-citation>
          </citation-alternatives>
        </ref>
        <ref id="CR9">
          <label>9.</label>
          <citation-alternatives>
            <element-citation id="ec-CR9" publication-type="journal">
              <person-group person-group-type="author">
                <name name-style="western">
                  <surname>Li</surname>
                  <given-names>H-S</given-names>
                </name>
                <name name-style="western">
                  <surname>Yang</surname>
                  <given-names>K</given-names>
                </name>
                <name name-style="western">
                  <surname>Wang</surname>
                  <given-names>Y</given-names>
                </name>
              </person-group>
              <article-title>Remarkable response of <italic toggle="yes">BRAF</italic> V600E-mutated metastatic pancreatic cancer to BRAF/MEK inhibition: a case report</article-title>
              <source>Gastroenterol. Rep.</source>
              <year>2022</year>
              <volume>10</volume>
              <fpage>goab031</fpage>
              <pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/gastro/goab031</pub-id>
              <pub-id pub-id-type="pmcid">PMC8972987</pub-id>
              <pub-id pub-id-type="pmid">35382161</pub-id>
            </element-citation>
            <mixed-citation id="mc-CR9" publication-type="journal">Li, H.-S., Yang, K. &amp; Wang, Y. Remarkable response of <italic toggle="yes">BRAF</italic> V600E-mutated metastatic pancreatic cancer to BRAF/MEK inhibition: a case report. <italic toggle="yes">Gastroenterol. Rep.</italic><bold>10</bold>, goab031 (2022).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/gastro/goab031</pub-id><pub-id pub-id-type="pmcid">PMC8972987</pub-id><pub-id pub-id-type="pmid">35382161</pub-id></mixed-citation>
          </citation-alternatives>
        </ref>
        <ref id="CR10">
          <label>10.</label>
          <citation-alternatives>
            <element-citation id="ec-CR10" publication-type="journal">
              <person-group person-group-type="author">
                <name name-style="western">
                  <surname>Schram</surname>
                  <given-names>AM</given-names>
                </name>
                <etal/>
              </person-group>
              <article-title>Zenocutuzumab, a HER2xHER3 bispecific antibody, is effective therapy for tumors driven by <italic toggle="yes">NRG1</italic> gene rearrangements</article-title>
              <source>Cancer Discov.</source>
              <year>2022</year>
              <volume>12</volume>
              <fpage>1233</fpage>
              <lpage>1247</lpage>
              <pub-id pub-id-type="pmid">35135829</pub-id>
              <pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/2159-8290.CD-21-1119</pub-id>
              <pub-id pub-id-type="pmcid">PMC9394398</pub-id>
            </element-citation>
            <mixed-citation id="mc-CR10" publication-type="journal">Schram, A. M. et al. Zenocutuzumab, a HER2xHER3 bispecific antibody, is effective therapy for tumors driven by <italic toggle="yes">NRG1</italic> gene rearrangements. <italic toggle="yes">Cancer Discov.</italic><bold>12</bold>, 1233–1247 (2022).<pub-id pub-id-type="pmid">35135829</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/2159-8290.CD-21-1119</pub-id><pub-id pub-id-type="pmcid">PMC9394398</pub-id></mixed-citation>
          </citation-alternatives>
        </ref>
        <ref id="CR11">
          <label>11.</label>
          <citation-alternatives>
            <element-citation id="ec-CR11" publication-type="journal">
              <person-group person-group-type="author">
                <name name-style="western">
                  <surname>Philip</surname>
                  <given-names>PA</given-names>
                </name>
                <etal/>
              </person-group>
              <article-title>Molecular characterization of <italic toggle="yes">KRAS</italic> wild-type tumors in patients with pancreatic adenocarcinoma</article-title>
              <source>Clin. Cancer Res.</source>
              <year>2022</year>
              <volume>28</volume>
              <fpage>2704</fpage>
              <lpage>2714</lpage>
              <pub-id pub-id-type="pmid">35302596</pub-id>
              <pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/1078-0432.CCR-21-3581</pub-id>
              <pub-id pub-id-type="pmcid">PMC9541577</pub-id>
            </element-citation>
            <mixed-citation id="mc-CR11" publication-type="journal">Philip, P. A. et al. Molecular characterization of <italic toggle="yes">KRAS</italic> wild-type tumors in patients with pancreatic adenocarcinoma. <italic toggle="yes">Clin. Cancer Res.</italic><bold>28</bold>, 2704–2714 (2022).<pub-id pub-id-type="pmid">35302596</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/1078-0432.CCR-21-3581</pub-id><pub-id pub-id-type="pmcid">PMC9541577</pub-id></mixed-citation>
          </citation-alternatives>
        </ref>
        <ref id="CR12">
          <label>12.</label>
          <citation-alternatives>
            <element-citation id="ec-CR12" publication-type="journal">
              <person-group person-group-type="author">
                <name name-style="western">
                  <surname>Le</surname>
                  <given-names>DT</given-names>
                </name>
                <etal/>
              </person-group>
              <article-title>PD-1 blockade in tumors with mismatch-repair deficiency</article-title>
              <source>N. Engl. J. Med.</source>
              <year>2015</year>
              <volume>372</volume>
              <fpage>2509</fpage>
              <lpage>2520</lpage>
              <pub-id pub-id-type="pmid">26028255</pub-id>
              <pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa1500596</pub-id>
              <pub-id pub-id-type="pmcid">PMC4481136</pub-id>
            </element-citation>
            <mixed-citation id="mc-CR12" publication-type="journal">Le, D. T. et al. PD-1 blockade in tumors with mismatch-repair deficiency. <italic toggle="yes">N. Engl. J. Med.</italic><bold>372</bold>, 2509–2520 (2015).<pub-id pub-id-type="pmid">26028255</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa1500596</pub-id><pub-id pub-id-type="pmcid">PMC4481136</pub-id></mixed-citation>
          </citation-alternatives>
        </ref>
        <ref id="CR13">
          <label>13.</label>
          <citation-alternatives>
            <element-citation id="ec-CR13" publication-type="journal">
              <person-group person-group-type="author">
                <name name-style="western">
                  <surname>Topham</surname>
                  <given-names>JT</given-names>
                </name>
                <etal/>
              </person-group>
              <article-title>Integrative analysis of KRAS wildtype metastatic pancreatic ductal adenocarcinoma reveals mutation and expression-based similarities to cholangiocarcinoma</article-title>
              <source>Nat. Commun.</source>
              <year>2022</year>
              <volume>13</volume>
              <fpage>5941</fpage>
              <pub-id pub-id-type="pmid">36209277</pub-id>
              <pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-022-33718-7</pub-id>
              <pub-id pub-id-type="pmcid">PMC9547977</pub-id>
            </element-citation>
            <mixed-citation id="mc-CR13" publication-type="journal">Topham, J. T. et al. Integrative analysis of KRAS wildtype metastatic pancreatic ductal adenocarcinoma reveals mutation and expression-based similarities to cholangiocarcinoma. <italic toggle="yes">Nat. Commun.</italic><bold>13</bold>, 5941 (2022).<pub-id pub-id-type="pmid">36209277</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-022-33718-7</pub-id><pub-id pub-id-type="pmcid">PMC9547977</pub-id></mixed-citation>
          </citation-alternatives>
        </ref>
        <ref id="CR14">
          <label>14.</label>
          <citation-alternatives>
            <element-citation id="ec-CR14" publication-type="journal">
              <person-group person-group-type="author">
                <name name-style="western">
                  <surname>Singh</surname>
                  <given-names>H</given-names>
                </name>
                <etal/>
              </person-group>
              <article-title>Oncogenic drivers and therapeutic vulnerabilities in KRAS wild-type pancreatic cancer</article-title>
              <source>Clin. Cancer Res.</source>
              <year>2023</year>
              <volume>29</volume>
              <fpage>4627</fpage>
              <lpage>4643</lpage>
              <pub-id pub-id-type="pmid">37463056</pub-id>
              <pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/1078-0432.CCR-22-3930</pub-id>
              <pub-id pub-id-type="pmcid">PMC10795103</pub-id>
            </element-citation>
            <mixed-citation id="mc-CR14" publication-type="journal">Singh, H. et al. Oncogenic drivers and therapeutic vulnerabilities in KRAS wild-type pancreatic cancer. <italic toggle="yes">Clin. Cancer Res.</italic><bold>29</bold>, 4627–4643 (2023).<pub-id pub-id-type="pmid">37463056</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/1078-0432.CCR-22-3930</pub-id><pub-id pub-id-type="pmcid">PMC10795103</pub-id></mixed-citation>
          </citation-alternatives>
        </ref>
        <ref id="CR15">
          <label>15.</label>
          <citation-alternatives>
            <element-citation id="ec-CR15" publication-type="journal">
              <person-group person-group-type="author">
                <name name-style="western">
                  <surname>Pishvaian</surname>
                  <given-names>MJ</given-names>
                </name>
                <etal/>
              </person-group>
              <article-title>Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: a retrospective analysis of the Know Your Tumor registry trial</article-title>
              <source>Lancet Oncol.</source>
              <year>2020</year>
              <volume>21</volume>
              <fpage>508</fpage>
              <lpage>518</lpage>
              <pub-id pub-id-type="pmid">32135080</pub-id>
              <pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1470-2045(20)30074-7</pub-id>
              <pub-id pub-id-type="pmcid">PMC7453743</pub-id>
            </element-citation>
            <mixed-citation id="mc-CR15" publication-type="journal">Pishvaian, M. J. et al. Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: a retrospective analysis of the Know Your Tumor registry trial. <italic toggle="yes">Lancet Oncol.</italic><bold>21</bold>, 508–518 (2020).<pub-id pub-id-type="pmid">32135080</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1470-2045(20)30074-7</pub-id><pub-id pub-id-type="pmcid">PMC7453743</pub-id></mixed-citation>
          </citation-alternatives>
        </ref>
        <ref id="CR16">
          <label>16.</label>
          <citation-alternatives>
            <element-citation id="ec-CR16" publication-type="journal">
              <person-group person-group-type="author">
                <name name-style="western">
                  <surname>Golan</surname>
                  <given-names>T</given-names>
                </name>
                <etal/>
              </person-group>
              <article-title>Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer</article-title>
              <source>N. Engl. J. Med.</source>
              <year>2019</year>
              <volume>381</volume>
              <fpage>317</fpage>
              <lpage>327</lpage>
              <pub-id pub-id-type="pmid">31157963</pub-id>
              <pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa1903387</pub-id>
              <pub-id pub-id-type="pmcid">PMC6810605</pub-id>
            </element-citation>
            <mixed-citation id="mc-CR16" publication-type="journal">Golan, T. et al. Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. <italic toggle="yes">N. Engl. J. Med.</italic><bold>381</bold>, 317–327 (2019).<pub-id pub-id-type="pmid">31157963</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa1903387</pub-id><pub-id pub-id-type="pmcid">PMC6810605</pub-id></mixed-citation>
          </citation-alternatives>
        </ref>
        <ref id="CR17">
          <label>17.</label>
          <citation-alternatives>
            <element-citation id="ec-CR17" publication-type="journal">
              <person-group person-group-type="author">
                <name name-style="western">
                  <surname>O’Reilly</surname>
                  <given-names>EM</given-names>
                </name>
                <etal/>
              </person-group>
              <article-title>Randomized, multicenter, phase II trial of gemcitabine and cisplatin with or without veliparib in patients with pancreas adenocarcinoma and a germline <italic toggle="yes">BRCA</italic>/<italic toggle="yes">PALB2</italic> mutation</article-title>
              <source>J. Clin. Oncol.</source>
              <year>2020</year>
              <volume>38</volume>
              <fpage>1378</fpage>
              <lpage>1388</lpage>
              <pub-id pub-id-type="pmid">31976786</pub-id>
              <pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.19.02931</pub-id>
              <pub-id pub-id-type="pmcid">PMC7193749</pub-id>
            </element-citation>
            <mixed-citation id="mc-CR17" publication-type="journal">O’Reilly, E. M. et al. Randomized, multicenter, phase II trial of gemcitabine and cisplatin with or without veliparib in patients with pancreas adenocarcinoma and a germline <italic toggle="yes">BRCA</italic>/<italic toggle="yes">PALB2</italic> mutation. <italic toggle="yes">J. Clin. Oncol.</italic><bold>38</bold>, 1378–1388 (2020).<pub-id pub-id-type="pmid">31976786</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.19.02931</pub-id><pub-id pub-id-type="pmcid">PMC7193749</pub-id></mixed-citation>
          </citation-alternatives>
        </ref>
        <ref id="CR18">
          <label>18.</label>
          <citation-alternatives>
            <element-citation id="ec-CR18" publication-type="journal">
              <person-group person-group-type="author">
                <name name-style="western">
                  <surname>Park</surname>
                  <given-names>W</given-names>
                </name>
                <etal/>
              </person-group>
              <article-title>Genomic methods identify homologous recombination deficiency in pancreas adenocarcinoma and optimize treatment selection</article-title>
              <source>Clin. Cancer Res.</source>
              <year>2020</year>
              <volume>26</volume>
              <fpage>3239</fpage>
              <lpage>3247</lpage>
              <pub-id pub-id-type="pmid">32444418</pub-id>
              <pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/1078-0432.CCR-20-0418</pub-id>
              <pub-id pub-id-type="pmcid">PMC7380542</pub-id>
            </element-citation>
            <mixed-citation id="mc-CR18" publication-type="journal">Park, W. et al. Genomic methods identify homologous recombination deficiency in pancreas adenocarcinoma and optimize treatment selection. <italic toggle="yes">Clin. Cancer Res.</italic><bold>26</bold>, 3239–3247 (2020).<pub-id pub-id-type="pmid">32444418</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/1078-0432.CCR-20-0418</pub-id><pub-id pub-id-type="pmcid">PMC7380542</pub-id></mixed-citation>
          </citation-alternatives>
        </ref>
        <ref id="CR19">
          <label>19.</label>
          <citation-alternatives>
            <element-citation id="ec-CR19" publication-type="journal">
              <person-group person-group-type="author">
                <name name-style="western">
                  <surname>Blackford</surname>
                  <given-names>A</given-names>
                </name>
                <etal/>
              </person-group>
              <article-title><italic toggle="yes">SMAD4</italic> gene mutations are associated with poor prognosis in pancreatic cancer</article-title>
              <source>Clin. Cancer Res.</source>
              <year>2009</year>
              <volume>15</volume>
              <fpage>4674</fpage>
              <lpage>4679</lpage>
              <pub-id pub-id-type="pmid">19584151</pub-id>
              <pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/1078-0432.CCR-09-0227</pub-id>
              <pub-id pub-id-type="pmcid">PMC2819274</pub-id>
            </element-citation>
            <mixed-citation id="mc-CR19" publication-type="journal">Blackford, A. et al. <italic toggle="yes">SMAD4</italic> gene mutations are associated with poor prognosis in pancreatic cancer. <italic toggle="yes">Clin. Cancer Res.</italic><bold>15</bold>, 4674–4679 (2009).<pub-id pub-id-type="pmid">19584151</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/1078-0432.CCR-09-0227</pub-id><pub-id pub-id-type="pmcid">PMC2819274</pub-id></mixed-citation>
          </citation-alternatives>
        </ref>
        <ref id="CR20">
          <label>20.</label>
          <citation-alternatives>
            <element-citation id="ec-CR20" publication-type="journal">
              <person-group person-group-type="author">
                <name name-style="western">
                  <surname>Crane</surname>
                  <given-names>CH</given-names>
                </name>
                <etal/>
              </person-group>
              <article-title>Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: correlation of <italic toggle="yes">Smad4(Dpc4)</italic> immunostaining with pattern of disease progression</article-title>
              <source>J. Clin. Oncol.</source>
              <year>2011</year>
              <volume>29</volume>
              <fpage>3037</fpage>
              <lpage>3043</lpage>
              <pub-id pub-id-type="pmid">21709185</pub-id>
              <pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.2010.33.8038</pub-id>
              <pub-id pub-id-type="pmcid">PMC3157965</pub-id>
            </element-citation>
            <mixed-citation id="mc-CR20" publication-type="journal">Crane, C. H. et al. Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: correlation of <italic toggle="yes">Smad4(Dpc4)</italic> immunostaining with pattern of disease progression. <italic toggle="yes">J. Clin. Oncol.</italic><bold>29</bold>, 3037–3043 (2011).<pub-id pub-id-type="pmid">21709185</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.2010.33.8038</pub-id><pub-id pub-id-type="pmcid">PMC3157965</pub-id></mixed-citation>
          </citation-alternatives>
        </ref>
        <ref id="CR21">
          <label>21.</label>
          <citation-alternatives>
            <element-citation id="ec-CR21" publication-type="journal">
              <person-group person-group-type="author">
                <name name-style="western">
                  <surname>Raphael</surname>
                  <given-names>BJ</given-names>
                </name>
                <etal/>
              </person-group>
              <article-title>Integrated genomic characterization of pancreatic ductal adenocarcinoma</article-title>
              <source>Cancer Cell</source>
              <year>2017</year>
              <volume>32</volume>
              <fpage>185</fpage>
              <lpage>203.e13</lpage>
              <pub-id pub-id-type="pmid">28810144</pub-id>
              <pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ccell.2017.07.007</pub-id>
              <pub-id pub-id-type="pmcid">PMC5964983</pub-id>
            </element-citation>
            <mixed-citation id="mc-CR21" publication-type="journal">Raphael, B. J. et al. Integrated genomic characterization of pancreatic ductal adenocarcinoma. <italic toggle="yes">Cancer Cell</italic><bold>32</bold>, 185–203.e13 (2017).<pub-id pub-id-type="pmid">28810144</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ccell.2017.07.007</pub-id><pub-id pub-id-type="pmcid">PMC5964983</pub-id></mixed-citation>
          </citation-alternatives>
        </ref>
        <ref id="CR22">
          <label>22.</label>
          <citation-alternatives>
            <element-citation id="ec-CR22" publication-type="journal">
              <person-group person-group-type="author">
                <name name-style="western">
                  <surname>Lowery</surname>
                  <given-names>MA</given-names>
                </name>
                <etal/>
              </person-group>
              <article-title>Real-time genomic profiling of pancreatic ductal adenocarcinoma: potential actionability and correlation with clinical phenotype</article-title>
              <source>Clin. Cancer Res.</source>
              <year>2017</year>
              <volume>23</volume>
              <fpage>6094</fpage>
              <lpage>6100</lpage>
              <pub-id pub-id-type="pmid">28754816</pub-id>
              <pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/1078-0432.CCR-17-0899</pub-id>
            </element-citation>
            <mixed-citation id="mc-CR22" publication-type="journal">Lowery, M. A. et al. Real-time genomic profiling of pancreatic ductal adenocarcinoma: potential actionability and correlation with clinical phenotype. <italic toggle="yes">Clin. Cancer Res.</italic><bold>23</bold>, 6094–6100 (2017).<pub-id pub-id-type="pmid">28754816</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/1078-0432.CCR-17-0899</pub-id></mixed-citation>
          </citation-alternatives>
        </ref>
        <ref id="CR23">
          <label>23.</label>
          <citation-alternatives>
            <element-citation id="ec-CR23" publication-type="journal">
              <person-group person-group-type="author">
                <name name-style="western">
                  <surname>Bailey</surname>
                  <given-names>P</given-names>
                </name>
                <etal/>
              </person-group>
              <article-title>Genomic analyses identify molecular subtypes of pancreatic cancer</article-title>
              <source>Nature</source>
              <year>2016</year>
              <volume>531</volume>
              <fpage>47</fpage>
              <lpage>52</lpage>
              <pub-id pub-id-type="pmid">26909576</pub-id>
              <pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nature16965</pub-id>
            </element-citation>
            <mixed-citation id="mc-CR23" publication-type="journal">Bailey, P. et al. Genomic analyses identify molecular subtypes of pancreatic cancer. <italic toggle="yes">Nature</italic><bold>531</bold>, 47–52 (2016).<pub-id pub-id-type="pmid">26909576</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nature16965</pub-id></mixed-citation>
          </citation-alternatives>
        </ref>
        <ref id="CR24">
          <label>24.</label>
          <citation-alternatives>
            <element-citation id="ec-CR24" publication-type="journal">
              <person-group person-group-type="author">
                <name name-style="western">
                  <surname>Collisson</surname>
                  <given-names>EA</given-names>
                </name>
                <etal/>
              </person-group>
              <article-title>Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy</article-title>
              <source>Nat. Med.</source>
              <year>2011</year>
              <volume>17</volume>
              <fpage>500</fpage>
              <lpage>503</lpage>
              <pub-id pub-id-type="pmid">21460848</pub-id>
              <pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nm.2344</pub-id>
              <pub-id pub-id-type="pmcid">PMC3755490</pub-id>
            </element-citation>
            <mixed-citation id="mc-CR24" publication-type="journal">Collisson, E. A. et al. Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. <italic toggle="yes">Nat. Med.</italic><bold>17</bold>, 500–503 (2011).<pub-id pub-id-type="pmid">21460848</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nm.2344</pub-id><pub-id pub-id-type="pmcid">PMC3755490</pub-id></mixed-citation>
          </citation-alternatives>
        </ref>
        <ref id="CR25">
          <label>25.</label>
          <citation-alternatives>
            <element-citation id="ec-CR25" publication-type="journal">
              <person-group person-group-type="author">
                <name name-style="western">
                  <surname>Moffitt</surname>
                  <given-names>RA</given-names>
                </name>
                <etal/>
              </person-group>
              <article-title>Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma</article-title>
              <source>Nat. Genet.</source>
              <year>2015</year>
              <volume>47</volume>
              <fpage>1168</fpage>
              <lpage>1178</lpage>
              <pub-id pub-id-type="pmid">26343385</pub-id>
              <pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/ng.3398</pub-id>
              <pub-id pub-id-type="pmcid">PMC4912058</pub-id>
            </element-citation>
            <mixed-citation id="mc-CR25" publication-type="journal">Moffitt, R. A. et al. Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma. <italic toggle="yes">Nat. Genet.</italic><bold>47</bold>, 1168–1178 (2015).<pub-id pub-id-type="pmid">26343385</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/ng.3398</pub-id><pub-id pub-id-type="pmcid">PMC4912058</pub-id></mixed-citation>
          </citation-alternatives>
        </ref>
        <ref id="CR26">
          <label>26.</label>
          <citation-alternatives>
            <element-citation id="ec-CR26" publication-type="journal">
              <person-group person-group-type="author">
                <name name-style="western">
                  <surname>Waddell</surname>
                  <given-names>N</given-names>
                </name>
                <etal/>
              </person-group>
              <article-title>Whole genomes redefine the mutational landscape of pancreatic cancer</article-title>
              <source>Nature</source>
              <year>2015</year>
              <volume>518</volume>
              <fpage>495</fpage>
              <lpage>501</lpage>
              <pub-id pub-id-type="pmid">25719666</pub-id>
              <pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nature14169</pub-id>
              <pub-id pub-id-type="pmcid">PMC4523082</pub-id>
            </element-citation>
            <mixed-citation id="mc-CR26" publication-type="journal">Waddell, N. et al. Whole genomes redefine the mutational landscape of pancreatic cancer. <italic toggle="yes">Nature</italic><bold>518</bold>, 495–501 (2015).<pub-id pub-id-type="pmid">25719666</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nature14169</pub-id><pub-id pub-id-type="pmcid">PMC4523082</pub-id></mixed-citation>
          </citation-alternatives>
        </ref>
        <ref id="CR27">
          <label>27.</label>
          <citation-alternatives>
            <element-citation id="ec-CR27" publication-type="journal">
              <person-group person-group-type="author">
                <name name-style="western">
                  <surname>Puleo</surname>
                  <given-names>F</given-names>
                </name>
                <etal/>
              </person-group>
              <article-title>Stratification of pancreatic ductal adenocarcinomas based on tumor and microenvironment features</article-title>
              <source>Gastroenterology</source>
              <year>2018</year>
              <volume>155</volume>
              <fpage>1999</fpage>
              <lpage>2013.e3</lpage>
              <pub-id pub-id-type="pmid">30165049</pub-id>
              <pub-id pub-id-type="doi" assigning-authority="pmc">10.1053/j.gastro.2018.08.033</pub-id>
            </element-citation>
            <mixed-citation id="mc-CR27" publication-type="journal">Puleo, F. et al. Stratification of pancreatic ductal adenocarcinomas based on tumor and microenvironment features. <italic toggle="yes">Gastroenterology</italic><bold>155</bold>, 1999–2013.e3 (2018).<pub-id pub-id-type="pmid">30165049</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1053/j.gastro.2018.08.033</pub-id></mixed-citation>
          </citation-alternatives>
        </ref>
        <ref id="CR28">
          <label>28.</label>
          <citation-alternatives>
            <element-citation id="ec-CR28" publication-type="journal">
              <person-group person-group-type="author">
                <name name-style="western">
                  <surname>Bielski</surname>
                  <given-names>CM</given-names>
                </name>
                <etal/>
              </person-group>
              <article-title>Widespread selection for oncogenic mutant allele imbalance in cancer</article-title>
              <source>Cancer Cell</source>
              <year>2018</year>
              <volume>34</volume>
              <fpage>852</fpage>
              <lpage>862.e4</lpage>
              <pub-id pub-id-type="pmid">30393068</pub-id>
              <pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ccell.2018.10.003</pub-id>
              <pub-id pub-id-type="pmcid">PMC6234065</pub-id>
            </element-citation>
            <mixed-citation id="mc-CR28" publication-type="journal">Bielski, C. M. et al. Widespread selection for oncogenic mutant allele imbalance in cancer. <italic toggle="yes">Cancer Cell</italic><bold>34</bold>, 852–862.e4 (2018).<pub-id pub-id-type="pmid">30393068</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ccell.2018.10.003</pub-id><pub-id pub-id-type="pmcid">PMC6234065</pub-id></mixed-citation>
          </citation-alternatives>
        </ref>
        <ref id="CR29">
          <label>29.</label>
          <citation-alternatives>
            <element-citation id="ec-CR29" publication-type="journal">
              <person-group person-group-type="author">
                <name name-style="western">
                  <surname>Mueller</surname>
                  <given-names>S</given-names>
                </name>
                <etal/>
              </person-group>
              <article-title>Evolutionary routes and KRAS dosage define pancreatic cancer phenotypes</article-title>
              <source>Nature</source>
              <year>2018</year>
              <volume>554</volume>
              <fpage>62</fpage>
              <lpage>68</lpage>
              <pub-id pub-id-type="pmid">29364867</pub-id>
              <pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nature25459</pub-id>
              <pub-id pub-id-type="pmcid">PMC6097607</pub-id>
            </element-citation>
            <mixed-citation id="mc-CR29" publication-type="journal">Mueller, S. et al. Evolutionary routes and KRAS dosage define pancreatic cancer phenotypes. <italic toggle="yes">Nature</italic><bold>554</bold>, 62–68 (2018).<pub-id pub-id-type="pmid">29364867</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nature25459</pub-id><pub-id pub-id-type="pmcid">PMC6097607</pub-id></mixed-citation>
          </citation-alternatives>
        </ref>
        <ref id="CR30">
          <label>30.</label>
          <citation-alternatives>
            <element-citation id="ec-CR30" publication-type="journal">
              <person-group person-group-type="author">
                <name name-style="western">
                  <surname>Bielski</surname>
                  <given-names>CM</given-names>
                </name>
                <etal/>
              </person-group>
              <article-title>Genome doubling shapes the evolution and prognosis of advanced cancers</article-title>
              <source>Nat. Genet.</source>
              <year>2018</year>
              <volume>50</volume>
              <fpage>1189</fpage>
              <lpage>1195</lpage>
              <pub-id pub-id-type="pmid">30013179</pub-id>
              <pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41588-018-0165-1</pub-id>
              <pub-id pub-id-type="pmcid">PMC6072608</pub-id>
            </element-citation>
            <mixed-citation id="mc-CR30" publication-type="journal">Bielski, C. M. et al. Genome doubling shapes the evolution and prognosis of advanced cancers. <italic toggle="yes">Nat. Genet.</italic><bold>50</bold>, 1189–1195 (2018).<pub-id pub-id-type="pmid">30013179</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41588-018-0165-1</pub-id><pub-id pub-id-type="pmcid">PMC6072608</pub-id></mixed-citation>
          </citation-alternatives>
        </ref>
        <ref id="CR31">
          <label>31.</label>
          <citation-alternatives>
            <element-citation id="ec-CR31" publication-type="journal">
              <person-group person-group-type="author">
                <name name-style="western">
                  <surname>Chan-Seng-Yue</surname>
                  <given-names>M</given-names>
                </name>
                <etal/>
              </person-group>
              <article-title>Transcription phenotypes of pancreatic cancer are driven by genomic events during tumor evolution</article-title>
              <source>Nat. Genet.</source>
              <year>2020</year>
              <volume>52</volume>
              <fpage>231</fpage>
              <lpage>240</lpage>
              <pub-id pub-id-type="pmid">31932696</pub-id>
              <pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41588-019-0566-9</pub-id>
            </element-citation>
            <mixed-citation id="mc-CR31" publication-type="journal">Chan-Seng-Yue, M. et al. Transcription phenotypes of pancreatic cancer are driven by genomic events during tumor evolution. <italic toggle="yes">Nat. Genet.</italic><bold>52</bold>, 231–240 (2020).<pub-id pub-id-type="pmid">31932696</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41588-019-0566-9</pub-id></mixed-citation>
          </citation-alternatives>
        </ref>
        <ref id="CR32">
          <label>32.</label>
          <citation-alternatives>
            <element-citation id="ec-CR32" publication-type="journal">
              <person-group person-group-type="author">
                <name name-style="western">
                  <surname>Cheng</surname>
                  <given-names>DT</given-names>
                </name>
                <etal/>
              </person-group>
              <article-title>Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): a hybridization capture-based next-generation sequencing clinical assay for solid tumor molecular oncology</article-title>
              <source>J. Mol. Diagn.</source>
              <year>2015</year>
              <volume>17</volume>
              <fpage>251</fpage>
              <lpage>264</lpage>
              <pub-id pub-id-type="pmid">25801821</pub-id>
              <pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jmoldx.2014.12.006</pub-id>
              <pub-id pub-id-type="pmcid">PMC5808190</pub-id>
            </element-citation>
            <mixed-citation id="mc-CR32" publication-type="journal">Cheng, D. T. et al. Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): a hybridization capture-based next-generation sequencing clinical assay for solid tumor molecular oncology. <italic toggle="yes">J. Mol. Diagn.</italic><bold>17</bold>, 251–264 (2015).<pub-id pub-id-type="pmid">25801821</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jmoldx.2014.12.006</pub-id><pub-id pub-id-type="pmcid">PMC5808190</pub-id></mixed-citation>
          </citation-alternatives>
        </ref>
        <ref id="CR33">
          <label>33.</label>
          <citation-alternatives>
            <element-citation id="ec-CR33" publication-type="journal">
              <person-group person-group-type="author">
                <name name-style="western">
                  <surname>Zehir</surname>
                  <given-names>A</given-names>
                </name>
                <etal/>
              </person-group>
              <article-title>Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients</article-title>
              <source>Nat. Med.</source>
              <year>2017</year>
              <volume>23</volume>
              <fpage>703</fpage>
              <lpage>713</lpage>
              <pub-id pub-id-type="pmid">28481359</pub-id>
              <pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nm.4333</pub-id>
              <pub-id pub-id-type="pmcid">PMC5461196</pub-id>
            </element-citation>
            <mixed-citation id="mc-CR33" publication-type="journal">Zehir, A. et al. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. <italic toggle="yes">Nat. Med.</italic><bold>23</bold>, 703–713 (2017).<pub-id pub-id-type="pmid">28481359</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nm.4333</pub-id><pub-id pub-id-type="pmcid">PMC5461196</pub-id></mixed-citation>
          </citation-alternatives>
        </ref>
        <ref id="CR34">
          <label>34.</label>
          <citation-alternatives>
            <element-citation id="ec-CR34" publication-type="journal">
              <person-group person-group-type="author">
                <name name-style="western">
                  <surname>Chakravarty</surname>
                  <given-names>D</given-names>
                </name>
                <etal/>
              </person-group>
              <article-title>OncoKB: a precision oncology knowledge base</article-title>
              <source>JCO Precis. Oncol.</source>
              <year>2017</year>
              <volume>2017</volume>
              <fpage>PO.17.00011</fpage>
              <pub-id pub-id-type="pmid">28890946</pub-id>
              <pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/PO.17.00011</pub-id>
              <pub-id pub-id-type="pmcid">PMC5586540</pub-id>
            </element-citation>
            <mixed-citation id="mc-CR34" publication-type="journal">Chakravarty, D. et al. OncoKB: a precision oncology knowledge base. <italic toggle="yes">JCO Precis. Oncol.</italic><bold>2017</bold>, PO.17.00011 (2017).<pub-id pub-id-type="pmid">28890946</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/PO.17.00011</pub-id><pub-id pub-id-type="pmcid">PMC5586540</pub-id></mixed-citation>
          </citation-alternatives>
        </ref>
        <ref id="CR35">
          <label>35.</label>
          <citation-alternatives>
            <element-citation id="ec-CR35" publication-type="journal">
              <person-group person-group-type="author">
                <name name-style="western">
                  <surname>Foster</surname>
                  <given-names>SA</given-names>
                </name>
                <etal/>
              </person-group>
              <article-title>Activation mechanism of oncogenic deletion mutations in BRAF, EGFR, and HER2</article-title>
              <source>Cancer Cell</source>
              <year>2016</year>
              <volume>29</volume>
              <fpage>477</fpage>
              <lpage>493</lpage>
              <pub-id pub-id-type="pmid">26996308</pub-id>
              <pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ccell.2016.02.010</pub-id>
            </element-citation>
            <mixed-citation id="mc-CR35" publication-type="journal">Foster, S. A. et al. Activation mechanism of oncogenic deletion mutations in BRAF, EGFR, and HER2. <italic toggle="yes">Cancer Cell</italic><bold>29</bold>, 477–493 (2016).<pub-id pub-id-type="pmid">26996308</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ccell.2016.02.010</pub-id></mixed-citation>
          </citation-alternatives>
        </ref>
        <ref id="CR36">
          <label>36.</label>
          <citation-alternatives>
            <element-citation id="ec-CR36" publication-type="journal">
              <person-group person-group-type="author">
                <name name-style="western">
                  <surname>Collisson</surname>
                  <given-names>EA</given-names>
                </name>
                <etal/>
              </person-group>
              <article-title>A central role for RAF→MEK→ERK signaling in the genesis of pancreatic ductal adenocarcinoma</article-title>
              <source>Cancer Discov.</source>
              <year>2012</year>
              <volume>2</volume>
              <fpage>685</fpage>
              <lpage>693</lpage>
              <pub-id pub-id-type="pmid">22628411</pub-id>
              <pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/2159-8290.CD-11-0347</pub-id>
              <pub-id pub-id-type="pmcid">PMC3425446</pub-id>
            </element-citation>
            <mixed-citation id="mc-CR36" publication-type="journal">Collisson, E. A. et al. A central role for RAF→MEK→ERK signaling in the genesis of pancreatic ductal adenocarcinoma. <italic toggle="yes">Cancer Discov.</italic><bold>2</bold>, 685–693 (2012).<pub-id pub-id-type="pmid">22628411</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/2159-8290.CD-11-0347</pub-id><pub-id pub-id-type="pmcid">PMC3425446</pub-id></mixed-citation>
          </citation-alternatives>
        </ref>
        <ref id="CR37">
          <label>37.</label>
          <citation-alternatives>
            <element-citation id="ec-CR37" publication-type="journal">
              <person-group person-group-type="author">
                <name name-style="western">
                  <surname>Agaimy</surname>
                  <given-names>A</given-names>
                </name>
                <etal/>
              </person-group>
              <article-title>Pancreatic undifferentiated rhabdoid carcinoma: KRAS alterations and SMARCB1 expression status define two subtypes</article-title>
              <source>Mod. Pathol.</source>
              <year>2015</year>
              <volume>28</volume>
              <fpage>248</fpage>
              <lpage>260</lpage>
              <pub-id pub-id-type="pmid">25103069</pub-id>
              <pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/modpathol.2014.100</pub-id>
            </element-citation>
            <mixed-citation id="mc-CR37" publication-type="journal">Agaimy, A. et al. Pancreatic undifferentiated rhabdoid carcinoma: KRAS alterations and SMARCB1 expression status define two subtypes. <italic toggle="yes">Mod. Pathol.</italic><bold>28</bold>, 248–260 (2015).<pub-id pub-id-type="pmid">25103069</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/modpathol.2014.100</pub-id></mixed-citation>
          </citation-alternatives>
        </ref>
        <ref id="CR38">
          <label>38.</label>
          <citation-alternatives>
            <element-citation id="ec-CR38" publication-type="journal">
              <person-group person-group-type="author">
                <name name-style="western">
                  <surname>Hosoda</surname>
                  <given-names>W</given-names>
                </name>
                <etal/>
              </person-group>
              <article-title>GNAS mutation is a frequent event in pancreatic intraductal papillary mucinous neoplasms and associated adenocarcinomas</article-title>
              <source>Virchows Arch.</source>
              <year>2015</year>
              <volume>466</volume>
              <fpage>665</fpage>
              <lpage>674</lpage>
              <pub-id pub-id-type="pmid">25796395</pub-id>
              <pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00428-015-1751-6</pub-id>
            </element-citation>
            <mixed-citation id="mc-CR38" publication-type="journal">Hosoda, W. et al. GNAS mutation is a frequent event in pancreatic intraductal papillary mucinous neoplasms and associated adenocarcinomas. <italic toggle="yes">Virchows Arch.</italic><bold>466</bold>, 665–674 (2015).<pub-id pub-id-type="pmid">25796395</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00428-015-1751-6</pub-id></mixed-citation>
          </citation-alternatives>
        </ref>
        <ref id="CR39">
          <label>39.</label>
          <citation-alternatives>
            <element-citation id="ec-CR39" publication-type="journal">
              <person-group person-group-type="author">
                <name name-style="western">
                  <surname>McGinnis</surname>
                  <given-names>T</given-names>
                </name>
                <etal/>
              </person-group>
              <article-title>Survival outcomes of pancreatic intraepithelial neoplasm (PanIN) versus intraductal papillary mucinous neoplasm (IPMN) associated pancreatic adenocarcinoma</article-title>
              <source>J. Clin. Med.</source>
              <year>2020</year>
              <volume>9</volume>
              <fpage>3102</fpage>
              <pub-id pub-id-type="pmid">32992976</pub-id>
              <pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/jcm9103102</pub-id>
              <pub-id pub-id-type="pmcid">PMC7600023</pub-id>
            </element-citation>
            <mixed-citation id="mc-CR39" publication-type="journal">McGinnis, T. et al. Survival outcomes of pancreatic intraepithelial neoplasm (PanIN) versus intraductal papillary mucinous neoplasm (IPMN) associated pancreatic adenocarcinoma. <italic toggle="yes">J. Clin. Med.</italic><bold>9</bold>, 3102 (2020).<pub-id pub-id-type="pmid">32992976</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/jcm9103102</pub-id><pub-id pub-id-type="pmcid">PMC7600023</pub-id></mixed-citation>
          </citation-alternatives>
        </ref>
        <ref id="CR40">
          <label>40.</label>
          <citation-alternatives>
            <element-citation id="ec-CR40" publication-type="journal">
              <person-group person-group-type="author">
                <name name-style="western">
                  <surname>Middha</surname>
                  <given-names>S</given-names>
                </name>
                <etal/>
              </person-group>
              <article-title>Reliable pan-cancer microsatellite instability assessment by using targeted next-generation sequencing data</article-title>
              <source>JCO Precis. Oncol.</source>
              <year>2017</year>
              <volume>2017</volume>
              <fpage>PO.17.00084</fpage>
              <pub-id pub-id-type="pmid">30211344</pub-id>
              <pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/PO.17.00084</pub-id>
              <pub-id pub-id-type="pmcid">PMC6130812</pub-id>
            </element-citation>
            <mixed-citation id="mc-CR40" publication-type="journal">Middha, S. et al. Reliable pan-cancer microsatellite instability assessment by using targeted next-generation sequencing data. <italic toggle="yes">JCO Precis. Oncol.</italic><bold>2017</bold>, PO.17.00084 (2017).<pub-id pub-id-type="pmid">30211344</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/PO.17.00084</pub-id><pub-id pub-id-type="pmcid">PMC6130812</pub-id></mixed-citation>
          </citation-alternatives>
        </ref>
        <ref id="CR41">
          <label>41.</label>
          <citation-alternatives>
            <element-citation id="ec-CR41" publication-type="journal">
              <person-group person-group-type="author">
                <name name-style="western">
                  <surname>O’Connor</surname>
                  <given-names>CA</given-names>
                </name>
                <etal/>
              </person-group>
              <article-title>Lynch syndrome and somatic mismatch repair variants in pancreas cancer</article-title>
              <source>JAMA Oncol.</source>
              <year>2024</year>
              <volume>5</volume>
              <fpage>e243651</fpage>
              <pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamaoncol.2024.3651</pub-id>
              <pub-id pub-id-type="pmcid">PMC11378065</pub-id>
              <pub-id pub-id-type="pmid">39235819</pub-id>
            </element-citation>
            <mixed-citation id="mc-CR41" publication-type="journal">O’Connor, C. A. et al. Lynch syndrome and somatic mismatch repair variants in pancreas cancer. <italic toggle="yes">JAMA Oncol.</italic><bold>5</bold>, e243651 (2024).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamaoncol.2024.3651</pub-id><pub-id pub-id-type="pmcid">PMC11378065</pub-id><pub-id pub-id-type="pmid">39235819</pub-id></mixed-citation>
          </citation-alternatives>
        </ref>
        <ref id="CR42">
          <label>42.</label>
          <citation-alternatives>
            <element-citation id="ec-CR42" publication-type="journal">
              <person-group person-group-type="author">
                <name name-style="western">
                  <surname>Noë</surname>
                  <given-names>M</given-names>
                </name>
                <etal/>
              </person-group>
              <article-title>Genomic characterization of malignant progression in neoplastic pancreatic cysts</article-title>
              <source>Nat. Commun.</source>
              <year>2020</year>
              <volume>11</volume>
              <fpage>4085</fpage>
              <pub-id pub-id-type="pmid">32796935</pub-id>
              <pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-020-17917-8</pub-id>
              <pub-id pub-id-type="pmcid">PMC7428044</pub-id>
            </element-citation>
            <mixed-citation id="mc-CR42" publication-type="journal">Noë, M. et al. Genomic characterization of malignant progression in neoplastic pancreatic cysts. <italic toggle="yes">Nat. Commun.</italic><bold>11</bold>, 4085 (2020).<pub-id pub-id-type="pmid">32796935</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-020-17917-8</pub-id><pub-id pub-id-type="pmcid">PMC7428044</pub-id></mixed-citation>
          </citation-alternatives>
        </ref>
        <ref id="CR43">
          <label>43.</label>
          <citation-alternatives>
            <element-citation id="ec-CR43" publication-type="journal">
              <person-group person-group-type="author">
                <name name-style="western">
                  <surname>Skaro</surname>
                  <given-names>M</given-names>
                </name>
                <etal/>
              </person-group>
              <article-title>Prevalence of germline mutations associated with cancer risk in patients with intraductal papillary mucinous neoplasms</article-title>
              <source>Gastroenterology</source>
              <year>2019</year>
              <volume>156</volume>
              <fpage>1905</fpage>
              <lpage>1913</lpage>
              <pub-id pub-id-type="pmid">30716324</pub-id>
              <pub-id pub-id-type="doi" assigning-authority="pmc">10.1053/j.gastro.2019.01.254</pub-id>
              <pub-id pub-id-type="pmcid">PMC6475492</pub-id>
            </element-citation>
            <mixed-citation id="mc-CR43" publication-type="journal">Skaro, M. et al. Prevalence of germline mutations associated with cancer risk in patients with intraductal papillary mucinous neoplasms. <italic toggle="yes">Gastroenterology</italic><bold>156</bold>, 1905–1913 (2019).<pub-id pub-id-type="pmid">30716324</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1053/j.gastro.2019.01.254</pub-id><pub-id pub-id-type="pmcid">PMC6475492</pub-id></mixed-citation>
          </citation-alternatives>
        </ref>
        <ref id="CR44">
          <label>44.</label>
          <citation-alternatives>
            <element-citation id="ec-CR44" publication-type="journal">
              <person-group person-group-type="author">
                <name name-style="western">
                  <surname>Park</surname>
                  <given-names>W</given-names>
                </name>
                <etal/>
              </person-group>
              <article-title>Clinico-genomic characterization of <italic toggle="yes">ATM</italic> and HRD in pancreas cancer: application for practice</article-title>
              <source>Clin. Cancer Res.</source>
              <year>2022</year>
              <volume>28</volume>
              <fpage>4782</fpage>
              <lpage>4792</lpage>
              <pub-id pub-id-type="pmid">36040493</pub-id>
              <pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/1078-0432.CCR-22-1483</pub-id>
              <pub-id pub-id-type="pmcid">PMC9634347</pub-id>
            </element-citation>
            <mixed-citation id="mc-CR44" publication-type="journal">Park, W. et al. Clinico-genomic characterization of <italic toggle="yes">ATM</italic> and HRD in pancreas cancer: application for practice. <italic toggle="yes">Clin. Cancer Res.</italic><bold>28</bold>, 4782–4792 (2022).<pub-id pub-id-type="pmid">36040493</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/1078-0432.CCR-22-1483</pub-id><pub-id pub-id-type="pmcid">PMC9634347</pub-id></mixed-citation>
          </citation-alternatives>
        </ref>
        <ref id="CR45">
          <label>45.</label>
          <citation-alternatives>
            <element-citation id="ec-CR45" publication-type="journal">
              <person-group person-group-type="author">
                <name name-style="western">
                  <surname>Momtaz</surname>
                  <given-names>P</given-names>
                </name>
                <etal/>
              </person-group>
              <article-title>Pancreas cancer and BRCA: a critical subset of patients with improving therapeutic outcomes</article-title>
              <source>Cancer</source>
              <year>2021</year>
              <volume>127</volume>
              <fpage>4393</fpage>
              <lpage>4402</lpage>
              <pub-id pub-id-type="pmid">34351646</pub-id>
              <pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cncr.33812</pub-id>
              <pub-id pub-id-type="pmcid">PMC9301324</pub-id>
            </element-citation>
            <mixed-citation id="mc-CR45" publication-type="journal">Momtaz, P. et al. Pancreas cancer and BRCA: a critical subset of patients with improving therapeutic outcomes. <italic toggle="yes">Cancer</italic><bold>127</bold>, 4393–4402 (2021).<pub-id pub-id-type="pmid">34351646</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cncr.33812</pub-id><pub-id pub-id-type="pmcid">PMC9301324</pub-id></mixed-citation>
          </citation-alternatives>
        </ref>
        <ref id="CR46">
          <label>46.</label>
          <citation-alternatives>
            <element-citation id="ec-CR46" publication-type="journal">
              <person-group person-group-type="author">
                <name name-style="western">
                  <surname>Reiss</surname>
                  <given-names>KA</given-names>
                </name>
                <etal/>
              </person-group>
              <article-title>Phase II study of maintenance rucaparib in patients with platinum-sensitive advanced pancreatic cancer and a pathogenic germline or somatic variant in <italic toggle="yes">BRCA1</italic>, <italic toggle="yes">BRCA2</italic>, or <italic toggle="yes">PALB2</italic></article-title>
              <source>J. Clin. Oncol.</source>
              <year>2021</year>
              <volume>39</volume>
              <fpage>2497</fpage>
              <lpage>2505</lpage>
              <pub-id pub-id-type="pmid">33970687</pub-id>
              <pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.21.00003</pub-id>
            </element-citation>
            <mixed-citation id="mc-CR46" publication-type="journal">Reiss, K. A. et al. Phase II study of maintenance rucaparib in patients with platinum-sensitive advanced pancreatic cancer and a pathogenic germline or somatic variant in <italic toggle="yes">BRCA1</italic>, <italic toggle="yes">BRCA2</italic>, or <italic toggle="yes">PALB2</italic>. <italic toggle="yes">J. Clin. Oncol.</italic><bold>39</bold>, 2497–2505 (2021).<pub-id pub-id-type="pmid">33970687</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.21.00003</pub-id></mixed-citation>
          </citation-alternatives>
        </ref>
        <ref id="CR47">
          <label>47.</label>
          <citation-alternatives>
            <element-citation id="ec-CR47" publication-type="journal">
              <person-group person-group-type="author">
                <name name-style="western">
                  <surname>Buller</surname>
                  <given-names>RE</given-names>
                </name>
                <etal/>
              </person-group>
              <article-title>The p53 mutational spectrum associated with BRCA1 mutant ovarian cancer1</article-title>
              <source>Clin. Cancer Res.</source>
              <year>2001</year>
              <volume>7</volume>
              <fpage>831</fpage>
              <lpage>838</lpage>
              <pub-id pub-id-type="pmid">11309330</pub-id>
            </element-citation>
            <mixed-citation id="mc-CR47" publication-type="journal">Buller, R. E. et al. The p53 mutational spectrum associated with BRCA1 mutant ovarian cancer1. <italic toggle="yes">Clin. Cancer Res.</italic><bold>7</bold>, 831–838 (2001).<pub-id pub-id-type="pmid">11309330</pub-id></mixed-citation>
          </citation-alternatives>
        </ref>
        <ref id="CR48">
          <label>48.</label>
          <citation-alternatives>
            <element-citation id="ec-CR48" publication-type="journal">
              <person-group person-group-type="author">
                <name name-style="western">
                  <surname>Ambrogio</surname>
                  <given-names>C</given-names>
                </name>
                <etal/>
              </person-group>
              <article-title>KRAS dimerization impacts MEK inhibitor sensitivity and oncogenic activity of mutant KRAS</article-title>
              <source>Cell</source>
              <year>2018</year>
              <volume>172</volume>
              <fpage>857</fpage>
              <lpage>868.e15</lpage>
              <pub-id pub-id-type="pmid">29336889</pub-id>
              <pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2017.12.020</pub-id>
            </element-citation>
            <mixed-citation id="mc-CR48" publication-type="journal">Ambrogio, C. et al. KRAS dimerization impacts MEK inhibitor sensitivity and oncogenic activity of mutant KRAS. <italic toggle="yes">Cell</italic><bold>172</bold>, 857–868.e15 (2018).<pub-id pub-id-type="pmid">29336889</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2017.12.020</pub-id></mixed-citation>
          </citation-alternatives>
        </ref>
        <ref id="CR49">
          <label>49.</label>
          <citation-alternatives>
            <element-citation id="ec-CR49" publication-type="journal">
              <person-group person-group-type="author">
                <name name-style="western">
                  <surname>Zhang</surname>
                  <given-names>Z</given-names>
                </name>
                <etal/>
              </person-group>
              <article-title>Wildtype Kras2 can inhibit lung carcinogenesis in mice</article-title>
              <source>Nat. Genet.</source>
              <year>2001</year>
              <volume>29</volume>
              <fpage>25</fpage>
              <lpage>33</lpage>
              <pub-id pub-id-type="pmid">11528387</pub-id>
              <pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/ng721</pub-id>
            </element-citation>
            <mixed-citation id="mc-CR49" publication-type="journal">Zhang, Z. et al. Wildtype Kras2 can inhibit lung carcinogenesis in mice. <italic toggle="yes">Nat. Genet.</italic><bold>29</bold>, 25–33 (2001).<pub-id pub-id-type="pmid">11528387</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/ng721</pub-id></mixed-citation>
          </citation-alternatives>
        </ref>
        <ref id="CR50">
          <label>50.</label>
          <citation-alternatives>
            <element-citation id="ec-CR50" publication-type="journal">
              <person-group person-group-type="author">
                <name name-style="western">
                  <surname>To</surname>
                  <given-names>MD</given-names>
                </name>
                <etal/>
              </person-group>
              <article-title>Kras regulatory elements and exon 4A determine mutation specificity in lung cancer</article-title>
              <source>Nat. Genet.</source>
              <year>2008</year>
              <volume>40</volume>
              <fpage>1240</fpage>
              <lpage>1244</lpage>
              <pub-id pub-id-type="pmid">18758463</pub-id>
              <pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/ng.211</pub-id>
              <pub-id pub-id-type="pmcid">PMC2654781</pub-id>
            </element-citation>
            <mixed-citation id="mc-CR50" publication-type="journal">To, M. D. et al. Kras regulatory elements and exon 4A determine mutation specificity in lung cancer. <italic toggle="yes">Nat. Genet.</italic><bold>40</bold>, 1240–1244 (2008).<pub-id pub-id-type="pmid">18758463</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/ng.211</pub-id><pub-id pub-id-type="pmcid">PMC2654781</pub-id></mixed-citation>
          </citation-alternatives>
        </ref>
        <ref id="CR51">
          <label>51.</label>
          <citation-alternatives>
            <element-citation id="ec-CR51" publication-type="journal">
              <person-group person-group-type="author">
                <name name-style="western">
                  <surname>Westcott</surname>
                  <given-names>PMK</given-names>
                </name>
                <etal/>
              </person-group>
              <article-title>The mutational landscapes of genetic and chemical models of Kras-driven lung cancer</article-title>
              <source>Nature</source>
              <year>2015</year>
              <volume>517</volume>
              <fpage>489</fpage>
              <lpage>492</lpage>
              <pub-id pub-id-type="pmid">25363767</pub-id>
              <pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nature13898</pub-id>
              <pub-id pub-id-type="pmcid">PMC4304785</pub-id>
            </element-citation>
            <mixed-citation id="mc-CR51" publication-type="journal">Westcott, P. M. K. et al. The mutational landscapes of genetic and chemical models of Kras-driven lung cancer. <italic toggle="yes">Nature</italic><bold>517</bold>, 489–492 (2015).<pub-id pub-id-type="pmid">25363767</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nature13898</pub-id><pub-id pub-id-type="pmcid">PMC4304785</pub-id></mixed-citation>
          </citation-alternatives>
        </ref>
        <ref id="CR52">
          <label>52.</label>
          <citation-alternatives>
            <element-citation id="ec-CR52" publication-type="journal">
              <person-group person-group-type="author">
                <name name-style="western">
                  <surname>Hobbs</surname>
                  <given-names>GA</given-names>
                </name>
                <etal/>
              </person-group>
              <article-title>Atypical KRASG12R mutant is impaired in PI3K signaling and macropinocytosis in pancreatic cancer</article-title>
              <source>Cancer Discov.</source>
              <year>2020</year>
              <volume>10</volume>
              <fpage>104</fpage>
              <lpage>123</lpage>
              <pub-id pub-id-type="pmid">31649109</pub-id>
              <pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/2159-8290.CD-19-1006</pub-id>
              <pub-id pub-id-type="pmcid">PMC6954322</pub-id>
            </element-citation>
            <mixed-citation id="mc-CR52" publication-type="journal">Hobbs, G. A. et al. Atypical KRASG12R mutant is impaired in PI3K signaling and macropinocytosis in pancreatic cancer. <italic toggle="yes">Cancer Discov.</italic><bold>10</bold>, 104–123 (2020).<pub-id pub-id-type="pmid">31649109</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/2159-8290.CD-19-1006</pub-id><pub-id pub-id-type="pmcid">PMC6954322</pub-id></mixed-citation>
          </citation-alternatives>
        </ref>
        <ref id="CR53">
          <label>53.</label>
          <citation-alternatives>
            <element-citation id="ec-CR53" publication-type="journal">
              <person-group person-group-type="author">
                <name name-style="western">
                  <surname>Yousef</surname>
                  <given-names>A</given-names>
                </name>
                <etal/>
              </person-group>
              <article-title>Impact of KRAS mutations and co-mutations on clinical outcomes in pancreatic ductal adenocarcinoma</article-title>
              <source>NPJ Precis. Oncol.</source>
              <year>2024</year>
              <volume>8</volume>
              <fpage>27</fpage>
              <pub-id pub-id-type="pmid">38310130</pub-id>
              <pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41698-024-00505-0</pub-id>
              <pub-id pub-id-type="pmcid">PMC10838312</pub-id>
            </element-citation>
            <mixed-citation id="mc-CR53" publication-type="journal">Yousef, A. et al. Impact of KRAS mutations and co-mutations on clinical outcomes in pancreatic ductal adenocarcinoma. <italic toggle="yes">NPJ Precis. Oncol.</italic><bold>8</bold>, 27 (2024).<pub-id pub-id-type="pmid">38310130</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41698-024-00505-0</pub-id><pub-id pub-id-type="pmcid">PMC10838312</pub-id></mixed-citation>
          </citation-alternatives>
        </ref>
        <ref id="CR54">
          <label>54.</label>
          <citation-alternatives>
            <element-citation id="ec-CR54" publication-type="journal">
              <person-group person-group-type="author">
                <name name-style="western">
                  <surname>Conroy</surname>
                  <given-names>T</given-names>
                </name>
                <etal/>
              </person-group>
              <article-title>FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer</article-title>
              <source>N. Engl. J. Med.</source>
              <year>2018</year>
              <volume>379</volume>
              <fpage>2395</fpage>
              <lpage>2406</lpage>
              <pub-id pub-id-type="pmid">30575490</pub-id>
              <pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa1809775</pub-id>
            </element-citation>
            <mixed-citation id="mc-CR54" publication-type="journal">Conroy, T. et al. FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer. <italic toggle="yes">N. Engl. J. Med.</italic><bold>379</bold>, 2395–2406 (2018).<pub-id pub-id-type="pmid">30575490</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa1809775</pub-id></mixed-citation>
          </citation-alternatives>
        </ref>
        <ref id="CR55">
          <label>55.</label>
          <citation-alternatives>
            <element-citation id="ec-CR55" publication-type="journal">
              <person-group person-group-type="author">
                <name name-style="western">
                  <surname>Stossel</surname>
                  <given-names>C</given-names>
                </name>
                <etal/>
              </person-group>
              <article-title>Spectrum of response to platinum and PARP inhibitors in germline <italic toggle="yes">BRCA</italic>–associated pancreatic cancer in the clinical and preclinical setting</article-title>
              <source>Cancer Discov.</source>
              <year>2023</year>
              <volume>13</volume>
              <fpage>1826</fpage>
              <lpage>1843</lpage>
              <pub-id pub-id-type="pmid">37449843</pub-id>
              <pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/2159-8290.CD-22-0412</pub-id>
              <pub-id pub-id-type="pmcid">PMC10401074</pub-id>
            </element-citation>
            <mixed-citation id="mc-CR55" publication-type="journal">Stossel, C. et al. Spectrum of response to platinum and PARP inhibitors in germline <italic toggle="yes">BRCA</italic>–associated pancreatic cancer in the clinical and preclinical setting. <italic toggle="yes">Cancer Discov.</italic><bold>13</bold>, 1826–1843 (2023).<pub-id pub-id-type="pmid">37449843</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/2159-8290.CD-22-0412</pub-id><pub-id pub-id-type="pmcid">PMC10401074</pub-id></mixed-citation>
          </citation-alternatives>
        </ref>
        <ref id="CR56">
          <label>56.</label>
          <citation-alternatives>
            <element-citation id="ec-CR56" publication-type="journal">
              <person-group person-group-type="author">
                <name name-style="western">
                  <surname>Kindler</surname>
                  <given-names>HL</given-names>
                </name>
                <etal/>
              </person-group>
              <article-title>Overall survival results from the POLO trial: a phase III study of active maintenance olaparib versus placebo for germline BRCA-mutated metastatic pancreatic cancer</article-title>
              <source>J. Clin. Oncol.</source>
              <year>2022</year>
              <volume>40</volume>
              <fpage>3929</fpage>
              <lpage>3939</lpage>
              <pub-id pub-id-type="pmid">35834777</pub-id>
              <pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.21.01604</pub-id>
              <pub-id pub-id-type="pmcid">PMC10476841</pub-id>
            </element-citation>
            <mixed-citation id="mc-CR56" publication-type="journal">Kindler, H. L. et al. Overall survival results from the POLO trial: a phase III study of active maintenance olaparib versus placebo for germline BRCA-mutated metastatic pancreatic cancer. <italic toggle="yes">J. Clin. Oncol.</italic><bold>40</bold>, 3929–3939 (2022).<pub-id pub-id-type="pmid">35834777</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.21.01604</pub-id><pub-id pub-id-type="pmcid">PMC10476841</pub-id></mixed-citation>
          </citation-alternatives>
        </ref>
        <ref id="CR57">
          <label>57.</label>
          <citation-alternatives>
            <element-citation id="ec-CR57" publication-type="journal">
              <person-group person-group-type="author">
                <name name-style="western">
                  <surname>Hosein</surname>
                  <given-names>AN</given-names>
                </name>
                <etal/>
              </person-group>
              <article-title>Loss of Rnf43 accelerates Kras-mediated neoplasia and remodels the tumor immune microenvironment in pancreatic adenocarcinoma</article-title>
              <source>Gastroenterology</source>
              <year>2022</year>
              <volume>162</volume>
              <fpage>1303</fpage>
              <lpage>1318.e18</lpage>
              <pub-id pub-id-type="pmid">34973294</pub-id>
              <pub-id pub-id-type="doi" assigning-authority="pmc">10.1053/j.gastro.2021.12.273</pub-id>
              <pub-id pub-id-type="pmcid">PMC8934289</pub-id>
            </element-citation>
            <mixed-citation id="mc-CR57" publication-type="journal">Hosein, A. N. et al. Loss of Rnf43 accelerates Kras-mediated neoplasia and remodels the tumor immune microenvironment in pancreatic adenocarcinoma. <italic toggle="yes">Gastroenterology</italic><bold>162</bold>, 1303–1318.e18 (2022).<pub-id pub-id-type="pmid">34973294</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1053/j.gastro.2021.12.273</pub-id><pub-id pub-id-type="pmcid">PMC8934289</pub-id></mixed-citation>
          </citation-alternatives>
        </ref>
        <ref id="CR58">
          <label>58.</label>
          <citation-alternatives>
            <element-citation id="ec-CR58" publication-type="journal">
              <person-group person-group-type="author">
                <name name-style="western">
                  <surname>Lin</surname>
                  <given-names>L</given-names>
                </name>
                <etal/>
              </person-group>
              <article-title>The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies</article-title>
              <source>Nat. Genet.</source>
              <year>2015</year>
              <volume>47</volume>
              <fpage>250</fpage>
              <lpage>256</lpage>
              <pub-id pub-id-type="pmid">25665005</pub-id>
              <pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/ng.3218</pub-id>
              <pub-id pub-id-type="pmcid">PMC4930244</pub-id>
            </element-citation>
            <mixed-citation id="mc-CR58" publication-type="journal">Lin, L. et al. The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies. <italic toggle="yes">Nat. Genet.</italic><bold>47</bold>, 250–256 (2015).<pub-id pub-id-type="pmid">25665005</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/ng.3218</pub-id><pub-id pub-id-type="pmcid">PMC4930244</pub-id></mixed-citation>
          </citation-alternatives>
        </ref>
        <ref id="CR59">
          <label>59.</label>
          <citation-alternatives>
            <element-citation id="ec-CR59" publication-type="journal">
              <person-group person-group-type="author">
                <name name-style="western">
                  <surname>Abboud</surname>
                  <given-names>Y</given-names>
                </name>
                <etal/>
              </person-group>
              <article-title>Increasing pancreatic cancer incidence in young women in the United States: a population-based time-trend analysis, 2001–2018</article-title>
              <source>Gastroenterology</source>
              <year>2023</year>
              <volume>164</volume>
              <fpage>978</fpage>
              <lpage>989.e6</lpage>
              <pub-id pub-id-type="pmid">36775072</pub-id>
              <pub-id pub-id-type="doi" assigning-authority="pmc">10.1053/j.gastro.2023.01.022</pub-id>
              <pub-id pub-id-type="pmcid">PMC11364483</pub-id>
            </element-citation>
            <mixed-citation id="mc-CR59" publication-type="journal">Abboud, Y. et al. Increasing pancreatic cancer incidence in young women in the United States: a population-based time-trend analysis, 2001–2018. <italic toggle="yes">Gastroenterology</italic><bold>164</bold>, 978–989.e6 (2023).<pub-id pub-id-type="pmid">36775072</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1053/j.gastro.2023.01.022</pub-id><pub-id pub-id-type="pmcid">PMC11364483</pub-id></mixed-citation>
          </citation-alternatives>
        </ref>
        <ref id="CR60">
          <label>60.</label>
          <citation-alternatives>
            <element-citation id="ec-CR60" publication-type="journal">
              <person-group person-group-type="author">
                <name name-style="western">
                  <surname>Arora</surname>
                  <given-names>K</given-names>
                </name>
                <etal/>
              </person-group>
              <article-title>Genetic ancestry correlates with somatic differences in a real-world clinical cancer sequencing cohort</article-title>
              <source>Cancer Discov.</source>
              <year>2022</year>
              <volume>12</volume>
              <fpage>2552</fpage>
              <lpage>2565</lpage>
              <pub-id pub-id-type="pmid">36048199</pub-id>
              <pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/2159-8290.CD-22-0312</pub-id>
              <pub-id pub-id-type="pmcid">PMC9633436</pub-id>
            </element-citation>
            <mixed-citation id="mc-CR60" publication-type="journal">Arora, K. et al. Genetic ancestry correlates with somatic differences in a real-world clinical cancer sequencing cohort. <italic toggle="yes">Cancer Discov.</italic><bold>12</bold>, 2552–2565 (2022).<pub-id pub-id-type="pmid">36048199</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/2159-8290.CD-22-0312</pub-id><pub-id pub-id-type="pmcid">PMC9633436</pub-id></mixed-citation>
          </citation-alternatives>
        </ref>
        <ref id="CR61">
          <label>61.</label>
          <citation-alternatives>
            <element-citation id="ec-CR61" publication-type="journal">
              <person-group person-group-type="author">
                <name name-style="western">
                  <surname>Sanchez-Vega</surname>
                  <given-names>F</given-names>
                </name>
                <etal/>
              </person-group>
              <article-title>Oncogenic signaling pathways in The Cancer Genome Atlas</article-title>
              <source>Cell</source>
              <year>2018</year>
              <volume>173</volume>
              <fpage>321</fpage>
              <lpage>337.e10</lpage>
              <pub-id pub-id-type="pmid">29625050</pub-id>
              <pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2018.03.035</pub-id>
              <pub-id pub-id-type="pmcid">PMC6070353</pub-id>
            </element-citation>
            <mixed-citation id="mc-CR61" publication-type="journal">Sanchez-Vega, F. et al. Oncogenic signaling pathways in The Cancer Genome Atlas. <italic toggle="yes">Cell</italic><bold>173</bold>, 321–337.e10 (2018).<pub-id pub-id-type="pmid">29625050</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2018.03.035</pub-id><pub-id pub-id-type="pmcid">PMC6070353</pub-id></mixed-citation>
          </citation-alternatives>
        </ref>
        <ref id="CR62">
          <label>62.</label>
          <citation-alternatives>
            <element-citation id="ec-CR62" publication-type="journal">
              <person-group person-group-type="author">
                <name name-style="western">
                  <surname>Cheng</surname>
                  <given-names>DT</given-names>
                </name>
                <etal/>
              </person-group>
              <article-title>Comprehensive detection of germline variants by MSK-IMPACT, a clinical diagnostic platform for solid tumor molecular oncology and concurrent cancer predisposition testing</article-title>
              <source>BMC Med. Genomics</source>
              <year>2017</year>
              <volume>10</volume>
              <fpage>33</fpage>
              <pub-id pub-id-type="pmid">28526081</pub-id>
              <pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12920-017-0271-4</pub-id>
              <pub-id pub-id-type="pmcid">PMC5437632</pub-id>
            </element-citation>
            <mixed-citation id="mc-CR62" publication-type="journal">Cheng, D. T. et al. Comprehensive detection of germline variants by MSK-IMPACT, a clinical diagnostic platform for solid tumor molecular oncology and concurrent cancer predisposition testing. <italic toggle="yes">BMC Med. Genomics</italic><bold>10</bold>, 33 (2017).<pub-id pub-id-type="pmid">28526081</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12920-017-0271-4</pub-id><pub-id pub-id-type="pmcid">PMC5437632</pub-id></mixed-citation>
          </citation-alternatives>
        </ref>
        <ref id="CR63">
          <label>63.</label>
          <citation-alternatives>
            <element-citation id="ec-CR63" publication-type="journal">
              <person-group person-group-type="author">
                <name name-style="western">
                  <surname>Srinivasan</surname>
                  <given-names>P</given-names>
                </name>
                <etal/>
              </person-group>
              <article-title>The context-specific role of germline pathogenicity in tumorigenesis</article-title>
              <source>Nat. Genet.</source>
              <year>2021</year>
              <volume>53</volume>
              <fpage>1577</fpage>
              <lpage>1585</lpage>
              <pub-id pub-id-type="pmid">34741162</pub-id>
              <pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41588-021-00949-1</pub-id>
              <pub-id pub-id-type="pmcid">PMC8957388</pub-id>
            </element-citation>
            <mixed-citation id="mc-CR63" publication-type="journal">Srinivasan, P. et al. The context-specific role of germline pathogenicity in tumorigenesis. <italic toggle="yes">Nat. Genet.</italic><bold>53</bold>, 1577–1585 (2021).<pub-id pub-id-type="pmid">34741162</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41588-021-00949-1</pub-id><pub-id pub-id-type="pmcid">PMC8957388</pub-id></mixed-citation>
          </citation-alternatives>
        </ref>
        <ref id="CR64">
          <label>64.</label>
          <citation-alternatives>
            <element-citation id="ec-CR64" publication-type="journal">
              <person-group person-group-type="author">
                <name name-style="western">
                  <surname>Niu</surname>
                  <given-names>B</given-names>
                </name>
                <etal/>
              </person-group>
              <article-title>MSIsensor: microsatellite instability detection using paired tumor-normal sequence data</article-title>
              <source>Bioinformatics</source>
              <year>2014</year>
              <volume>30</volume>
              <fpage>1015</fpage>
              <lpage>1016</lpage>
              <pub-id pub-id-type="pmid">24371154</pub-id>
              <pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/bioinformatics/btt755</pub-id>
              <pub-id pub-id-type="pmcid">PMC3967115</pub-id>
            </element-citation>
            <mixed-citation id="mc-CR64" publication-type="journal">Niu, B. et al. MSIsensor: microsatellite instability detection using paired tumor-normal sequence data. <italic toggle="yes">Bioinformatics</italic><bold>30</bold>, 1015–1016 (2014).<pub-id pub-id-type="pmid">24371154</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/bioinformatics/btt755</pub-id><pub-id pub-id-type="pmcid">PMC3967115</pub-id></mixed-citation>
          </citation-alternatives>
        </ref>
        <ref id="CR65">
          <label>65.</label>
          <citation-alternatives>
            <element-citation id="ec-CR65" publication-type="journal">
              <person-group person-group-type="author">
                <name name-style="western">
                  <surname>Hu</surname>
                  <given-names>ZI</given-names>
                </name>
                <etal/>
              </person-group>
              <article-title>Evaluating mismatch repair deficiency in pancreatic adenocarcinoma: challenges and recommendations</article-title>
              <source>Clin. Cancer Res.</source>
              <year>2018</year>
              <volume>24</volume>
              <fpage>1326</fpage>
              <lpage>1336</lpage>
              <pub-id pub-id-type="pmid">29367431</pub-id>
              <pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/1078-0432.CCR-17-3099</pub-id>
              <pub-id pub-id-type="pmcid">PMC5856632</pub-id>
            </element-citation>
            <mixed-citation id="mc-CR65" publication-type="journal">Hu, Z. I. et al. Evaluating mismatch repair deficiency in pancreatic adenocarcinoma: challenges and recommendations. <italic toggle="yes">Clin. Cancer Res.</italic><bold>24</bold>, 1326–1336 (2018).<pub-id pub-id-type="pmid">29367431</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/1078-0432.CCR-17-3099</pub-id><pub-id pub-id-type="pmcid">PMC5856632</pub-id></mixed-citation>
          </citation-alternatives>
        </ref>
        <ref id="CR66">
          <label>66.</label>
          <citation-alternatives>
            <element-citation id="ec-CR66" publication-type="journal">
              <person-group person-group-type="author">
                <name name-style="western">
                  <surname>Benayed</surname>
                  <given-names>R</given-names>
                </name>
                <etal/>
              </person-group>
              <article-title>High yield of RNA sequencing for targetable kinase fusions in lung adenocarcinomas with no mitogenic driver alteration detected by DNA sequencing and low tumor mutation burden</article-title>
              <source>Clin. Cancer Res.</source>
              <year>2019</year>
              <volume>25</volume>
              <fpage>4712</fpage>
              <lpage>4722</lpage>
              <pub-id pub-id-type="pmid">31028088</pub-id>
              <pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/1078-0432.CCR-19-0225</pub-id>
              <pub-id pub-id-type="pmcid">PMC6679790</pub-id>
            </element-citation>
            <mixed-citation id="mc-CR66" publication-type="journal">Benayed, R. et al. High yield of RNA sequencing for targetable kinase fusions in lung adenocarcinomas with no mitogenic driver alteration detected by DNA sequencing and low tumor mutation burden. <italic toggle="yes">Clin. Cancer Res.</italic><bold>25</bold>, 4712–4722 (2019).<pub-id pub-id-type="pmid">31028088</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/1078-0432.CCR-19-0225</pub-id><pub-id pub-id-type="pmcid">PMC6679790</pub-id></mixed-citation>
          </citation-alternatives>
        </ref>
        <ref id="CR67">
          <label>67.</label>
          <citation-alternatives>
            <element-citation id="ec-CR67" publication-type="journal">
              <person-group person-group-type="author">
                <name name-style="western">
                  <surname>Shen</surname>
                  <given-names>R</given-names>
                </name>
                <name name-style="western">
                  <surname>Seshan</surname>
                  <given-names>VE</given-names>
                </name>
              </person-group>
              <article-title>FACETS: allele-specific copy number and clonal heterogeneity analysis tool for high-throughput DNA sequencing</article-title>
              <source>Nucleic Acids Res.</source>
              <year>2016</year>
              <volume>44</volume>
              <fpage>e131</fpage>
              <pub-id pub-id-type="pmid">27270079</pub-id>
              <pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/nar/gkw520</pub-id>
              <pub-id pub-id-type="pmcid">PMC5027494</pub-id>
            </element-citation>
            <mixed-citation id="mc-CR67" publication-type="journal">Shen, R. &amp; Seshan, V. E. FACETS: allele-specific copy number and clonal heterogeneity analysis tool for high-throughput DNA sequencing. <italic toggle="yes">Nucleic Acids Res.</italic><bold>44</bold>, e131 (2016).<pub-id pub-id-type="pmid">27270079</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/nar/gkw520</pub-id><pub-id pub-id-type="pmcid">PMC5027494</pub-id></mixed-citation>
          </citation-alternatives>
        </ref>
        <ref id="CR68">
          <label>68.</label>
          <citation-alternatives>
            <element-citation id="ec-CR68" publication-type="journal">
              <person-group person-group-type="author">
                <name name-style="western">
                  <surname>Jonsson</surname>
                  <given-names>P</given-names>
                </name>
                <etal/>
              </person-group>
              <article-title>Tumour lineage shapes BRCA-mediated phenotypes</article-title>
              <source>Nature</source>
              <year>2019</year>
              <volume>571</volume>
              <fpage>576</fpage>
              <lpage>579</lpage>
              <pub-id pub-id-type="pmid">31292550</pub-id>
              <pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41586-019-1382-1</pub-id>
              <pub-id pub-id-type="pmcid">PMC7048239</pub-id>
            </element-citation>
            <mixed-citation id="mc-CR68" publication-type="journal">Jonsson, P. et al. Tumour lineage shapes BRCA-mediated phenotypes. <italic toggle="yes">Nature</italic><bold>571</bold>, 576–579 (2019).<pub-id pub-id-type="pmid">31292550</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41586-019-1382-1</pub-id><pub-id pub-id-type="pmcid">PMC7048239</pub-id></mixed-citation>
          </citation-alternatives>
        </ref>
        <ref id="CR69">
          <label>69.</label>
          <citation-alternatives>
            <element-citation id="ec-CR69" publication-type="journal">
              <person-group person-group-type="author">
                <name name-style="western">
                  <surname>Dentro</surname>
                  <given-names>SC</given-names>
                </name>
                <name name-style="western">
                  <surname>Wedge</surname>
                  <given-names>DC</given-names>
                </name>
                <name name-style="western">
                  <surname>Van Loo</surname>
                  <given-names>P</given-names>
                </name>
              </person-group>
              <article-title>Principles of reconstructing the subclonal architecture of cancers</article-title>
              <source>Cold Spring Harb. Perspect. Med.</source>
              <year>2017</year>
              <volume>7</volume>
              <fpage>a026625</fpage>
              <pub-id pub-id-type="pmid">28270531</pub-id>
              <pub-id pub-id-type="doi" assigning-authority="pmc">10.1101/cshperspect.a026625</pub-id>
              <pub-id pub-id-type="pmcid">PMC5538405</pub-id>
            </element-citation>
            <mixed-citation id="mc-CR69" publication-type="journal">Dentro, S. C., Wedge, D. C. &amp; Van Loo, P. Principles of reconstructing the subclonal architecture of cancers. <italic toggle="yes">Cold Spring Harb. Perspect. Med.</italic><bold>7</bold>, a026625 (2017).<pub-id pub-id-type="pmid">28270531</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1101/cshperspect.a026625</pub-id><pub-id pub-id-type="pmcid">PMC5538405</pub-id></mixed-citation>
          </citation-alternatives>
        </ref>
        <ref id="CR70">
          <label>70.</label>
          <citation-alternatives>
            <element-citation id="ec-CR70" publication-type="journal">
              <person-group person-group-type="author">
                <name name-style="western">
                  <surname>Cerami</surname>
                  <given-names>E</given-names>
                </name>
                <etal/>
              </person-group>
              <article-title>The cBio Cancer Genomics Portal: an open platform for exploring multidimensional cancer genomics data</article-title>
              <source>Cancer Discov.</source>
              <year>2012</year>
              <volume>2</volume>
              <fpage>401</fpage>
              <lpage>404</lpage>
              <pub-id pub-id-type="pmid">22588877</pub-id>
              <pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/2159-8290.CD-12-0095</pub-id>
              <pub-id pub-id-type="pmcid">PMC3956037</pub-id>
            </element-citation>
            <mixed-citation id="mc-CR70" publication-type="journal">Cerami, E. et al. The cBio Cancer Genomics Portal: an open platform for exploring multidimensional cancer genomics data. <italic toggle="yes">Cancer Discov.</italic><bold>2</bold>, 401–404 (2012).<pub-id pub-id-type="pmid">22588877</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/2159-8290.CD-12-0095</pub-id><pub-id pub-id-type="pmcid">PMC3956037</pub-id></mixed-citation>
          </citation-alternatives>
        </ref>
        <ref id="CR71">
          <label>71.</label>
          <citation-alternatives>
            <element-citation id="ec-CR71" publication-type="journal">
              <person-group person-group-type="author">
                <name name-style="western">
                  <surname>Gao</surname>
                  <given-names>J</given-names>
                </name>
                <etal/>
              </person-group>
              <article-title>Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal</article-title>
              <source>Sci. Signal</source>
              <year>2013</year>
              <volume>6</volume>
              <fpage>pl1</fpage>
              <pub-id pub-id-type="pmid">23550210</pub-id>
              <pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/scisignal.2004088</pub-id>
              <pub-id pub-id-type="pmcid">PMC4160307</pub-id>
            </element-citation>
            <mixed-citation id="mc-CR71" publication-type="journal">Gao, J. et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. <italic toggle="yes">Sci. Signal</italic><bold>6</bold>, pl1 (2013).<pub-id pub-id-type="pmid">23550210</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/scisignal.2004088</pub-id><pub-id pub-id-type="pmcid">PMC4160307</pub-id></mixed-citation>
          </citation-alternatives>
        </ref>
        <ref id="CR72">
          <label>72.</label>
          <citation-alternatives>
            <element-citation id="ec-CR72" publication-type="journal">
              <person-group person-group-type="author">
                <name name-style="western">
                  <surname>De Bruijn</surname>
                  <given-names>I</given-names>
                </name>
                <etal/>
              </person-group>
              <article-title>Analysis and visualization of longitudinal genomic and clinical data from the AACR Project GENIE Biopharma Collaborative in cBioPortal</article-title>
              <source>Cancer Res.</source>
              <year>2023</year>
              <volume>83</volume>
              <fpage>3861</fpage>
              <lpage>3867</lpage>
              <pub-id pub-id-type="pmid">37668528</pub-id>
              <pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/0008-5472.CAN-23-0816</pub-id>
              <pub-id pub-id-type="pmcid">PMC10690089</pub-id>
            </element-citation>
            <mixed-citation id="mc-CR72" publication-type="journal">De Bruijn, I. et al. Analysis and visualization of longitudinal genomic and clinical data from the AACR Project GENIE Biopharma Collaborative in cBioPortal. <italic toggle="yes">Cancer Res.</italic><bold>83</bold>, 3861–3867 (2023).<pub-id pub-id-type="pmid">37668528</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/0008-5472.CAN-23-0816</pub-id><pub-id pub-id-type="pmcid">PMC10690089</pub-id></mixed-citation>
          </citation-alternatives>
        </ref>
      </ref-list>
    </back>
  </article>
</pmc-articleset>
